Background  ||| S:24 E:43 ||| NN
A  ||| S:43 E:45 ||| DT
near-universal  ||| S:45 E:60 ||| JJ
feature  ||| S:60 E:68 ||| NN
of  ||| S:68 E:71 ||| IN
cell  ||| S:71 E:76 ||| NN
signaling  ||| S:76 E:95 ||| VBG
via  ||| S:95 E:99 ||| IN
seven  ||| S:99 E:105 ||| CD
transmembrane ||| S:105 E:118 ||| NN
,  ||| S:118 E:120 ||| ,
G  ||| S:120 E:130 ||| NNP
protein-coupled  ||| S:130 E:146 ||| JJ
receptors  ||| S:146 E:156 ||| NN
is  ||| S:156 E:159 ||| VBZ
attenuation  ||| S:159 E:171 ||| VBN
of  ||| S:171 E:174 ||| IN
a  ||| S:174 E:176 ||| DT
cellular  ||| S:176 E:193 ||| JJ
response  ||| S:193 E:202 ||| NN
upon  ||| S:202 E:207 ||| IN
prolonged  ||| S:207 E:217 ||| JJ
exposure  ||| S:217 E:226 ||| NN
to  ||| S:226 E:229 ||| TO
an  ||| S:229 E:232 ||| DT
extracellular  ||| S:232 E:254 ||| JJ
stimulus  ||| S:254 E:263 ||| NNS
[  ||| S:263 E:265 ||| -LRB-
1  ||| S:265 E:267 ||| LS
]  ||| S:267 E:269 ||| -RRB-
.  ||| S:269 E:271 ||| .
This  ||| S:271 E:276 ||| DT
desensitization  ||| S:276 E:292 ||| JJ
process  ||| S:292 E:300 ||| NN
is  ||| S:300 E:311 ||| VBZ
well-established  ||| S:311 E:328 ||| JJ
for  ||| S:328 E:332 ||| IN
GnRH-stimulated  ||| S:332 E:348 ||| NNP
LH  ||| S:348 E:351 ||| NNP
secretion  ||| S:351 E:361 ||| NN
from  ||| S:361 E:374 ||| IN
pituitary  ||| S:374 E:384 ||| JJ
gonadotropes  ||| S:384 E:397 ||| NNS
[  ||| S:397 E:399 ||| -LRB-
2  ||| S:399 E:401 ||| CD
3  ||| S:401 E:403 ||| CD
]  ||| S:403 E:405 ||| -RRB-
,  ||| S:405 E:407 ||| ,
and  ||| S:407 E:411 ||| CC
occurs  ||| S:411 E:418 ||| VBZ
after  ||| S:418 E:424 ||| IN
about  ||| S:424 E:430 ||| IN
6  ||| S:430 E:432 ||| CD
h  ||| S:432 E:442 ||| NN
of  ||| S:442 E:445 ||| IN
continued  ||| S:445 E:455 ||| JJ
exposure  ||| S:455 E:464 ||| NN
to  ||| S:464 E:467 ||| TO
GnRH  ||| S:467 E:472 ||| JJ
in  ||| S:472 E:475 ||| IN
rats  ||| S:475 E:480 ||| NNS
[  ||| S:480 E:482 ||| -LRB-
3  ||| S:482 E:484 ||| LS
]  ||| S:484 E:486 ||| -RRB-
;  ||| S:486 E:488 ||| :
removal  ||| S:488 E:496 ||| NN
of  ||| S:496 E:507 ||| IN
GnRH  ||| S:507 E:512 ||| JJ
permits  ||| S:512 E:520 ||| NNS
recovery  ||| S:520 E:529 ||| NN
from  ||| S:529 E:534 ||| IN
the  ||| S:534 E:538 ||| DT
profound  ||| S:538 E:547 ||| JJ
suppression  ||| S:547 E:559 ||| NN
of  ||| S:559 E:562 ||| IN
LH  ||| S:562 E:573 ||| NNP
secretion ||| S:573 E:582 ||| NN
,  ||| S:582 E:584 ||| ,
albeit  ||| S:584 E:591 ||| IN
rather  ||| S:591 E:598 ||| RB
slowly  ||| S:598 E:605 ||| RB
( ||| S:605 E:606 ||| -LRB-
2-4  ||| S:606 E:610 ||| CD
days ||| S:610 E:614 ||| NNS
;  ||| S:614 E:616 ||| :
4 ||| S:616 E:617 ||| LS
) ||| S:617 E:618 ||| -RRB-
.  ||| S:618 E:620 ||| .
The  ||| S:620 E:632 ||| DT
molecular  ||| S:632 E:642 ||| JJ
mechanisms  ||| S:642 E:653 ||| NNS
involved  ||| S:653 E:662 ||| VBN
in  ||| S:662 E:665 ||| IN
GnRH-induced  ||| S:665 E:686 ||| JJ
desensitization  ||| S:686 E:702 ||| NNS
are  ||| S:702 E:706 ||| VBP
poorly  ||| S:706 E:713 ||| RB
understood ||| S:713 E:723 ||| VBN
,  ||| S:723 E:725 ||| ,
but  ||| S:725 E:729 ||| CC
they  ||| S:729 E:734 ||| PRP
do  ||| S:734 E:737 ||| VBP
not  ||| S:737 E:749 ||| RB
appear  ||| S:749 E:756 ||| VB
to  ||| S:756 E:759 ||| TO
be  ||| S:759 E:762 ||| VB
due  ||| S:762 E:766 ||| JJ
to  ||| S:766 E:769 ||| TO
alterations  ||| S:769 E:781 ||| VB
in  ||| S:781 E:784 ||| IN
GnRH  ||| S:784 E:789 ||| JJ
receptor  ||| S:789 E:798 ||| NN
expression  ||| S:798 E:817 ||| NN
[  ||| S:817 E:819 ||| -LRB-
5  ||| S:819 E:821 ||| CD
6  ||| S:821 E:823 ||| CD
]  ||| S:823 E:825 ||| -RRB-
or  ||| S:825 E:828 ||| CC
to  ||| S:828 E:831 ||| TO
changes  ||| S:831 E:839 ||| NNS
in  ||| S:839 E:842 ||| IN
LH  ||| S:842 E:845 ||| NNP
concentrations  ||| S:845 E:860 ||| NNS
in  ||| S:860 E:863 ||| IN
the  ||| S:863 E:867 ||| DT
pituitary  ||| S:867 E:885 ||| JJ
gland  ||| S:885 E:891 ||| NNS
[  ||| S:891 E:893 ||| -LRB-
7  ||| S:893 E:895 ||| CD
8  ||| S:895 E:897 ||| CD
]  ||| S:897 E:899 ||| -RRB-
.  ||| S:899 E:909 ||| .
Earlier ||| S:909 E:916 ||| RBR
,  ||| S:916 E:918 ||| ,
we  ||| S:918 E:921 ||| PRP
presented  ||| S:921 E:931 ||| VBD
evidence  ||| S:931 E:940 ||| NN
that  ||| S:940 E:945 ||| IN
a  ||| S:945 E:947 ||| DT
regulator  ||| S:947 E:957 ||| NN
of  ||| S:957 E:960 ||| IN
G  ||| S:960 E:970 ||| NNP
protein  ||| S:970 E:978 ||| NN
signaling ||| S:978 E:987 ||| NN
,  ||| S:987 E:989 ||| ,
RGS3 ||| S:989 E:993 ||| NNP
,  ||| S:993 E:995 ||| ,
might  ||| S:995 E:1001 ||| MD
participate  ||| S:1001 E:1013 ||| VB
in  ||| S:1013 E:1016 ||| IN
the  ||| S:1016 E:1028 ||| DT
regulation  ||| S:1028 E:1039 ||| NN
of  ||| S:1039 E:1042 ||| IN
GnRH  ||| S:1042 E:1047 ||| JJ
receptor  ||| S:1047 E:1056 ||| NN
signaling  ||| S:1056 E:1066 ||| NNS
[  ||| S:1066 E:1068 ||| -LRB-
9  ||| S:1068 E:1070 ||| CD
]  ||| S:1070 E:1072 ||| -RRB-
.  ||| S:1072 E:1074 ||| .
The  ||| S:1074 E:1078 ||| DT
mechanism  ||| S:1078 E:1096 ||| NN
of  ||| S:1096 E:1099 ||| IN
RGS  ||| S:1099 E:1103 ||| NNP
action  ||| S:1103 E:1110 ||| NN
is  ||| S:1110 E:1113 ||| VBZ
antagonism  ||| S:1113 E:1124 ||| VBN
of  ||| S:1124 E:1127 ||| IN
the  ||| S:1127 E:1131 ||| DT
Gα  ||| S:1131 E:1134 ||| JJ
protein  ||| S:1134 E:1142 ||| NN
either  ||| S:1142 E:1149 ||| CC
by  ||| S:1149 E:1160 ||| IN
accelerating  ||| S:1160 E:1173 ||| VBG
its  ||| S:1173 E:1177 ||| PRP$
hydrolysis  ||| S:1177 E:1188 ||| NN
of  ||| S:1188 E:1191 ||| IN
GTP ||| S:1191 E:1194 ||| NNP
,  ||| S:1194 E:1196 ||| ,
thereby  ||| S:1196 E:1204 ||| RB
prematurely  ||| S:1204 E:1224 ||| RB
terminating  ||| S:1224 E:1236 ||| VBP
signaling  ||| S:1236 E:1246 ||| VBG
due  ||| S:1246 E:1250 ||| JJ
to  ||| S:1250 E:1253 ||| TO
reassociation  ||| S:1253 E:1267 ||| VB
of  ||| S:1267 E:1270 ||| IN
the  ||| S:1270 E:1274 ||| DT
Gα  ||| S:1274 E:1277 ||| NNP
and  ||| S:1277 E:1289 ||| CC
Gβγ  ||| S:1289 E:1293 ||| NNP
complexes  ||| S:1293 E:1303 ||| NNS
[  ||| S:1303 E:1305 ||| -LRB-
10  ||| S:1305 E:1308 ||| CD
]  ||| S:1308 E:1310 ||| -RRB-
,  ||| S:1310 E:1312 ||| ,
or  ||| S:1312 E:1315 ||| CC
by  ||| S:1315 E:1318 ||| IN
antagonizing  ||| S:1318 E:1331 ||| JJ
interaction  ||| S:1331 E:1343 ||| NN
of  ||| S:1343 E:1354 ||| IN
the  ||| S:1354 E:1358 ||| DT
Gα  ||| S:1358 E:1361 ||| JJ
protein  ||| S:1361 E:1369 ||| NN
with  ||| S:1369 E:1374 ||| IN
its  ||| S:1374 E:1378 ||| PRP$
effector  ||| S:1378 E:1387 ||| JJ
such  ||| S:1387 E:1392 ||| JJ
as  ||| S:1392 E:1395 ||| IN
phospholipase  ||| S:1395 E:1409 ||| JJ
Cβ  ||| S:1409 E:1412 ||| NNP
[  ||| S:1412 E:1422 ||| -LRB-
11  ||| S:1422 E:1425 ||| CD
12  ||| S:1425 E:1428 ||| CD
]  ||| S:1428 E:1430 ||| -RRB-
.  ||| S:1430 E:1432 ||| .
A  ||| S:1432 E:1434 ||| DT
large  ||| S:1434 E:1440 ||| JJ
number  ||| S:1440 E:1447 ||| NN
of  ||| S:1447 E:1450 ||| IN
RGS  ||| S:1450 E:1454 ||| NNP
genes  ||| S:1454 E:1460 ||| NNS
have  ||| S:1460 E:1465 ||| VBP
been  ||| S:1465 E:1470 ||| VBN
identified  ||| S:1470 E:1489 ||| VBN
in  ||| S:1489 E:1492 ||| IN
mammals  ||| S:1492 E:1500 ||| VBG
based  ||| S:1500 E:1506 ||| VBN
on  ||| S:1506 E:1509 ||| IN
the  ||| S:1509 E:1513 ||| DT
presence  ||| S:1513 E:1522 ||| NN
of  ||| S:1522 E:1525 ||| IN
a  ||| S:1525 E:1527 ||| DT
120  ||| S:1527 E:1531 ||| CD
amino  ||| S:1531 E:1537 ||| JJ
acid  ||| S:1537 E:1542 ||| NN
core  ||| S:1542 E:1555 ||| NN
domain  ||| S:1555 E:1562 ||| NN
[  ||| S:1562 E:1564 ||| -LRB-
13  ||| S:1564 E:1567 ||| CD
14  ||| S:1567 E:1570 ||| CD
15  ||| S:1570 E:1573 ||| CD
16  ||| S:1573 E:1576 ||| CD
]  ||| S:1576 E:1578 ||| -RRB-
.  ||| S:1578 E:1580 ||| .
RGS  ||| S:1580 E:1584 ||| NNP
proteins  ||| S:1584 E:1593 ||| NNS
have  ||| S:1593 E:1598 ||| VBP
been  ||| S:1598 E:1603 ||| VBN
described  ||| S:1603 E:1621 ||| VBN
that  ||| S:1621 E:1626 ||| IN
interact  ||| S:1626 E:1635 ||| NN
with  ||| S:1635 E:1640 ||| IN
the  ||| S:1640 E:1644 ||| DT
G  ||| S:1644 E:1655 ||| NNP
i  ||| S:1655 E:1657 ||| FW
α  ||| S:1657 E:1659 ||| FW
and  ||| S:1659 E:1663 ||| CC
G  ||| S:1663 E:1674 ||| NNP
qα  ||| S:1674 E:1677 ||| NN
members  ||| S:1677 E:1685 ||| NNS
of  ||| S:1685 E:1688 ||| IN
the  ||| S:1688 E:1692 ||| DT
G  ||| S:1692 E:1694 ||| NNP
protein  ||| S:1694 E:1702 ||| NN
family  ||| S:1702 E:1709 ||| NN
[  ||| S:1709 E:1711 ||| -LRB-
17  ||| S:1711 E:1722 ||| CD
18  ||| S:1722 E:1725 ||| CD
19  ||| S:1725 E:1728 ||| CD
20  ||| S:1728 E:1731 ||| CD
21  ||| S:1731 E:1734 ||| CD
]  ||| S:1734 E:1736 ||| -RRB-
.  ||| S:1736 E:1746 ||| .
Previously ||| S:1746 E:1756 ||| RB
,  ||| S:1756 E:1758 ||| ,
we  ||| S:1758 E:1761 ||| PRP
showed  ||| S:1761 E:1768 ||| VBD
that  ||| S:1768 E:1773 ||| IN
RSG3  ||| S:1773 E:1778 ||| NNP
was  ||| S:1778 E:1782 ||| VBD
expressed  ||| S:1782 E:1800 ||| VBN
endogenously  ||| S:1800 E:1813 ||| VBN
in  ||| S:1813 E:1816 ||| IN
rat  ||| S:1816 E:1820 ||| JJ
pituitary  ||| S:1820 E:1830 ||| JJ
cells  ||| S:1830 E:1836 ||| NNS
and ||| S:1836 E:1839 ||| CC
,  ||| S:1839 E:1841 ||| ,
when  ||| S:1841 E:1854 ||| WRB
experimentally  ||| S:1854 E:1869 ||| JJ
co-expressed  ||| S:1869 E:1882 ||| NN
together  ||| S:1882 E:1891 ||| RB
with  ||| S:1891 E:1896 ||| IN
GnRH  ||| S:1896 E:1901 ||| JJ
receptors  ||| S:1901 E:1911 ||| NNS
in  ||| S:1911 E:1922 ||| IN
a  ||| S:1922 E:1924 ||| DT
heterologous  ||| S:1924 E:1937 ||| JJ
cell  ||| S:1937 E:1942 ||| NN
line  ||| S:1942 E:1947 ||| NN
( ||| S:1947 E:1948 ||| -LRB-
COS1 ||| S:1948 E:1952 ||| NNP
) ||| S:1952 E:1953 ||| -RRB-
,  ||| S:1953 E:1955 ||| ,
it  ||| S:1955 E:1958 ||| PRP
suppressed  ||| S:1958 E:1977 ||| VBD
GnRH-stimulated  ||| S:1977 E:1993 ||| JJ
inositol  ||| S:1993 E:2002 ||| JJ
trisphosphate  ||| S:2002 E:2016 ||| JJ
production  ||| S:2016 E:2027 ||| NN
[  ||| S:2027 E:2029 ||| -LRB-
9  ||| S:2029 E:2031 ||| CD
]  ||| S:2031 E:2033 ||| -RRB-
.  ||| S:2033 E:2043 ||| .
Here ||| S:2043 E:2047 ||| RB
,  ||| S:2047 E:2049 ||| ,
those  ||| S:2049 E:2055 ||| DT
studies  ||| S:2055 E:2063 ||| NNS
have  ||| S:2063 E:2068 ||| VBP
been  ||| S:2068 E:2073 ||| VBN
extended  ||| S:2073 E:2082 ||| VBN
to  ||| S:2082 E:2085 ||| TO
include  ||| S:2085 E:2101 ||| VB
GnRH-stimulated  ||| S:2101 E:2117 ||| JJ
LH  ||| S:2117 E:2120 ||| NNS
secretion  ||| S:2120 E:2130 ||| VBP
using  ||| S:2130 E:2136 ||| VBG
adenovirus-mediated  ||| S:2136 E:2156 ||| JJ
gene  ||| S:2156 E:2169 ||| NN
transfer  ||| S:2169 E:2178 ||| NN
of  ||| S:2178 E:2181 ||| IN
RGS3  ||| S:2181 E:2186 ||| CD
complementary  ||| S:2186 E:2200 ||| JJ
DNA  ||| S:2200 E:2204 ||| NN
into  ||| S:2204 E:2209 ||| IN
normal  ||| S:2209 E:2216 ||| JJ
rat  ||| S:2216 E:2228 ||| NN
pituitary  ||| S:2228 E:2238 ||| NN
gonadotropes ||| S:2238 E:2250 ||| NN
.  ||| S:2250 E:2252 ||| .
RGS3  ||| S:2252 E:2257 ||| NNP
was  ||| S:2257 E:2261 ||| VBD
found  ||| S:2261 E:2267 ||| VBN
to  ||| S:2267 E:2270 ||| TO
profoundly  ||| S:2270 E:2289 ||| RB
inhibit  ||| S:2289 E:2297 ||| VB
GnRH-stimulated  ||| S:2297 E:2313 ||| JJ
LH  ||| S:2313 E:2316 ||| NNP
secretion  ||| S:2316 E:2326 ||| NN
and  ||| S:2326 E:2330 ||| CC
3H-inositol  ||| S:2330 E:2350 ||| CD
phosphate  ||| S:2350 E:2360 ||| JJ
accumulation ||| S:2360 E:2372 ||| NN
.  ||| S:2372 E:2374 ||| .
However ||| S:2374 E:2381 ||| RB
,  ||| S:2381 E:2383 ||| ,
a  ||| S:2383 E:2385 ||| DT
calcium  ||| S:2385 E:2393 ||| FW
ionophore  ||| S:2393 E:2411 ||| FW
stimulated  ||| S:2411 E:2422 ||| FW
LH  ||| S:2422 E:2425 ||| FW
secretion  ||| S:2425 E:2435 ||| FW
in  ||| S:2435 E:2438 ||| FW
RGS3-expressing  ||| S:2438 E:2454 ||| FW
gonadotropes ||| S:2454 E:2466 ||| FW
,  ||| S:2466 E:2476 ||| ,
confirming  ||| S:2476 E:2487 ||| VBG
a  ||| S:2487 E:2489 ||| DT
specific  ||| S:2489 E:2498 ||| JJ
site  ||| S:2498 E:2503 ||| NN
of  ||| S:2503 E:2506 ||| IN
action  ||| S:2506 E:2513 ||| NN
occurring  ||| S:2513 E:2523 ||| VBG
at  ||| S:2523 E:2534 ||| IN
phospholipase  ||| S:2534 E:2548 ||| JJ
Cβ  ||| S:2548 E:2551 ||| NNP
or  ||| S:2551 E:2554 ||| CC
earlier  ||| S:2554 E:2562 ||| RBR
in  ||| S:2562 E:2565 ||| IN
the  ||| S:2565 E:2569 ||| DT
signal  ||| S:2569 E:2576 ||| NN
transduction  ||| S:2576 E:2597 ||| NN
pathway ||| S:2597 E:2604 ||| NN
.  ||| S:2604 E:2628 ||| .
Results  ||| S:2628 E:2644 ||| NNS
The  ||| S:2644 E:2648 ||| DT
initial  ||| S:2648 E:2656 ||| JJ
experiments  ||| S:2656 E:2668 ||| NNS
were  ||| S:2668 E:2673 ||| VBD
performed  ||| S:2673 E:2683 ||| VBN
to  ||| S:2683 E:2686 ||| TO
confirm  ||| S:2686 E:2694 ||| VB
our  ||| S:2694 E:2706 ||| PRP$
earlier  ||| S:2706 E:2714 ||| JJR
finding  ||| S:2714 E:2722 ||| NN
that  ||| S:2722 E:2727 ||| IN
RGS3  ||| S:2727 E:2732 ||| NNP
suppressed  ||| S:2732 E:2743 ||| VBD
GnRH-stimulated  ||| S:2743 E:2759 ||| NNP
IP  ||| S:2759 E:2771 ||| NNP
3  ||| S:2771 E:2773 ||| CD
production  ||| S:2773 E:2784 ||| NN
in  ||| S:2784 E:2787 ||| IN
COS-1  ||| S:2787 E:2793 ||| CD
cells  ||| S:2793 E:2799 ||| NNS
[  ||| S:2799 E:2801 ||| -LRB-
9  ||| S:2801 E:2803 ||| CD
]  ||| S:2803 E:2805 ||| -RRB-
and  ||| S:2805 E:2809 ||| CC
to  ||| S:2809 E:2820 ||| TO
test  ||| S:2820 E:2825 ||| VB
a  ||| S:2825 E:2827 ||| DT
truncated  ||| S:2827 E:2837 ||| JJ
form  ||| S:2837 E:2842 ||| NN
of  ||| S:2842 E:2845 ||| IN
RGS3 ||| S:2845 E:2849 ||| NNP
,  ||| S:2849 E:2851 ||| ,
RGS3T  ||| S:2851 E:2857 ||| NNP
( ||| S:2857 E:2858 ||| -LRB-
RGS3  ||| S:2858 E:2863 ||| NNP
314-519 ||| S:2863 E:2870 ||| NNP
)  ||| S:2870 E:2872 ||| -RRB-
[  ||| S:2872 E:2874 ||| -LRB-
24  ||| S:2874 E:2877 ||| CD
]  ||| S:2877 E:2887 ||| -RRB-
for  ||| S:2887 E:2891 ||| IN
suppressive  ||| S:2891 E:2903 ||| JJ
activity  ||| S:2903 E:2912 ||| NN
in  ||| S:2912 E:2915 ||| IN
the  ||| S:2915 E:2919 ||| DT
same  ||| S:2919 E:2924 ||| JJ
assay  ||| S:2924 E:2930 ||| NNS
( ||| S:2930 E:2931 ||| -LRB-
Fig.  ||| S:2931 E:2936 ||| CD
1 ||| S:2936 E:2937 ||| CD
) ||| S:2937 E:2938 ||| -RRB-
.  ||| S:2938 E:2940 ||| .
cDNAs  ||| S:2940 E:2954 ||| JJ
representing  ||| S:2954 E:2967 ||| VBG
the  ||| S:2967 E:2971 ||| DT
GnRH  ||| S:2971 E:2976 ||| JJ
receptor  ||| S:2976 E:2985 ||| NN
and  ||| S:2985 E:2989 ||| CC
RGS3  ||| S:2989 E:2994 ||| NNP
or  ||| S:2994 E:2997 ||| CC
RGS3T  ||| S:2997 E:3003 ||| NNP
were  ||| S:3003 E:3016 ||| VBD
co-transfected  ||| S:3016 E:3031 ||| JJ
into  ||| S:3031 E:3036 ||| IN
COS-1  ||| S:3036 E:3042 ||| CD
cells  ||| S:3042 E:3048 ||| NNS
for  ||| S:3048 E:3052 ||| IN
GnRH-A  ||| S:3052 E:3059 ||| JJ
treatment  ||| S:3059 E:3069 ||| NN
72  ||| S:3069 E:3072 ||| CD
h  ||| S:3072 E:3082 ||| NNS
later ||| S:3082 E:3087 ||| RB
;  ||| S:3087 E:3089 ||| :
intracellular  ||| S:3089 E:3103 ||| JJ
IP  ||| S:3103 E:3115 ||| NNP
3  ||| S:3115 E:3117 ||| CD
concentrations  ||| S:3117 E:3132 ||| NNS
were  ||| S:3132 E:3137 ||| VBD
measured  ||| S:3137 E:3146 ||| VBN
at  ||| S:3146 E:3149 ||| IN
0 ||| S:3149 E:3150 ||| CD
,  ||| S:3150 E:3152 ||| ,
10 ||| S:3152 E:3154 ||| CD
,  ||| S:3154 E:3164 ||| ,
20 ||| S:3164 E:3166 ||| CD
,  ||| S:3166 E:3168 ||| ,
and  ||| S:3168 E:3172 ||| CC
30  ||| S:3172 E:3175 ||| CD
sec  ||| S:3175 E:3179 ||| NN
after  ||| S:3179 E:3185 ||| IN
addition  ||| S:3185 E:3194 ||| NN
of  ||| S:3194 E:3197 ||| IN
10  ||| S:3197 E:3200 ||| CD
-7M  ||| S:3200 E:3204 ||| CD
GnRH-A  ||| S:3204 E:3211 ||| NNS
( ||| S:3211 E:3212 ||| -LRB-
Fig.  ||| S:3212 E:3217 ||| CD
1 ||| S:3217 E:3218 ||| CD
) ||| S:3218 E:3219 ||| -RRB-
.  ||| S:3219 E:3221 ||| .
As  ||| S:3221 E:3232 ||| RB
expected ||| S:3232 E:3240 ||| VBN
,  ||| S:3240 E:3242 ||| ,
RGS3  ||| S:3242 E:3247 ||| NNP
exerted  ||| S:3247 E:3255 ||| VBD
a  ||| S:3255 E:3257 ||| DT
profound  ||| S:3257 E:3266 ||| JJ
suppression  ||| S:3266 E:3278 ||| NN
of  ||| S:3278 E:3281 ||| IN
IP  ||| S:3281 E:3293 ||| NNP
3  ||| S:3293 E:3295 ||| CD
production  ||| S:3295 E:3306 ||| NN
at  ||| S:3306 E:3309 ||| IN
each  ||| S:3309 E:3314 ||| DT
of  ||| S:3314 E:3317 ||| IN
the  ||| S:3317 E:3321 ||| DT
time  ||| S:3321 E:3326 ||| NN
points  ||| S:3326 E:3341 ||| NNS
during  ||| S:3341 E:3348 ||| IN
the  ||| S:3348 E:3352 ||| DT
30  ||| S:3352 E:3355 ||| CD
sec  ||| S:3355 E:3359 ||| NN
after  ||| S:3359 E:3365 ||| IN
agonist  ||| S:3365 E:3373 ||| JJ
treatment  ||| S:3373 E:3383 ||| NN
( ||| S:3383 E:3384 ||| -LRB-
p  ||| S:3384 E:3386 ||| CD
< ||| S:3386 E:3388 ||| SYM
0.05 ||| S:3388 E:3392 ||| CD
)  ||| S:3392 E:3402 ||| -RRB-
( ||| S:3402 E:3403 ||| -LRB-
Fig.  ||| S:3403 E:3408 ||| CD
1 ||| S:3408 E:3409 ||| CD
) ||| S:3409 E:3410 ||| -RRB-
.  ||| S:3410 E:3412 ||| .
RGS3T  ||| S:3412 E:3418 ||| NNP
is  ||| S:3418 E:3421 ||| VBZ
comprised  ||| S:3421 E:3431 ||| VBN
primarily  ||| S:3431 E:3441 ||| RB
by  ||| S:3441 E:3444 ||| IN
the  ||| S:3444 E:3448 ||| DT
consensus  ||| S:3448 E:3458 ||| NN
RGS  ||| S:3458 E:3470 ||| NNP
domain  ||| S:3470 E:3477 ||| NN
and  ||| S:3477 E:3481 ||| CC
was  ||| S:3481 E:3485 ||| VBD
originally  ||| S:3485 E:3496 ||| RB
reported  ||| S:3496 E:3505 ||| VBN
to  ||| S:3505 E:3508 ||| TO
decrease  ||| S:3508 E:3517 ||| VB
the  ||| S:3517 E:3521 ||| DT
growth  ||| S:3521 E:3536 ||| NN
rate  ||| S:3536 E:3541 ||| NN
of  ||| S:3541 E:3544 ||| IN
yeast  ||| S:3544 E:3550 ||| NN
and  ||| S:3550 E:3554 ||| CC
to  ||| S:3554 E:3557 ||| TO
inhibit  ||| S:3557 E:3565 ||| VB
IL-8  ||| S:3565 E:3570 ||| CD
receptor  ||| S:3570 E:3579 ||| NN
mediated  ||| S:3579 E:3596 ||| NN
activation  ||| S:3596 E:3607 ||| NN
of  ||| S:3607 E:3610 ||| IN
MAP  ||| S:3610 E:3614 ||| NNP
kinase  ||| S:3614 E:3621 ||| NN
by  ||| S:3621 E:3624 ||| IN
a  ||| S:3624 E:3626 ||| DT
factor  ||| S:3626 E:3633 ||| NN
of  ||| S:3633 E:3636 ||| IN
3-10  ||| S:3636 E:3641 ||| NNP
fold  ||| S:3641 E:3646 ||| VBP
as  ||| S:3646 E:3657 ||| RB
compared  ||| S:3657 E:3666 ||| VBN
to  ||| S:3666 E:3669 ||| TO
RGS3  ||| S:3669 E:3674 ||| CD
[  ||| S:3674 E:3676 ||| -LRB-
24  ||| S:3676 E:3679 ||| CD
]  ||| S:3679 E:3681 ||| -RRB-
and  ||| S:3681 E:3685 ||| CC
was  ||| S:3685 E:3689 ||| VBD
subsequently  ||| S:3689 E:3702 ||| RB
reported  ||| S:3702 E:3711 ||| VBN
to  ||| S:3711 E:3714 ||| TO
be  ||| S:3714 E:3725 ||| VB
a  ||| S:3725 E:3727 ||| DT
normally  ||| S:3727 E:3736 ||| RB
expressed  ||| S:3736 E:3746 ||| VBD
variant  ||| S:3746 E:3754 ||| VBN
of  ||| S:3754 E:3757 ||| IN
RGS3  ||| S:3757 E:3762 ||| NNP
[  ||| S:3762 E:3764 ||| -LRB-
37  ||| S:3764 E:3767 ||| CD
]  ||| S:3767 E:3769 ||| -RRB-
.  ||| S:3769 E:3771 ||| .
Therefore ||| S:3771 E:3780 ||| RB
,  ||| S:3780 E:3782 ||| ,
we  ||| S:3782 E:3793 ||| PRP
compared  ||| S:3793 E:3802 ||| VBD
it  ||| S:3802 E:3805 ||| PRP
to  ||| S:3805 E:3808 ||| TO
RGS3  ||| S:3808 E:3813 ||| CD
for  ||| S:3813 E:3817 ||| IN
attenuation  ||| S:3817 E:3829 ||| NN
of  ||| S:3829 E:3832 ||| IN
GnRH-stimulated  ||| S:3832 E:3848 ||| NNP
IP  ||| S:3848 E:3860 ||| NNP
3  ||| S:3860 E:3862 ||| CD
production  ||| S:3862 E:3873 ||| NN
in  ||| S:3873 E:3876 ||| IN
COS-1  ||| S:3876 E:3882 ||| CD
cells  ||| S:3882 E:3888 ||| NNS
( ||| S:3888 E:3889 ||| -LRB-
Fig.  ||| S:3889 E:3894 ||| CD
1 ||| S:3894 E:3895 ||| CD
) ||| S:3895 E:3896 ||| -RRB-
.  ||| S:3896 E:3898 ||| .
As  ||| S:3898 E:3909 ||| RB
reported  ||| S:3909 E:3918 ||| VBN
by  ||| S:3918 E:3921 ||| IN
others  ||| S:3921 E:3928 ||| NNS
[  ||| S:3928 E:3930 ||| -LRB-
24  ||| S:3930 E:3933 ||| CD
37  ||| S:3933 E:3936 ||| CD
]  ||| S:3936 E:3938 ||| -RRB-
,  ||| S:3938 E:3940 ||| ,
we  ||| S:3940 E:3943 ||| PRP
found  ||| S:3943 E:3949 ||| VBD
that  ||| S:3949 E:3954 ||| IN
RGS3T  ||| S:3954 E:3960 ||| NNP
was  ||| S:3960 E:3964 ||| VBD
more  ||| S:3964 E:3977 ||| RBR
potent  ||| S:3977 E:3984 ||| JJ
than  ||| S:3984 E:3989 ||| IN
RGS3  ||| S:3989 E:3994 ||| NNP
( ||| S:3994 E:3995 ||| -LRB-
p  ||| S:3995 E:3997 ||| CD
< ||| S:3997 E:3999 ||| SYM
0.05 ||| S:3999 E:4003 ||| CD
)  ||| S:4003 E:4005 ||| -RRB-
( ||| S:4005 E:4006 ||| -LRB-
Fig.  ||| S:4006 E:4011 ||| CD
1 ||| S:4011 E:4012 ||| CD
) ||| S:4012 E:4013 ||| -RRB-
.  ||| S:4013 E:4015 ||| .
Identification  ||| S:4015 E:4030 ||| NN
of  ||| S:4030 E:4041 ||| IN
a  ||| S:4041 E:4043 ||| DT
C-terminal  ||| S:4043 E:4054 ||| JJ
205  ||| S:4054 E:4058 ||| CD
amino  ||| S:4058 E:4064 ||| JJ
acid  ||| S:4064 E:4069 ||| NN
variant  ||| S:4069 E:4077 ||| NN
of  ||| S:4077 E:4080 ||| IN
RGS3  ||| S:4080 E:4085 ||| NNP
that  ||| S:4085 E:4090 ||| WDT
has  ||| S:4090 E:4094 ||| VBZ
equal  ||| S:4094 E:4108 ||| JJ
or  ||| S:4108 E:4111 ||| CC
greater  ||| S:4111 E:4119 ||| JJR
potency  ||| S:4119 E:4127 ||| NN
than  ||| S:4127 E:4132 ||| IN
the  ||| S:4132 E:4136 ||| DT
full-length  ||| S:4136 E:4148 ||| JJ
519  ||| S:4148 E:4152 ||| CD
amino  ||| S:4152 E:4158 ||| JJ
acid  ||| S:4158 E:4163 ||| NN
RGS3  ||| S:4163 E:4176 ||| NN
will  ||| S:4176 E:4181 ||| MD
facilitate  ||| S:4181 E:4192 ||| VB
the  ||| S:4192 E:4196 ||| DT
identification  ||| S:4196 E:4211 ||| NN
of  ||| S:4211 E:4214 ||| IN
RGS3  ||| S:4214 E:4219 ||| CD
functional  ||| S:4219 E:4238 ||| JJ
protein  ||| S:4238 E:4246 ||| NN
domains  ||| S:4246 E:4254 ||| NNS
that  ||| S:4254 E:4259 ||| WDT
are  ||| S:4259 E:4263 ||| VBP
important  ||| S:4263 E:4273 ||| JJ
for  ||| S:4273 E:4277 ||| IN
its  ||| S:4277 E:4281 ||| PRP$
activity ||| S:4281 E:4289 ||| NN
.  ||| S:4289 E:4299 ||| .
The  ||| S:4299 E:4303 ||| DT
family  ||| S:4303 E:4310 ||| NN
of  ||| S:4310 E:4313 ||| IN
RGS  ||| S:4313 E:4317 ||| NNP
proteins  ||| S:4317 E:4326 ||| NNS
are  ||| S:4326 E:4330 ||| VBP
established  ||| S:4330 E:4342 ||| VBN
to  ||| S:4342 E:4345 ||| TO
interact  ||| S:4345 E:4362 ||| VB
with  ||| S:4362 E:4367 ||| IN
various  ||| S:4367 E:4375 ||| JJ
Gα-protein  ||| S:4375 E:4386 ||| JJ
subunits ||| S:4386 E:4394 ||| NN
,  ||| S:4394 E:4396 ||| ,
thereby  ||| S:4396 E:4404 ||| RB
antagonizing  ||| S:4404 E:4425 ||| VB
their  ||| S:4425 E:4431 ||| PRP$
activities  ||| S:4431 E:4442 ||| NNS
[  ||| S:4442 E:4444 ||| -LRB-
13  ||| S:4444 E:4447 ||| CD
14  ||| S:4447 E:4450 ||| CD
15  ||| S:4450 E:4453 ||| CD
16  ||| S:4453 E:4456 ||| CD
17  ||| S:4456 E:4459 ||| CD
18  ||| S:4459 E:4462 ||| CD
24  ||| S:4462 E:4465 ||| CD
]  ||| S:4465 E:4467 ||| -RRB-
.  ||| S:4467 E:4469 ||| .
Indeed ||| S:4469 E:4475 ||| RB
,  ||| S:4475 E:4477 ||| ,
we  ||| S:4477 E:4488 ||| PRP
previously  ||| S:4488 E:4499 ||| RB
reported  ||| S:4499 E:4508 ||| VBN
that  ||| S:4508 E:4513 ||| IN
RGS3  ||| S:4513 E:4518 ||| FW
bound  ||| S:4518 E:4524 ||| FW
Gqα  ||| S:4524 E:4528 ||| FW
[  ||| S:4528 E:4530 ||| -LRB-
9  ||| S:4530 E:4532 ||| CD
]  ||| S:4532 E:4534 ||| -RRB-
,  ||| S:4534 E:4536 ||| ,
the  ||| S:4536 E:4540 ||| DT
G  ||| S:4540 E:4550 ||| NNP
protein  ||| S:4550 E:4558 ||| NN
subunit  ||| S:4558 E:4566 ||| NN
that  ||| S:4566 E:4571 ||| IN
mediates  ||| S:4571 E:4580 ||| JJ
GnRH  ||| S:4580 E:4585 ||| JJ
receptor  ||| S:4585 E:4594 ||| NN
signaling  ||| S:4594 E:4604 ||| NNS
[  ||| S:4604 E:4606 ||| -LRB-
38  ||| S:4606 E:4617 ||| CD
]  ||| S:4617 E:4619 ||| -RRB-
.  ||| S:4619 E:4621 ||| .
Here ||| S:4621 E:4625 ||| RB
,  ||| S:4625 E:4627 ||| ,
we  ||| S:4627 E:4630 ||| PRP
have  ||| S:4630 E:4635 ||| VBP
extended  ||| S:4635 E:4644 ||| VBN
those  ||| S:4644 E:4650 ||| DT
binding  ||| S:4650 E:4658 ||| JJ
studies  ||| S:4658 E:4666 ||| NNS
to  ||| S:4666 E:4669 ||| TO
include  ||| S:4669 E:4685 ||| VB
other  ||| S:4685 E:4691 ||| JJ
Gα  ||| S:4691 E:4694 ||| JJ
proteins  ||| S:4694 E:4703 ||| NNS
( ||| S:4703 E:4704 ||| -LRB-
Fig.  ||| S:4704 E:4709 ||| CD
2 ||| S:4709 E:4710 ||| CD
) ||| S:4710 E:4711 ||| -RRB-
.  ||| S:4711 E:4713 ||| .
An  ||| S:4713 E:4716 ||| DT
RGS3-GST  ||| S:4716 E:4725 ||| JJ
fusion  ||| S:4725 E:4732 ||| NN
protein  ||| S:4732 E:4740 ||| NN
was  ||| S:4740 E:4752 ||| VBD
incubated  ||| S:4752 E:4762 ||| VBN
with  ||| S:4762 E:4767 ||| IN
an  ||| S:4767 E:4770 ||| DT
35S-Met-Gα-protein ||| S:4770 E:4788 ||| NNP
,  ||| S:4788 E:4790 ||| ,
and  ||| S:4790 E:4794 ||| CC
the  ||| S:4794 E:4798 ||| DT
amount  ||| S:4798 E:4805 ||| NN
of  ||| S:4805 E:4816 ||| IN
labeled  ||| S:4816 E:4824 ||| JJ
Gα-protein  ||| S:4824 E:4835 ||| NN
was  ||| S:4835 E:4839 ||| VBD
determined  ||| S:4839 E:4850 ||| VBN
using  ||| S:4850 E:4856 ||| VBG
glutathione-coupled  ||| S:4856 E:4884 ||| JJ
beads  ||| S:4884 E:4890 ||| NN
to  ||| S:4890 E:4893 ||| TO
"pull  ||| S:4893 E:4899 ||| CD
down ||| S:4899 E:4903 ||| IN
"  ||| S:4903 E:4905 ||| ``
the  ||| S:4905 E:4909 ||| DT
RGS3-GST ||| S:4909 E:4917 ||| CD
/  ||| S:4917 E:4919 ||| CD
35S-Gα-protein  ||| S:4919 E:4934 ||| CD
complex  ||| S:4934 E:4950 ||| NN
that  ||| S:4950 E:4955 ||| WDT
was  ||| S:4955 E:4959 ||| VBD
then  ||| S:4959 E:4964 ||| RB
separated  ||| S:4964 E:4974 ||| VBN
and  ||| S:4974 E:4978 ||| CC
quantified  ||| S:4978 E:4989 ||| VBN
by  ||| S:4989 E:4992 ||| IN
SDS ||| S:4992 E:4995 ||| NNP
/ ||| S:4995 E:4996 ||| NNP
PAGE  ||| S:4996 E:5001 ||| NNP
( ||| S:5001 E:5002 ||| -LRB-
Fig.  ||| S:5002 E:5015 ||| CD
2 ||| S:5015 E:5016 ||| CD
) ||| S:5016 E:5017 ||| -RRB-
.  ||| S:5017 E:5019 ||| .
More  ||| S:5019 E:5024 ||| JJR
Gqα  ||| S:5024 E:5028 ||| NNP
was  ||| S:5028 E:5032 ||| VBD
bound  ||| S:5032 E:5038 ||| VBN
by  ||| S:5038 E:5041 ||| IN
RGS3  ||| S:5041 E:5046 ||| CD
than  ||| S:5046 E:5051 ||| IN
any  ||| S:5051 E:5055 ||| DT
other  ||| S:5055 E:5061 ||| JJ
protein ||| S:5061 E:5068 ||| NN
,  ||| S:5068 E:5078 ||| ,
although  ||| S:5078 E:5087 ||| IN
its  ||| S:5087 E:5091 ||| PRP$
binding  ||| S:5091 E:5099 ||| NN
was  ||| S:5099 E:5103 ||| VBD
not  ||| S:5103 E:5107 ||| RB
significantly  ||| S:5107 E:5121 ||| RB
different  ||| S:5121 E:5131 ||| JJ
from  ||| S:5131 E:5144 ||| IN
that  ||| S:5144 E:5149 ||| DT
of  ||| S:5149 E:5152 ||| IN
Gzα  ||| S:5152 E:5156 ||| NNP
and  ||| S:5156 E:5160 ||| CC
Giα  ||| S:5160 E:5164 ||| NNP
( ||| S:5164 E:5165 ||| -LRB-
p  ||| S:5165 E:5167 ||| CD
>  ||| S:5167 E:5169 ||| CD
0.05 ||| S:5169 E:5173 ||| CD
) ||| S:5173 E:5174 ||| -RRB-
.  ||| S:5174 E:5176 ||| .
Significant  ||| S:5176 E:5188 ||| JJ
( ||| S:5188 E:5189 ||| -LRB-
p  ||| S:5189 E:5191 ||| CD
< ||| S:5191 E:5192 ||| SYM
0.05 ||| S:5201 E:5205 ||| CD
)  ||| S:5205 E:5207 ||| -RRB-
amounts  ||| S:5207 E:5215 ||| NNS
of  ||| S:5215 E:5218 ||| IN
Gi2α ||| S:5218 E:5222 ||| NNP
,  ||| S:5222 E:5224 ||| ,
Gi1α ||| S:5224 E:5228 ||| NNP
,  ||| S:5228 E:5230 ||| ,
Goα ||| S:5230 E:5233 ||| NNP
,  ||| S:5233 E:5235 ||| ,
and  ||| S:5235 E:5239 ||| CC
Gsα  ||| S:5239 E:5243 ||| NNP
also  ||| S:5243 E:5248 ||| RB
were  ||| S:5248 E:5253 ||| VBD
bound  ||| S:5253 E:5267 ||| VBN
but  ||| S:5267 E:5271 ||| CC
were  ||| S:5271 E:5276 ||| VBD
not  ||| S:5276 E:5280 ||| RB
as  ||| S:5280 E:5283 ||| IN
high  ||| S:5283 E:5288 ||| JJ
as  ||| S:5288 E:5291 ||| IN
Gqα ||| S:5291 E:5294 ||| NNP
,  ||| S:5294 E:5296 ||| ,
Gzα ||| S:5296 E:5299 ||| NNP
,  ||| S:5299 E:5301 ||| ,
and  ||| S:5301 E:5305 ||| CC
Gi3α ||| S:5305 E:5309 ||| NNP
.  ||| S:5309 E:5311 ||| .
These  ||| S:5311 E:5317 ||| DT
results  ||| S:5317 E:5333 ||| NNS
confirm  ||| S:5333 E:5341 ||| VBP
our  ||| S:5341 E:5345 ||| PRP$
previous  ||| S:5345 E:5354 ||| JJ
findings  ||| S:5354 E:5363 ||| NNS
that  ||| S:5363 E:5368 ||| IN
RGS3  ||| S:5368 E:5373 ||| CD
interacts  ||| S:5373 E:5383 ||| NN
with  ||| S:5383 E:5388 ||| IN
Gqα  ||| S:5388 E:5400 ||| NNP
but  ||| S:5400 E:5404 ||| CC
also  ||| S:5404 E:5409 ||| RB
show  ||| S:5409 E:5414 ||| VB
that  ||| S:5414 E:5419 ||| IN
it  ||| S:5419 E:5422 ||| PRP
has  ||| S:5422 E:5426 ||| VBZ
significant  ||| S:5426 E:5438 ||| JJ
interaction  ||| S:5438 E:5450 ||| NN
with  ||| S:5450 E:5455 ||| IN
all  ||| S:5455 E:5467 ||| DT
other  ||| S:5467 E:5473 ||| JJ
Gα-proteins  ||| S:5473 E:5485 ||| JJ
studied ||| S:5485 E:5492 ||| NN
.  ||| S:5492 E:5502 ||| .
The  ||| S:5502 E:5506 ||| DT
findings  ||| S:5506 E:5515 ||| NNS
of  ||| S:5515 E:5518 ||| IN
the  ||| S:5518 E:5522 ||| DT
current ||| S:5522 E:5529 ||| JJ
,  ||| S:5529 E:5531 ||| ,
and  ||| S:5531 E:5535 ||| CC
an  ||| S:5535 E:5538 ||| DT
earlier  ||| S:5538 E:5546 ||| JJR
study  ||| S:5546 E:5552 ||| NN
[  ||| S:5552 E:5554 ||| -LRB-
9  ||| S:5554 E:5556 ||| CD
]  ||| S:5556 E:5566 ||| -RRB-
,  ||| S:5566 E:5568 ||| ,
demonstrate  ||| S:5568 E:5580 ||| VBP
clearly  ||| S:5580 E:5588 ||| RB
that  ||| S:5588 E:5593 ||| IN
RGS3  ||| S:5593 E:5598 ||| CD
suppresses  ||| S:5598 E:5609 ||| CD
GnRH  ||| S:5609 E:5614 ||| JJ
receptor  ||| S:5614 E:5631 ||| NN
signaling  ||| S:5631 E:5641 ||| VBG
in  ||| S:5641 E:5644 ||| IN
a  ||| S:5644 E:5646 ||| DT
heterologous  ||| S:5646 E:5659 ||| JJ
cell  ||| S:5659 E:5664 ||| NN
system ||| S:5664 E:5670 ||| NN
.  ||| S:5670 E:5672 ||| .
Because  ||| S:5672 E:5680 ||| IN
of  ||| S:5680 E:5683 ||| IN
the  ||| S:5683 E:5695 ||| DT
evidence  ||| S:5695 E:5704 ||| NN
that  ||| S:5704 E:5709 ||| IN
the  ||| S:5709 E:5713 ||| DT
signal  ||| S:5713 E:5720 ||| NN
transduction  ||| S:5720 E:5733 ||| NN
pathway  ||| S:5733 E:5741 ||| NN
for  ||| S:5741 E:5745 ||| IN
GnRH  ||| S:5745 E:5750 ||| JJ
in  ||| S:5750 E:5761 ||| IN
gonadotropes  ||| S:5761 E:5774 ||| NN
involves  ||| S:5774 E:5783 ||| VBZ
the  ||| S:5783 E:5787 ||| DT
GnRH  ||| S:5787 E:5792 ||| JJ
receptor ||| S:5792 E:5800 ||| NN
,  ||| S:5800 E:5802 ||| ,
Gqα ||| S:5802 E:5805 ||| NNP
,  ||| S:5805 E:5807 ||| ,
phospholipase  ||| S:5807 E:5829 ||| VBG
Cβ ||| S:5829 E:5831 ||| NNP
,  ||| S:5831 E:5833 ||| ,
and  ||| S:5833 E:5837 ||| CC
cellular  ||| S:5837 E:5846 ||| JJ
IP  ||| S:5846 E:5858 ||| NNP
3  ||| S:5858 E:5860 ||| CD
release  ||| S:5860 E:5868 ||| NN
[  ||| S:5868 E:5870 ||| -LRB-
39  ||| S:5870 E:5873 ||| CD
40  ||| S:5873 E:5876 ||| CD
]  ||| S:5876 E:5878 ||| -RRB-
,  ||| S:5878 E:5880 ||| ,
we  ||| S:5880 E:5883 ||| PRP
determined  ||| S:5883 E:5894 ||| VBD
the  ||| S:5894 E:5906 ||| DT
effect  ||| S:5906 E:5913 ||| NN
of  ||| S:5913 E:5916 ||| IN
RGS3  ||| S:5916 E:5921 ||| CD
on  ||| S:5921 E:5924 ||| IN
GnRH-stimulated  ||| S:5924 E:5940 ||| NNP
LH  ||| S:5940 E:5943 ||| NNP
secretion  ||| S:5943 E:5953 ||| VBZ
using  ||| S:5953 E:5967 ||| VBG
adenoviral-mediated  ||| S:5967 E:5987 ||| JJ
gene  ||| S:5987 E:5992 ||| NN
transfer  ||| S:5992 E:6001 ||| NN
in  ||| S:6001 E:6004 ||| IN
rat  ||| S:6004 E:6008 ||| JJ
pituitary  ||| S:6008 E:6018 ||| JJ
cells  ||| S:6018 E:6032 ||| NNS
( ||| S:6032 E:6033 ||| -LRB-
Fig.  ||| S:6033 E:6038 ||| CD
3 ||| S:6038 E:6039 ||| CD
) ||| S:6039 E:6040 ||| -RRB-
.  ||| S:6040 E:6042 ||| .
In  ||| S:6042 E:6045 ||| IN
these  ||| S:6045 E:6051 ||| DT
experiments ||| S:6051 E:6062 ||| NNS
,  ||| S:6062 E:6064 ||| ,
we  ||| S:6064 E:6067 ||| PRP
performed  ||| S:6067 E:6077 ||| VBD
a  ||| S:6077 E:6087 ||| DT
dose-response  ||| S:6087 E:6101 ||| JJ
test  ||| S:6101 E:6106 ||| NN
that  ||| S:6106 E:6111 ||| WDT
included  ||| S:6111 E:6120 ||| VBD
three  ||| S:6120 E:6126 ||| CD
experimental  ||| S:6126 E:6139 ||| JJ
groups ||| S:6139 E:6145 ||| NNS
:  ||| S:6145 E:6155 ||| :
uninfected ||| S:6155 E:6165 ||| CD
,  ||| S:6165 E:6167 ||| ,
adeno-β  ||| S:6167 E:6175 ||| JJ
galactosidase ||| S:6175 E:6188 ||| NN
,  ||| S:6188 E:6190 ||| ,
and  ||| S:6190 E:6194 ||| CC
adeno-RGS3  ||| S:6194 E:6205 ||| CD
infected ||| S:6205 E:6213 ||| NNS
.  ||| S:6213 E:6223 ||| .
Adeno-βgal  ||| S:6223 E:6234 ||| JJ
infection  ||| S:6234 E:6244 ||| NN
was  ||| S:6244 E:6248 ||| VBD
used  ||| S:6248 E:6253 ||| VBN
for  ||| S:6253 E:6257 ||| IN
determination  ||| S:6257 E:6271 ||| NN
of  ||| S:6271 E:6274 ||| IN
the  ||| S:6274 E:6286 ||| DT
fraction  ||| S:6286 E:6295 ||| NN
of  ||| S:6295 E:6298 ||| IN
cells  ||| S:6298 E:6304 ||| NNS
infected  ||| S:6304 E:6313 ||| VBN
at  ||| S:6313 E:6316 ||| IN
each  ||| S:6316 E:6321 ||| DT
dose  ||| S:6321 E:6326 ||| NN
of  ||| S:6326 E:6329 ||| IN
virus  ||| S:6329 E:6335 ||| NN
( ||| S:6335 E:6336 ||| -LRB-
Fig.  ||| S:6336 E:6341 ||| CD
3 ||| S:6341 E:6342 ||| CD
,  ||| S:6342 E:6352 ||| ,
top  ||| S:6352 E:6356 ||| JJ
panel ||| S:6356 E:6361 ||| NN
)  ||| S:6361 E:6363 ||| -RRB-
and  ||| S:6363 E:6367 ||| CC
as  ||| S:6367 E:6370 ||| IN
a  ||| S:6370 E:6372 ||| DT
control  ||| S:6372 E:6380 ||| NN
for  ||| S:6380 E:6384 ||| IN
the  ||| S:6384 E:6388 ||| DT
effects  ||| S:6388 E:6396 ||| NNS
of  ||| S:6396 E:6399 ||| IN
adeno-RGS3  ||| S:6399 E:6418 ||| CD
on  ||| S:6418 E:6421 ||| IN
GnRH-stimulated  ||| S:6421 E:6437 ||| NNP
LH  ||| S:6437 E:6440 ||| NNP
secretion  ||| S:6440 E:6450 ||| NNS
( ||| S:6450 E:6451 ||| -LRB-
Fig.  ||| S:6451 E:6456 ||| CD
3 ||| S:6456 E:6457 ||| CD
,  ||| S:6457 E:6459 ||| ,
middle  ||| S:6459 E:6466 ||| JJ
panel ||| S:6466 E:6471 ||| NN
) ||| S:6471 E:6472 ||| -RRB-
.  ||| S:6472 E:6482 ||| .
Cell  ||| S:6482 E:6487 ||| NN
viability ||| S:6487 E:6496 ||| NN
,  ||| S:6496 E:6498 ||| ,
measured  ||| S:6498 E:6507 ||| VBN
as  ||| S:6507 E:6510 ||| IN
trypan  ||| S:6510 E:6517 ||| JJ
blue  ||| S:6517 E:6522 ||| JJ
exclusion ||| S:6522 E:6531 ||| NN
,  ||| S:6531 E:6533 ||| ,
varied  ||| S:6533 E:6548 ||| VBN
from  ||| S:6548 E:6553 ||| IN
98.5-100.0 ||| S:6553 E:6563 ||| CD
%  ||| S:6563 E:6565 ||| NN
( ||| S:6565 E:6566 ||| -LRB-
Fig.  ||| S:6566 E:6571 ||| CD
3 ||| S:6571 E:6572 ||| CD
,  ||| S:6572 E:6574 ||| ,
top  ||| S:6574 E:6578 ||| JJ
panel ||| S:6578 E:6583 ||| NN
) ||| S:6583 E:6584 ||| -RRB-
.  ||| S:6584 E:6586 ||| .
The  ||| S:6586 E:6590 ||| DT
fraction  ||| S:6590 E:6599 ||| NN
of  ||| S:6599 E:6602 ||| IN
cells  ||| S:6602 E:6616 ||| NNS
infected  ||| S:6616 E:6625 ||| VBN
by  ||| S:6625 E:6628 ||| IN
the  ||| S:6628 E:6632 ||| DT
adenovirus  ||| S:6632 E:6643 ||| NN
depended  ||| S:6643 E:6652 ||| VBD
on  ||| S:6652 E:6655 ||| IN
viral  ||| S:6655 E:6661 ||| JJ
dose  ||| S:6661 E:6666 ||| NN
( ||| S:6666 E:6667 ||| -LRB-
0-5.0  ||| S:6667 E:6681 ||| NNP
M.O.I. ||| S:6681 E:6687 ||| NNP
;  ||| S:6687 E:6689 ||| :
1  ||| S:6689 E:6691 ||| CD
M.O.I.  ||| S:6691 E:6698 ||| CD
=  ||| S:6698 E:6700 ||| SYM
1  ||| S:6700 E:6702 ||| CD
viral  ||| S:6702 E:6708 ||| FW
particle ||| S:6708 E:6716 ||| FW
/ ||| S:6716 E:6717 ||| FW
pituitary  ||| S:6717 E:6727 ||| FW
cell ||| S:6727 E:6731 ||| FW
)  ||| S:6731 E:6733 ||| -RRB-
and  ||| S:6733 E:6745 ||| CC
ranged  ||| S:6745 E:6752 ||| VBD
from  ||| S:6752 E:6757 ||| IN
about  ||| S:6757 E:6763 ||| IN
2 ||| S:6763 E:6764 ||| CD
%  ||| S:6764 E:6766 ||| NN
( ||| S:6766 E:6767 ||| -LRB-
no  ||| S:6767 E:6770 ||| UH
adenovirus ||| S:6770 E:6780 ||| UH
)  ||| S:6780 E:6782 ||| -RRB-
to  ||| S:6782 E:6785 ||| TO
99.5 ||| S:6785 E:6789 ||| CD
%  ||| S:6789 E:6791 ||| NN
( ||| S:6791 E:6792 ||| -LRB-
5.0  ||| S:6792 E:6796 ||| CD
M.O.I. ||| S:6796 E:6802 ||| CD
) ||| S:6802 E:6803 ||| -RRB-
.  ||| S:6803 E:6813 ||| .
Adeno-βgal  ||| S:6813 E:6824 ||| NNP
had  ||| S:6824 E:6828 ||| VBD
no  ||| S:6828 E:6831 ||| DT
effect  ||| S:6831 E:6838 ||| NN
on  ||| S:6838 E:6841 ||| IN
LH  ||| S:6841 E:6844 ||| NNP
secretion  ||| S:6844 E:6854 ||| NN
at  ||| S:6854 E:6857 ||| IN
any  ||| S:6857 E:6861 ||| DT
dose  ||| S:6861 E:6874 ||| NN
compared  ||| S:6874 E:6883 ||| VBN
to  ||| S:6883 E:6886 ||| TO
the  ||| S:6886 E:6890 ||| DT
uninfected  ||| S:6890 E:6901 ||| JJ
group  ||| S:6901 E:6907 ||| NN
( ||| S:6907 E:6908 ||| -LRB-
Fig.  ||| S:6908 E:6913 ||| CD
3 ||| S:6913 E:6914 ||| CD
,  ||| S:6914 E:6916 ||| ,
middle  ||| S:6916 E:6923 ||| JJ
panel ||| S:6923 E:6928 ||| NN
) ||| S:6928 E:6929 ||| -RRB-
.  ||| S:6929 E:6931 ||| .
In  ||| S:6931 E:6942 ||| IN
contrast ||| S:6942 E:6950 ||| NN
,  ||| S:6950 E:6952 ||| ,
an  ||| S:6952 E:6955 ||| DT
inverse  ||| S:6955 E:6963 ||| JJ
dose-related  ||| S:6963 E:6976 ||| JJ
effect  ||| S:6976 E:6983 ||| NN
was  ||| S:6983 E:6987 ||| VBD
observed  ||| S:6987 E:7004 ||| VBN
between  ||| S:7004 E:7012 ||| IN
adeno-RGS3  ||| S:7012 E:7023 ||| NNP
and  ||| S:7023 E:7027 ||| CC
GnRH-stimulated  ||| S:7027 E:7043 ||| NNP
LH  ||| S:7043 E:7046 ||| NNP
secretion  ||| S:7046 E:7056 ||| NNS
( ||| S:7056 E:7057 ||| -LRB-
Fig.  ||| S:7057 E:7070 ||| CD
3 ||| S:7070 E:7071 ||| CD
,  ||| S:7071 E:7073 ||| ,
bottom  ||| S:7073 E:7080 ||| JJ
panel ||| S:7080 E:7085 ||| NN
) ||| S:7085 E:7086 ||| -RRB-
.  ||| S:7086 E:7088 ||| .
RGS3  ||| S:7088 E:7093 ||| CD
0.2  ||| S:7093 E:7097 ||| CD
M.O.I.  ||| S:7097 E:7104 ||| CD
was  ||| S:7104 E:7108 ||| VBD
the  ||| S:7108 E:7112 ||| DT
lowest  ||| S:7112 E:7119 ||| JJS
dose  ||| S:7119 E:7124 ||| NN
to  ||| S:7124 E:7135 ||| TO
inhibit  ||| S:7135 E:7143 ||| VB
LH  ||| S:7143 E:7146 ||| JJ
secretion  ||| S:7146 E:7156 ||| NNS
( ||| S:7156 E:7157 ||| -LRB-
p  ||| S:7157 E:7159 ||| CD
< ||| S:7159 E:7161 ||| SYM
0.05 ||| S:7161 E:7165 ||| CD
) ||| S:7165 E:7166 ||| -RRB-
,  ||| S:7166 E:7168 ||| ,
and  ||| S:7168 E:7172 ||| CC
2.0  ||| S:7172 E:7176 ||| CD
and  ||| S:7176 E:7180 ||| CC
5.0  ||| S:7180 E:7184 ||| CD
M.O.I.  ||| S:7184 E:7199 ||| CD
exerted  ||| S:7199 E:7207 ||| NN
near  ||| S:7207 E:7212 ||| IN
complete  ||| S:7212 E:7221 ||| JJ
inhibition  ||| S:7221 E:7232 ||| NN
of  ||| S:7232 E:7235 ||| IN
LH  ||| S:7235 E:7238 ||| NNP
secretion ||| S:7238 E:7247 ||| NN
;  ||| S:7247 E:7249 ||| :
i.e.  ||| S:7249 E:7254 ||| FW
LH  ||| S:7254 E:7265 ||| FW
concentrations  ||| S:7265 E:7280 ||| NNS
in  ||| S:7280 E:7283 ||| IN
these  ||| S:7283 E:7289 ||| DT
two  ||| S:7289 E:7293 ||| CD
latter  ||| S:7293 E:7300 ||| JJ
GnRH-treated  ||| S:7300 E:7313 ||| JJ
groups  ||| S:7313 E:7320 ||| NNS
did  ||| S:7320 E:7332 ||| VBD
not  ||| S:7332 E:7336 ||| RB
differ  ||| S:7336 E:7343 ||| VB
from  ||| S:7343 E:7348 ||| IN
their  ||| S:7348 E:7354 ||| PRP$
cohort  ||| S:7354 E:7361 ||| JJ
controls  ||| S:7361 E:7370 ||| NNS
( ||| S:7370 E:7371 ||| -LRB-
p  ||| S:7371 E:7373 ||| CD
>  ||| S:7373 E:7375 ||| CD
0.05 ||| S:7375 E:7379 ||| CD
) ||| S:7379 E:7380 ||| -RRB-
.  ||| S:7380 E:7390 ||| .
The  ||| S:7390 E:7394 ||| DT
profound  ||| S:7394 E:7403 ||| JJ
inhibition  ||| S:7403 E:7414 ||| NN
of  ||| S:7414 E:7417 ||| IN
GnRH-stimulated  ||| S:7417 E:7433 ||| NNP
LH  ||| S:7433 E:7436 ||| NNP
secretion  ||| S:7436 E:7454 ||| VBD
observed  ||| S:7454 E:7463 ||| VBN
in  ||| S:7463 E:7466 ||| IN
Fig.  ||| S:7466 E:7471 ||| CD
3required  ||| S:7471 E:7481 ||| CD
verification  ||| S:7481 E:7494 ||| NN
that  ||| S:7494 E:7499 ||| IN
RGS3  ||| S:7499 E:7512 ||| CD
expression  ||| S:7512 E:7523 ||| NN
was  ||| S:7523 E:7527 ||| VBD
induced  ||| S:7527 E:7535 ||| VBN
by  ||| S:7535 E:7538 ||| IN
adeno-RGS3  ||| S:7538 E:7549 ||| CD
infection ||| S:7549 E:7558 ||| NN
.  ||| S:7558 E:7560 ||| .
To  ||| S:7560 E:7563 ||| TO
address  ||| S:7563 E:7579 ||| VB
this  ||| S:7579 E:7584 ||| DT
issue ||| S:7584 E:7589 ||| NN
,  ||| S:7589 E:7591 ||| ,
we  ||| S:7591 E:7594 ||| PRP
performed  ||| S:7594 E:7604 ||| VBD
RGS3  ||| S:7604 E:7609 ||| CD
immunoblots  ||| S:7609 E:7621 ||| NNS
( ||| S:7621 E:7622 ||| -LRB-
Fig.  ||| S:7622 E:7627 ||| CD
4 ||| S:7627 E:7628 ||| CD
)  ||| S:7628 E:7630 ||| -RRB-
which  ||| S:7630 E:7644 ||| WDT
showed  ||| S:7644 E:7651 ||| VBD
an  ||| S:7651 E:7654 ||| DT
increase  ||| S:7654 E:7663 ||| NN
in  ||| S:7663 E:7666 ||| IN
RGS3  ||| S:7666 E:7671 ||| CD
protein  ||| S:7671 E:7679 ||| NN
expression  ||| S:7679 E:7690 ||| NN
in  ||| S:7690 E:7693 ||| IN
adeno-RGS3  ||| S:7693 E:7712 ||| NNP
( ||| S:7712 E:7713 ||| -LRB-
5.0  ||| S:7713 E:7717 ||| CD
M.O.I. ||| S:7717 E:7723 ||| CD
)  ||| S:7723 E:7725 ||| -RRB-
infected  ||| S:7725 E:7734 ||| JJ
pituitary  ||| S:7734 E:7744 ||| JJ
cells  ||| S:7744 E:7750 ||| NNS
as  ||| S:7750 E:7753 ||| RB
compared  ||| S:7753 E:7762 ||| VBN
to  ||| S:7762 E:7765 ||| TO
low  ||| S:7765 E:7769 ||| JJ
to  ||| S:7769 E:7780 ||| TO
negligible  ||| S:7780 E:7791 ||| JJ
levels  ||| S:7791 E:7798 ||| NNS
of  ||| S:7798 E:7801 ||| IN
protein  ||| S:7801 E:7809 ||| NN
in  ||| S:7809 E:7812 ||| IN
the  ||| S:7812 E:7816 ||| DT
uninfected  ||| S:7816 E:7827 ||| NN
and  ||| S:7827 E:7839 ||| CC
adeno-βgal  ||| S:7839 E:7850 ||| JJ
infected  ||| S:7850 E:7859 ||| JJ
groups ||| S:7859 E:7865 ||| NNS
.  ||| S:7865 E:7875 ||| .
As  ||| S:7875 E:7878 ||| RB
evidenced  ||| S:7878 E:7888 ||| VBN
earlier ||| S:7888 E:7895 ||| RBR
,  ||| S:7895 E:7897 ||| ,
the  ||| S:7897 E:7901 ||| DT
molecular  ||| S:7901 E:7911 ||| JJ
locus  ||| S:7911 E:7917 ||| NN
of  ||| S:7917 E:7920 ||| IN
RGS  ||| S:7920 E:7924 ||| NNP
protein  ||| S:7924 E:7940 ||| NN
action  ||| S:7940 E:7947 ||| NN
is  ||| S:7947 E:7950 ||| VBZ
thought  ||| S:7950 E:7958 ||| VBN
to  ||| S:7958 E:7961 ||| TO
be  ||| S:7961 E:7964 ||| VB
the  ||| S:7964 E:7968 ||| DT
G  ||| S:7968 E:7970 ||| NNP
protein  ||| S:7970 E:7978 ||| FW
α  ||| S:7978 E:7980 ||| FW
subunit ||| S:7980 E:7987 ||| FW
,  ||| S:7987 E:7997 ||| ,
specifically  ||| S:7997 E:8010 ||| RB
Gqα  ||| S:8010 E:8014 ||| JJ
in  ||| S:8014 E:8017 ||| IN
the  ||| S:8017 E:8021 ||| DT
case  ||| S:8021 E:8026 ||| NN
of  ||| S:8026 E:8029 ||| IN
GnRH  ||| S:8029 E:8034 ||| JJ
receptor  ||| S:8034 E:8043 ||| NN
activation ||| S:8043 E:8053 ||| NN
.  ||| S:8053 E:8063 ||| .
The  ||| S:8063 E:8067 ||| DT
results  ||| S:8067 E:8075 ||| NNS
shown  ||| S:8075 E:8081 ||| VBN
in  ||| S:8081 E:8084 ||| IN
Fig.  ||| S:8084 E:8089 ||| CD
5are  ||| S:8089 E:8094 ||| CD
consistent  ||| S:8094 E:8105 ||| JJ
with  ||| S:8105 E:8110 ||| IN
this  ||| S:8110 E:8123 ||| DT
conclusion ||| S:8123 E:8133 ||| NN
:  ||| S:8133 E:8135 ||| :
adeno-RGS3  ||| S:8135 E:8146 ||| CD
infection  ||| S:8146 E:8156 ||| NN
of  ||| S:8156 E:8159 ||| IN
rat  ||| S:8159 E:8163 ||| FW
pituitary  ||| S:8163 E:8173 ||| FW
cells  ||| S:8173 E:8187 ||| FW
profoundly  ||| S:8187 E:8198 ||| FW
suppressed  ||| S:8198 E:8209 ||| FW
GnRH-stimulated  ||| S:8209 E:8225 ||| FW
3H-inositol  ||| S:8225 E:8237 ||| FW
phosphate  ||| S:8237 E:8255 ||| FW
accumulation ||| S:8255 E:8267 ||| FW
.  ||| S:8267 E:8269 ||| .
These  ||| S:8269 E:8275 ||| DT
results  ||| S:8275 E:8283 ||| NNS
are  ||| S:8283 E:8287 ||| VBP
compatible  ||| S:8287 E:8298 ||| JJ
with  ||| S:8298 E:8303 ||| IN
a  ||| S:8303 E:8305 ||| DT
molecular  ||| S:8305 E:8323 ||| JJ
site  ||| S:8323 E:8328 ||| NN
of  ||| S:8328 E:8331 ||| IN
action  ||| S:8331 E:8338 ||| NN
for  ||| S:8338 E:8342 ||| IN
RGS3  ||| S:8342 E:8347 ||| CD
being  ||| S:8347 E:8353 ||| VBG
at  ||| S:8353 E:8356 ||| IN
phospholipase  ||| S:8356 E:8370 ||| JJ
C  ||| S:8370 E:8372 ||| NNP
or  ||| S:8372 E:8375 ||| CC
earlier  ||| S:8375 E:8391 ||| RBR
in  ||| S:8391 E:8394 ||| IN
the  ||| S:8394 E:8398 ||| DT
signal  ||| S:8398 E:8405 ||| NN
transduction  ||| S:8405 E:8418 ||| NN
pathway ||| S:8418 E:8425 ||| NN
.  ||| S:8425 E:8435 ||| .
Another  ||| S:8435 E:8443 ||| DT
experiment  ||| S:8443 E:8454 ||| NN
conducted  ||| S:8454 E:8464 ||| VBN
to  ||| S:8464 E:8467 ||| TO
test  ||| S:8467 E:8472 ||| VB
the  ||| S:8472 E:8476 ||| DT
specificity  ||| S:8476 E:8488 ||| NN
and  ||| S:8488 E:8500 ||| CC
molecular  ||| S:8500 E:8510 ||| JJ
locus  ||| S:8510 E:8516 ||| NN
of  ||| S:8516 E:8519 ||| IN
RGS3  ||| S:8519 E:8524 ||| CD
action  ||| S:8524 E:8531 ||| NN
in  ||| S:8531 E:8534 ||| IN
inhibiting  ||| S:8534 E:8553 ||| JJ
GnRH-stimulated  ||| S:8553 E:8569 ||| JJ
LH  ||| S:8569 E:8572 ||| NNP
secretion  ||| S:8572 E:8582 ||| NN
was  ||| S:8582 E:8586 ||| VBD
treatment  ||| S:8586 E:8596 ||| NN
of  ||| S:8596 E:8599 ||| IN
adeno-RGS3  ||| S:8599 E:8618 ||| CD
infected  ||| S:8618 E:8627 ||| JJ
cells  ||| S:8627 E:8633 ||| NNS
with  ||| S:8633 E:8638 ||| IN
an  ||| S:8638 E:8641 ||| DT
agent  ||| S:8641 E:8647 ||| NN
that  ||| S:8647 E:8652 ||| WDT
increases  ||| S:8652 E:8662 ||| VBZ
intracellular  ||| S:8662 E:8684 ||| JJ
calcium  ||| S:8684 E:8692 ||| NN
( ||| S:8692 E:8693 ||| -LRB-
Fig.  ||| S:8693 E:8698 ||| CD
6 ||| S:8698 E:8699 ||| CD
) ||| S:8699 E:8700 ||| -RRB-
.  ||| S:8700 E:8702 ||| .
Calcium  ||| S:8702 E:8710 ||| NNP
is  ||| S:8710 E:8713 ||| VBZ
an  ||| S:8713 E:8716 ||| DT
established  ||| S:8716 E:8728 ||| JJ
stimulator  ||| S:8728 E:8739 ||| NN
of  ||| S:8739 E:8750 ||| IN
LH  ||| S:8750 E:8753 ||| NNP
secretion  ||| S:8753 E:8763 ||| NN
that  ||| S:8763 E:8768 ||| WDT
is  ||| S:8768 E:8771 ||| VBZ
thought  ||| S:8771 E:8779 ||| VBN
to  ||| S:8779 E:8782 ||| TO
act  ||| S:8782 E:8786 ||| VB
at  ||| S:8786 E:8789 ||| IN
sites  ||| S:8789 E:8795 ||| NNS
downstream  ||| S:8795 E:8806 ||| VBN
of  ||| S:8806 E:8817 ||| IN
phospholipase  ||| S:8817 E:8831 ||| JJ
C  ||| S:8831 E:8833 ||| NNP
[  ||| S:8833 E:8835 ||| -LRB-
39  ||| S:8835 E:8838 ||| CD
40  ||| S:8838 E:8841 ||| CD
]  ||| S:8841 E:8843 ||| -RRB-
.  ||| S:8843 E:8845 ||| .
Therefore ||| S:8845 E:8854 ||| RB
,  ||| S:8854 E:8856 ||| ,
adeno-RGS3  ||| S:8856 E:8867 ||| CD
infected  ||| S:8867 E:8884 ||| JJ
pituitary  ||| S:8884 E:8894 ||| JJ
cells  ||| S:8894 E:8900 ||| NNS
were  ||| S:8900 E:8905 ||| VBD
treated  ||| S:8905 E:8913 ||| VBN
with  ||| S:8913 E:8918 ||| IN
a  ||| S:8918 E:8920 ||| DT
calcium  ||| S:8920 E:8928 ||| JJ
ionophore  ||| S:8928 E:8946 ||| NNS
( ||| S:8946 E:8947 ||| -LRB-
A23187 ||| S:8947 E:8953 ||| NNP
) ||| S:8953 E:8954 ||| -RRB-
.  ||| S:8954 E:8956 ||| .
Adeno-RSG3  ||| S:8956 E:8967 ||| NNP
inhibited  ||| S:8967 E:8977 ||| VBD
LH  ||| S:8977 E:8980 ||| NNP
secretion  ||| S:8980 E:8990 ||| NN
in  ||| S:8990 E:8993 ||| IN
the  ||| S:8993 E:9005 ||| DT
GnRH-treated  ||| S:9005 E:9018 ||| JJ
control  ||| S:9018 E:9026 ||| NN
group  ||| S:9026 E:9032 ||| NN
as  ||| S:9032 E:9035 ||| IN
expected  ||| S:9035 E:9044 ||| VBN
( ||| S:9044 E:9045 ||| -LRB-
Fig.  ||| S:9045 E:9050 ||| CD
6 ||| S:9050 E:9051 ||| CD
) ||| S:9051 E:9052 ||| -RRB-
.  ||| S:9052 E:9054 ||| .
However ||| S:9054 E:9061 ||| RB
,  ||| S:9061 E:9071 ||| ,
the  ||| S:9071 E:9075 ||| DT
calcium  ||| S:9075 E:9083 ||| FW
ionphore  ||| S:9083 E:9092 ||| FW
stimulated  ||| S:9092 E:9103 ||| FW
LH  ||| S:9103 E:9106 ||| FW
secretion  ||| S:9106 E:9116 ||| FW
in  ||| S:9116 E:9127 ||| FW
RGS3-expressing  ||| S:9127 E:9143 ||| FW
gonadotropes  ||| S:9143 E:9156 ||| FW
( ||| S:9156 E:9157 ||| -LRB-
Fig.  ||| S:9157 E:9162 ||| CD
6 ||| S:9162 E:9163 ||| CD
) ||| S:9163 E:9164 ||| -RRB-
,  ||| S:9164 E:9166 ||| ,
an  ||| S:9166 E:9169 ||| DT
effect  ||| S:9169 E:9176 ||| NN
that  ||| S:9176 E:9181 ||| WDT
would  ||| S:9181 E:9195 ||| MD
be  ||| S:9195 E:9198 ||| VB
expected  ||| S:9198 E:9207 ||| VBN
if  ||| S:9207 E:9210 ||| IN
the  ||| S:9210 E:9214 ||| DT
RGS3  ||| S:9214 E:9219 ||| CD
inhibition  ||| S:9219 E:9230 ||| NNS
was  ||| S:9230 E:9234 ||| VBD
exerted  ||| S:9234 E:9242 ||| VBN
at  ||| S:9242 E:9245 ||| IN
the  ||| S:9245 E:9249 ||| DT
level  ||| S:9249 E:9263 ||| NN
of  ||| S:9263 E:9266 ||| IN
the  ||| S:9266 E:9270 ||| DT
Gqα  ||| S:9270 E:9274 ||| JJ
protein ||| S:9274 E:9281 ||| NN
.  ||| S:9281 E:9291 ||| .
In  ||| S:9291 E:9294 ||| IN
two  ||| S:9294 E:9298 ||| CD
final  ||| S:9298 E:9304 ||| JJ
control  ||| S:9304 E:9312 ||| NN
studies ||| S:9312 E:9319 ||| NNS
,  ||| S:9319 E:9321 ||| ,
we  ||| S:9321 E:9324 ||| PRP
investigated  ||| S:9324 E:9337 ||| VBD
the  ||| S:9337 E:9341 ||| DT
effect  ||| S:9341 E:9356 ||| NN
of  ||| S:9356 E:9359 ||| IN
adeno-RGS3  ||| S:9359 E:9370 ||| CD
on  ||| S:9370 E:9373 ||| IN
LH  ||| S:9373 E:9376 ||| NNP
concentrations  ||| S:9376 E:9391 ||| NNS
in  ||| S:9391 E:9394 ||| IN
pituitary  ||| S:9394 E:9404 ||| JJ
cells  ||| S:9404 E:9410 ||| NNS
and  ||| S:9410 E:9422 ||| CC
on  ||| S:9422 E:9425 ||| IN
GnRH  ||| S:9425 E:9430 ||| JJ
receptor  ||| S:9430 E:9439 ||| NN
binding  ||| S:9439 E:9447 ||| NNS
( ||| S:9447 E:9448 ||| -LRB-
Fig.  ||| S:9448 E:9453 ||| CD
7 ||| S:9453 E:9454 ||| CD
) ||| S:9454 E:9455 ||| -RRB-
.  ||| S:9455 E:9457 ||| .
In  ||| S:9457 E:9460 ||| IN
neither  ||| S:9460 E:9468 ||| DT
case  ||| S:9468 E:9473 ||| NN
did  ||| S:9473 E:9477 ||| VBD
RGS3  ||| S:9477 E:9490 ||| RB
affect  ||| S:9490 E:9497 ||| VB
these  ||| S:9497 E:9503 ||| DT
parameters  ||| S:9503 E:9514 ||| NN
of  ||| S:9514 E:9517 ||| IN
gonadotrope  ||| S:9517 E:9529 ||| JJ
function  ||| S:9529 E:9538 ||| NN
( ||| S:9538 E:9539 ||| -LRB-
p  ||| S:9539 E:9541 ||| CD
>  ||| S:9541 E:9551 ||| CD
0.05 ||| S:9551 E:9555 ||| CD
) ||| S:9555 E:9556 ||| -RRB-
.  ||| S:9556 E:9580 ||| .
Discussion  ||| S:9580 E:9599 ||| NN
The  ||| S:9599 E:9603 ||| DT
quantity  ||| S:9603 E:9612 ||| NN
of  ||| S:9612 E:9615 ||| IN
LH  ||| S:9615 E:9618 ||| NNP
secreted  ||| S:9618 E:9627 ||| NN
by  ||| S:9627 E:9630 ||| IN
the  ||| S:9630 E:9634 ||| DT
anterior  ||| S:9634 E:9643 ||| JJ
pituitary  ||| S:9643 E:9661 ||| JJ
gland  ||| S:9661 E:9667 ||| NN
is  ||| S:9667 E:9670 ||| VBZ
the  ||| S:9670 E:9674 ||| DT
outcome  ||| S:9674 E:9682 ||| NN
of  ||| S:9682 E:9685 ||| IN
an  ||| S:9685 E:9688 ||| DT
interaction  ||| S:9688 E:9700 ||| NN
between  ||| S:9700 E:9708 ||| IN
the  ||| S:9708 E:9712 ||| DT
amount  ||| S:9712 E:9727 ||| NN
of  ||| S:9727 E:9730 ||| IN
hypothalamic  ||| S:9730 E:9743 ||| JJ
GnRH  ||| S:9743 E:9748 ||| JJ
secretion  ||| S:9748 E:9758 ||| NN
and  ||| S:9758 E:9762 ||| CC
the  ||| S:9762 E:9766 ||| DT
level  ||| S:9766 E:9772 ||| NN
of  ||| S:9772 E:9775 ||| IN
gonadotrope  ||| S:9775 E:9795 ||| JJ
responsiveness  ||| S:9795 E:9810 ||| NN
to  ||| S:9810 E:9813 ||| TO
GnRH  ||| S:9813 E:9818 ||| NNP
[  ||| S:9818 E:9820 ||| -LRB-
7  ||| S:9820 E:9822 ||| CD
]  ||| S:9822 E:9824 ||| -RRB-
.  ||| S:9824 E:9826 ||| .
Quantitatively ||| S:9826 E:9840 ||| NNP
,  ||| S:9840 E:9842 ||| ,
gonadotrope  ||| S:9842 E:9862 ||| JJ
responsiveness  ||| S:9862 E:9877 ||| NN
is  ||| S:9877 E:9880 ||| VBZ
more  ||| S:9880 E:9885 ||| RBR
important  ||| S:9885 E:9895 ||| JJ
than  ||| S:9895 E:9900 ||| IN
the  ||| S:9900 E:9904 ||| DT
level  ||| S:9904 E:9910 ||| NN
of  ||| S:9910 E:9913 ||| IN
GnRH  ||| S:9913 E:9926 ||| JJ
secretion ||| S:9926 E:9935 ||| NN
;  ||| S:9935 E:9937 ||| :
for  ||| S:9937 E:9941 ||| IN
example ||| S:9941 E:9948 ||| NN
,  ||| S:9948 E:9950 ||| ,
during  ||| S:9950 E:9957 ||| IN
the  ||| S:9957 E:9961 ||| DT
estrogen-stimulated  ||| S:9961 E:9989 ||| JJ
preovulatory  ||| S:9989 E:10002 ||| JJ
surge  ||| S:10002 E:10008 ||| NN
of  ||| S:10008 E:10011 ||| IN
LH  ||| S:10011 E:10014 ||| NNP
secretion  ||| S:10014 E:10024 ||| NN
in  ||| S:10024 E:10027 ||| IN
the  ||| S:10027 E:10031 ||| DT
rat  ||| S:10031 E:10035 ||| NN
there  ||| S:10035 E:10041 ||| EX
is  ||| S:10041 E:10044 ||| VBZ
a  ||| S:10044 E:10054 ||| DT
5-fold  ||| S:10054 E:10061 ||| JJ
increase  ||| S:10061 E:10070 ||| NN
in  ||| S:10070 E:10073 ||| IN
GnRH  ||| S:10073 E:10078 ||| JJ
secretion  ||| S:10078 E:10088 ||| NN
but  ||| S:10088 E:10092 ||| CC
a  ||| S:10092 E:10094 ||| DT
50-fold  ||| S:10094 E:10102 ||| JJ
increase  ||| S:10102 E:10111 ||| NN
in  ||| S:10111 E:10122 ||| IN
LH  ||| S:10122 E:10125 ||| NNP
secretion  ||| S:10125 E:10135 ||| NNS
[  ||| S:10135 E:10137 ||| -LRB-
7  ||| S:10137 E:10139 ||| CD
]  ||| S:10139 E:10141 ||| -RRB-
.  ||| S:10141 E:10143 ||| .
Moreover ||| S:10143 E:10151 ||| RB
,  ||| S:10151 E:10153 ||| ,
a  ||| S:10153 E:10155 ||| DT
quantity  ||| S:10155 E:10164 ||| NN
of  ||| S:10164 E:10167 ||| IN
GnRH  ||| S:10167 E:10172 ||| NN
that  ||| S:10172 E:10177 ||| WDT
will  ||| S:10177 E:10190 ||| MD
evoke  ||| S:10190 E:10196 ||| VB
a  ||| S:10196 E:10198 ||| DT
normal  ||| S:10198 E:10205 ||| JJ
preovulatory  ||| S:10205 E:10218 ||| JJ
LH  ||| S:10218 E:10221 ||| NNP
surge  ||| S:10221 E:10227 ||| NN
during  ||| S:10227 E:10234 ||| IN
the  ||| S:10234 E:10238 ||| DT
period  ||| S:10238 E:10253 ||| NN
preceding  ||| S:10253 E:10263 ||| VBG
ovulation  ||| S:10263 E:10273 ||| NNS
will  ||| S:10273 E:10278 ||| MD
induce  ||| S:10278 E:10285 ||| VB
only  ||| S:10285 E:10290 ||| RB
a  ||| S:10290 E:10292 ||| DT
small  ||| S:10292 E:10298 ||| JJ
increase  ||| S:10298 E:10307 ||| NN
in  ||| S:10307 E:10310 ||| IN
LH  ||| S:10310 E:10321 ||| NNP
secretion  ||| S:10321 E:10331 ||| NN
at  ||| S:10331 E:10334 ||| IN
other  ||| S:10334 E:10340 ||| JJ
stages  ||| S:10340 E:10347 ||| NNS
of  ||| S:10347 E:10350 ||| IN
the  ||| S:10350 E:10354 ||| DT
estrous  ||| S:10354 E:10362 ||| JJ
cycle  ||| S:10362 E:10368 ||| NN
[  ||| S:10368 E:10370 ||| -LRB-
7  ||| S:10370 E:10372 ||| CD
]  ||| S:10372 E:10374 ||| -RRB-
.  ||| S:10374 E:10384 ||| .
Similarly ||| S:10384 E:10393 ||| RB
,  ||| S:10393 E:10395 ||| ,
termination  ||| S:10395 E:10407 ||| NN
of  ||| S:10407 E:10410 ||| IN
the  ||| S:10410 E:10414 ||| DT
preovulatory  ||| S:10414 E:10427 ||| JJ
LH  ||| S:10427 E:10430 ||| NNP
surge  ||| S:10430 E:10436 ||| NN
appears  ||| S:10436 E:10452 ||| VBZ
to  ||| S:10452 E:10455 ||| TO
be  ||| S:10455 E:10458 ||| VB
due  ||| S:10458 E:10462 ||| JJ
to  ||| S:10462 E:10465 ||| TO
desensitization  ||| S:10465 E:10481 ||| VB
of  ||| S:10481 E:10484 ||| IN
the  ||| S:10484 E:10488 ||| DT
gonadotrope  ||| S:10488 E:10500 ||| NN
to  ||| S:10500 E:10503 ||| TO
GnRH  ||| S:10503 E:10516 ||| JJ
action ||| S:10516 E:10522 ||| NN
;  ||| S:10522 E:10524 ||| :
in  ||| S:10524 E:10527 ||| IN
the  ||| S:10527 E:10531 ||| DT
sheep ||| S:10531 E:10536 ||| NN
,  ||| S:10536 E:10538 ||| ,
a  ||| S:10538 E:10540 ||| DT
decrease  ||| S:10540 E:10549 ||| NN
in  ||| S:10549 E:10552 ||| IN
LH  ||| S:10552 E:10555 ||| NNP
secretion  ||| S:10555 E:10565 ||| NN
precedes  ||| S:10565 E:10582 ||| VBZ
the  ||| S:10582 E:10586 ||| DT
decrease  ||| S:10586 E:10595 ||| NN
in  ||| S:10595 E:10598 ||| IN
GnRH  ||| S:10598 E:10603 ||| JJ
secretion  ||| S:10603 E:10613 ||| NNS
[  ||| S:10613 E:10615 ||| -LRB-
41  ||| S:10615 E:10618 ||| CD
]  ||| S:10618 E:10620 ||| -RRB-
,  ||| S:10620 E:10622 ||| ,
whereas  ||| S:10622 E:10630 ||| VBG
in  ||| S:10630 E:10633 ||| IN
the  ||| S:10633 E:10637 ||| DT
rat ||| S:10637 E:10640 ||| NN
,  ||| S:10640 E:10650 ||| ,
although  ||| S:10650 E:10659 ||| IN
the  ||| S:10659 E:10663 ||| DT
decrease  ||| S:10663 E:10672 ||| NN
in  ||| S:10672 E:10675 ||| IN
GnRH  ||| S:10675 E:10680 ||| JJ
and  ||| S:10680 E:10684 ||| CC
LH  ||| S:10684 E:10687 ||| NNP
secretion  ||| S:10687 E:10697 ||| NNS
are  ||| S:10697 E:10709 ||| VBP
co-incident  ||| S:10709 E:10721 ||| JJ
[  ||| S:10721 E:10723 ||| -LRB-
7  ||| S:10723 E:10725 ||| CD
]  ||| S:10725 E:10727 ||| -RRB-
,  ||| S:10727 E:10729 ||| ,
there  ||| S:10729 E:10735 ||| EX
is  ||| S:10735 E:10738 ||| VBZ
evidence  ||| S:10738 E:10747 ||| NN
that  ||| S:10747 E:10752 ||| IN
the  ||| S:10752 E:10756 ||| DT
gonadotrope  ||| S:10756 E:10776 ||| NN
is  ||| S:10776 E:10779 ||| VBZ
already  ||| S:10779 E:10787 ||| RB
desensitized  ||| S:10787 E:10800 ||| VBN
to  ||| S:10800 E:10803 ||| TO
GnRH  ||| S:10803 E:10808 ||| NNP
[  ||| S:10808 E:10810 ||| -LRB-
42  ||| S:10810 E:10813 ||| CD
43  ||| S:10813 E:10816 ||| CD
]  ||| S:10816 E:10818 ||| -RRB-
.  ||| S:10818 E:10828 ||| .
The  ||| S:10828 E:10832 ||| DT
mechanisms  ||| S:10832 E:10843 ||| NNS
that  ||| S:10843 E:10848 ||| WDT
alter  ||| S:10848 E:10854 ||| VBP
gonadotrope  ||| S:10854 E:10866 ||| JJ
responsiveness  ||| S:10866 E:10881 ||| NN
to  ||| S:10881 E:10892 ||| TO
GnRH  ||| S:10892 E:10897 ||| NNS
are  ||| S:10897 E:10901 ||| VBP
unknown  ||| S:10901 E:10909 ||| JJ
but  ||| S:10909 E:10913 ||| CC
they  ||| S:10913 E:10918 ||| PRP
do  ||| S:10918 E:10921 ||| VBP
not  ||| S:10921 E:10925 ||| RB
appear  ||| S:10925 E:10932 ||| VB
to  ||| S:10932 E:10935 ||| TO
be  ||| S:10935 E:10938 ||| VB
due  ||| S:10938 E:10942 ||| JJ
to  ||| S:10942 E:10945 ||| TO
GnRH  ||| S:10945 E:10958 ||| JJ
receptor  ||| S:10958 E:10967 ||| NN
number  ||| S:10967 E:10974 ||| NN
or  ||| S:10974 E:10977 ||| CC
LH  ||| S:10977 E:10980 ||| NNP
stores  ||| S:10980 E:10987 ||| NNS
in  ||| S:10987 E:10990 ||| IN
the  ||| S:10990 E:10994 ||| DT
pituitary  ||| S:10994 E:11004 ||| JJ
gland  ||| S:11004 E:11010 ||| NNS
[  ||| S:11010 E:11012 ||| -LRB-
5  ||| S:11012 E:11014 ||| CD
6  ||| S:11014 E:11016 ||| CD
7  ||| S:11016 E:11026 ||| CD
8  ||| S:11026 E:11028 ||| CD
]  ||| S:11028 E:11030 ||| -RRB-
.  ||| S:11030 E:11032 ||| .
However ||| S:11032 E:11039 ||| RB
,  ||| S:11039 E:11041 ||| ,
the  ||| S:11041 E:11045 ||| DT
fraction  ||| S:11045 E:11054 ||| NN
of  ||| S:11054 E:11057 ||| IN
LH  ||| S:11057 E:11060 ||| NNP
that  ||| S:11060 E:11065 ||| WDT
is  ||| S:11065 E:11068 ||| VBZ
released  ||| S:11068 E:11077 ||| VBN
by  ||| S:11077 E:11080 ||| IN
a  ||| S:11080 E:11090 ||| DT
maximal  ||| S:11090 E:11098 ||| JJ
dose  ||| S:11098 E:11103 ||| NN
of  ||| S:11103 E:11106 ||| IN
GnRH  ||| S:11106 E:11111 ||| JJ
does  ||| S:11111 E:11116 ||| NNS
vary  ||| S:11116 E:11121 ||| VBP
positively  ||| S:11121 E:11132 ||| RB
with  ||| S:11132 E:11137 ||| IN
gonadotrope  ||| S:11137 E:11157 ||| JJ
responsiveness  ||| S:11157 E:11172 ||| NNS
[  ||| S:11172 E:11174 ||| -LRB-
7  ||| S:11174 E:11176 ||| CD
]  ||| S:11176 E:11178 ||| -RRB-
,  ||| S:11178 E:11180 ||| ,
and  ||| S:11180 E:11184 ||| CC
elucidation  ||| S:11184 E:11196 ||| NN
of  ||| S:11196 E:11199 ||| IN
the  ||| S:11199 E:11203 ||| DT
mechanisms  ||| S:11203 E:11222 ||| NNS
altering  ||| S:11222 E:11231 ||| VBG
the  ||| S:11231 E:11235 ||| DT
fraction  ||| S:11235 E:11244 ||| NN
of  ||| S:11244 E:11247 ||| IN
releasable  ||| S:11247 E:11258 ||| JJ
LH  ||| S:11258 E:11261 ||| NNP
is  ||| S:11261 E:11264 ||| VBZ
likely  ||| S:11264 E:11271 ||| JJ
to  ||| S:11271 E:11282 ||| TO
illuminate  ||| S:11282 E:11293 ||| VB
mechanisms  ||| S:11293 E:11304 ||| NNS
of  ||| S:11304 E:11307 ||| IN
gonadotrope  ||| S:11307 E:11319 ||| JJ
responsiveness  ||| S:11319 E:11334 ||| NN
to  ||| S:11334 E:11337 ||| TO
GnRH  ||| S:11337 E:11350 ||| NNP
[  ||| S:11350 E:11352 ||| -LRB-
44  ||| S:11352 E:11355 ||| CD
]  ||| S:11355 E:11357 ||| -RRB-
.  ||| S:11357 E:11367 ||| .
Two  ||| S:11367 E:11371 ||| CD
molecular  ||| S:11371 E:11381 ||| JJ
loci  ||| S:11381 E:11386 ||| NNS
recently  ||| S:11386 E:11395 ||| RB
have  ||| S:11395 E:11400 ||| VBP
been  ||| S:11400 E:11405 ||| VBN
implicated  ||| S:11405 E:11416 ||| VBN
as  ||| S:11416 E:11427 ||| IN
potential  ||| S:11427 E:11437 ||| JJ
modulators  ||| S:11437 E:11448 ||| NN
of  ||| S:11448 E:11451 ||| IN
GnRH  ||| S:11451 E:11456 ||| JJ
receptor  ||| S:11456 E:11465 ||| NN
signaling ||| S:11465 E:11474 ||| NNS
:  ||| S:11474 E:11476 ||| :
one  ||| S:11476 E:11480 ||| PRP
is  ||| S:11480 E:11483 ||| VBZ
the  ||| S:11483 E:11495 ||| DT
receptor  ||| S:11495 E:11504 ||| NN
itself  ||| S:11504 E:11511 ||| PRP
[  ||| S:11511 E:11513 ||| -LRB-
23  ||| S:11513 E:11516 ||| CD
]  ||| S:11516 E:11518 ||| -RRB-
,  ||| S:11518 E:11520 ||| ,
and  ||| S:11520 E:11524 ||| CC
the  ||| S:11524 E:11528 ||| DT
other  ||| S:11528 E:11534 ||| JJ
is  ||| S:11534 E:11537 ||| VBZ
the  ||| S:11537 E:11541 ||| DT
G  ||| S:11541 E:11543 ||| NNP
protein  ||| S:11543 E:11559 ||| NN
that  ||| S:11559 E:11564 ||| IN
transduces  ||| S:11564 E:11575 ||| VBG
the  ||| S:11575 E:11579 ||| DT
signal  ||| S:11579 E:11586 ||| NN
generated  ||| S:11586 E:11596 ||| VBD
by  ||| S:11596 E:11599 ||| IN
binding  ||| S:11599 E:11607 ||| VBG
of  ||| S:11607 E:11610 ||| IN
the  ||| S:11610 E:11622 ||| DT
receptor  ||| S:11622 E:11631 ||| NN
to  ||| S:11631 E:11634 ||| TO
its  ||| S:11634 E:11638 ||| PRP$
agonist  ||| S:11638 E:11646 ||| NNS
[  ||| S:11646 E:11648 ||| -LRB-
9  ||| S:11648 E:11650 ||| CD
]  ||| S:11650 E:11652 ||| -RRB-
.  ||| S:11652 E:11654 ||| .
With  ||| S:11654 E:11659 ||| IN
respect  ||| S:11659 E:11667 ||| NN
to  ||| S:11667 E:11670 ||| TO
the  ||| S:11670 E:11674 ||| DT
former  ||| S:11674 E:11689 ||| JJ
locus ||| S:11689 E:11694 ||| NN
,  ||| S:11694 E:11696 ||| ,
G  ||| S:11696 E:11698 ||| NNP
protein  ||| S:11698 E:11706 ||| FW
coupled  ||| S:11706 E:11714 ||| FW
receptor  ||| S:11714 E:11723 ||| FW
kinases  ||| S:11723 E:11731 ||| FW
( ||| S:11731 E:11732 ||| -LRB-
GRKs ||| S:11732 E:11736 ||| NNP
)  ||| S:11736 E:11738 ||| -RRB-
act  ||| S:11738 E:11742 ||| NN
in  ||| S:11742 E:11745 ||| IN
an  ||| S:11745 E:11756 ||| DT
agonist-specific  ||| S:11756 E:11773 ||| JJ
manner  ||| S:11773 E:11780 ||| NN
to  ||| S:11780 E:11783 ||| TO
phosphorylate  ||| S:11783 E:11797 ||| VB
intracellular  ||| S:11797 E:11819 ||| JJ
regions  ||| S:11819 E:11827 ||| NNS
of  ||| S:11827 E:11830 ||| IN
the  ||| S:11830 E:11834 ||| DT
receptor  ||| S:11834 E:11843 ||| NN
thus  ||| S:11843 E:11848 ||| RB
permitting  ||| S:11848 E:11859 ||| VBG
β  ||| S:11859 E:11861 ||| JJ
arrestin  ||| S:11861 E:11870 ||| JJ
binding  ||| S:11870 E:11886 ||| NN
that  ||| S:11886 E:11891 ||| IN
sterically  ||| S:11891 E:11902 ||| JJ
inhibits  ||| S:11902 E:11911 ||| JJ
G  ||| S:11911 E:11913 ||| NNP
protein  ||| S:11913 E:11921 ||| NN
association  ||| S:11921 E:11933 ||| NN
with  ||| S:11933 E:11938 ||| IN
the  ||| S:11938 E:11950 ||| DT
receptor  ||| S:11950 E:11959 ||| NN
[  ||| S:11959 E:11961 ||| -LRB-
1  ||| S:11961 E:11963 ||| CD
45  ||| S:11963 E:11966 ||| CD
]  ||| S:11966 E:11968 ||| -RRB-
.  ||| S:11968 E:11970 ||| .
We  ||| S:11970 E:11973 ||| PRP
have  ||| S:11973 E:11978 ||| VBP
reported  ||| S:11978 E:11987 ||| VBN
previously  ||| S:11987 E:11998 ||| RB
that  ||| S:11998 E:12011 ||| IN
experimental  ||| S:12011 E:12024 ||| JJ
expression  ||| S:12024 E:12035 ||| NN
of  ||| S:12035 E:12038 ||| IN
GRKs  ||| S:12038 E:12043 ||| JJ
in  ||| S:12043 E:12046 ||| IN
GnRH  ||| S:12046 E:12051 ||| JJ
receptor-expressing  ||| S:12051 E:12079 ||| JJ
heterologous  ||| S:12079 E:12092 ||| JJ
cells  ||| S:12092 E:12098 ||| NNS
( ||| S:12098 E:12099 ||| -LRB-
COS-1 ||| S:12099 E:12104 ||| NNP
)  ||| S:12104 E:12106 ||| -RRB-
suppressed  ||| S:12106 E:12117 ||| VBD
GnRH-stimulated  ||| S:12117 E:12133 ||| NNP
IP  ||| S:12133 E:12145 ||| NNP
3  ||| S:12145 E:12147 ||| CD
production ||| S:12147 E:12157 ||| NN
,  ||| S:12157 E:12159 ||| ,
and  ||| S:12159 E:12163 ||| CC
that  ||| S:12163 E:12168 ||| DT
co-expression  ||| S:12168 E:12182 ||| JJ
of  ||| S:12182 E:12193 ||| IN
GRK2  ||| S:12193 E:12198 ||| NNP
and  ||| S:12198 E:12202 ||| CC
β-arrestin  ||| S:12202 E:12213 ||| JJ
2  ||| S:12213 E:12215 ||| CD
suppressed  ||| S:12215 E:12226 ||| CD
GnRH  ||| S:12226 E:12231 ||| JJ
receptor  ||| S:12231 E:12240 ||| NN
signaling  ||| S:12240 E:12258 ||| VBG
more  ||| S:12258 E:12263 ||| JJR
than  ||| S:12263 E:12268 ||| IN
that  ||| S:12268 E:12273 ||| DT
of  ||| S:12273 E:12276 ||| IN
either  ||| S:12276 E:12283 ||| DT
alone  ||| S:12283 E:12289 ||| RB
[  ||| S:12289 E:12291 ||| -LRB-
23  ||| S:12291 E:12294 ||| CD
]  ||| S:12294 E:12296 ||| -RRB-
.  ||| S:12296 E:12298 ||| .
Stronger  ||| S:12298 E:12307 ||| JJR
evidence  ||| S:12307 E:12324 ||| NN
that  ||| S:12324 E:12329 ||| IN
the  ||| S:12329 E:12333 ||| DT
GRK ||| S:12333 E:12336 ||| FW
/ ||| S:12336 E:12337 ||| FW
β  ||| S:12337 E:12339 ||| FW
arrestin  ||| S:12339 E:12348 ||| FW
paradigm  ||| S:12348 E:12357 ||| FW
may  ||| S:12357 E:12361 ||| MD
play  ||| S:12361 E:12366 ||| VB
a  ||| S:12366 E:12368 ||| DT
role  ||| S:12368 E:12373 ||| NN
in  ||| S:12373 E:12384 ||| IN
regulating  ||| S:12384 E:12395 ||| VBG
GnRH  ||| S:12395 E:12400 ||| JJ
receptor  ||| S:12400 E:12409 ||| NN
signaling  ||| S:12409 E:12419 ||| NN
is  ||| S:12419 E:12422 ||| VBZ
our  ||| S:12422 E:12426 ||| PRP$
recent  ||| S:12426 E:12433 ||| JJ
finding  ||| S:12433 E:12449 ||| NN
that  ||| S:12449 E:12454 ||| IN
adenovirus-mediated  ||| S:12454 E:12474 ||| JJ
gene  ||| S:12474 E:12479 ||| NN
transfer  ||| S:12479 E:12488 ||| NN
of  ||| S:12488 E:12491 ||| IN
GRK2  ||| S:12491 E:12496 ||| CD
into  ||| S:12496 E:12501 ||| IN
normal  ||| S:12501 E:12516 ||| JJ
pituitary  ||| S:12516 E:12526 ||| FW
gonadotropes  ||| S:12526 E:12539 ||| FW
suppressed  ||| S:12539 E:12550 ||| FW
GnRH-stimulated  ||| S:12550 E:12566 ||| FW
LH  ||| S:12566 E:12577 ||| FW
secretion  ||| S:12577 E:12587 ||| FW
and  ||| S:12587 E:12591 ||| CC
IP  ||| S:12591 E:12603 ||| NNP
3  ||| S:12603 E:12605 ||| CD
production  ||| S:12605 E:12616 ||| NN
[  ||| S:12616 E:12618 ||| -LRB-
31  ||| S:12618 E:12621 ||| CD
]  ||| S:12621 E:12623 ||| -RRB-
.  ||| S:12623 E:12625 ||| .
However ||| S:12625 E:12632 ||| RB
,  ||| S:12632 E:12634 ||| ,
no  ||| S:12634 E:12645 ||| DT
evidence  ||| S:12645 E:12654 ||| NN
has  ||| S:12654 E:12658 ||| VBZ
been  ||| S:12658 E:12663 ||| VBN
presented  ||| S:12663 E:12673 ||| VBN
for  ||| S:12673 E:12677 ||| IN
a  ||| S:12677 E:12679 ||| DT
direct  ||| S:12679 E:12686 ||| JJ
interaction  ||| S:12686 E:12706 ||| NN
between  ||| S:12706 E:12714 ||| IN
β-arrestin  ||| S:12714 E:12725 ||| JJ
and  ||| S:12725 E:12729 ||| CC
the  ||| S:12729 E:12733 ||| DT
GnRH  ||| S:12733 E:12738 ||| JJ
receptor ||| S:12738 E:12746 ||| NN
.  ||| S:12746 E:12756 ||| .
With  ||| S:12756 E:12761 ||| IN
respect  ||| S:12761 E:12769 ||| NN
to  ||| S:12769 E:12772 ||| TO
the  ||| S:12772 E:12776 ||| DT
G  ||| S:12776 E:12778 ||| NNP
protein  ||| S:12778 E:12786 ||| NN
as  ||| S:12786 E:12789 ||| IN
a  ||| S:12789 E:12791 ||| DT
locus  ||| S:12791 E:12797 ||| NN
for  ||| S:12797 E:12801 ||| IN
modulation  ||| S:12801 E:12820 ||| NN
of  ||| S:12820 E:12823 ||| IN
GnRH  ||| S:12823 E:12828 ||| JJ
receptor  ||| S:12828 E:12837 ||| NN
signaling ||| S:12837 E:12846 ||| NN
,  ||| S:12846 E:12848 ||| ,
we  ||| S:12848 E:12851 ||| PRP
reported  ||| S:12851 E:12860 ||| VBD
earlier  ||| S:12860 E:12868 ||| RBR
that  ||| S:12868 E:12881 ||| IN
experimental  ||| S:12881 E:12894 ||| JJ
expression  ||| S:12894 E:12905 ||| NN
of  ||| S:12905 E:12908 ||| IN
RGS3  ||| S:12908 E:12913 ||| NNP
but  ||| S:12913 E:12917 ||| CC
not  ||| S:12917 E:12921 ||| RB
RGS1 ||| S:12921 E:12925 ||| CD
,  ||| S:12925 E:12927 ||| ,
2 ||| S:12927 E:12928 ||| CD
,  ||| S:12928 E:12930 ||| ,
or  ||| S:12930 E:12933 ||| CC
4  ||| S:12933 E:12935 ||| CD
in  ||| S:12935 E:12946 ||| IN
GnRH  ||| S:12946 E:12951 ||| JJ
receptor  ||| S:12951 E:12960 ||| NN
expressing  ||| S:12960 E:12971 ||| VBG
COS-1  ||| S:12971 E:12977 ||| CD
cells  ||| S:12977 E:12983 ||| NNS
suppressed  ||| S:12983 E:13002 ||| VBD
GnRH-stimulated  ||| S:13002 E:13018 ||| NNP
IP  ||| S:13018 E:13030 ||| NNP
3  ||| S:13030 E:13032 ||| CD
production  ||| S:13032 E:13043 ||| NN
[  ||| S:13043 E:13045 ||| -LRB-
9  ||| S:13045 E:13047 ||| CD
]  ||| S:13047 E:13049 ||| -RRB-
.  ||| S:13049 E:13051 ||| .
In  ||| S:13051 E:13054 ||| IN
the  ||| S:13054 E:13058 ||| DT
current  ||| S:13058 E:13074 ||| JJ
report ||| S:13074 E:13080 ||| NN
,  ||| S:13080 E:13082 ||| ,
we  ||| S:13082 E:13085 ||| PRP
present  ||| S:13085 E:13093 ||| JJ
evidence  ||| S:13093 E:13102 ||| NN
strengthening  ||| S:13102 E:13116 ||| VBG
the  ||| S:13116 E:13120 ||| DT
hypothesis  ||| S:13120 E:13131 ||| NN
of  ||| S:13131 E:13142 ||| IN
a  ||| S:13142 E:13144 ||| DT
regulatory  ||| S:13144 E:13155 ||| JJ
role  ||| S:13155 E:13160 ||| NN
for  ||| S:13160 E:13164 ||| IN
RGS3  ||| S:13164 E:13169 ||| CD
in  ||| S:13169 E:13172 ||| IN
GnRH  ||| S:13172 E:13177 ||| JJ
receptor  ||| S:13177 E:13186 ||| NN
signaling ||| S:13186 E:13195 ||| NNS
:  ||| S:13195 E:13205 ||| :
adenovirus-mediated  ||| S:13205 E:13225 ||| JJ
expression  ||| S:13225 E:13236 ||| NN
of  ||| S:13236 E:13239 ||| IN
RGS3  ||| S:13239 E:13244 ||| CD
in  ||| S:13244 E:13247 ||| IN
normal  ||| S:13247 E:13254 ||| JJ
pituitary  ||| S:13254 E:13272 ||| FW
gonadotropes  ||| S:13272 E:13285 ||| FW
profoundly  ||| S:13285 E:13296 ||| FW
inhibited  ||| S:13296 E:13306 ||| FW
GnRH-stimulated  ||| S:13306 E:13322 ||| FW
LH  ||| S:13322 E:13333 ||| FW
secretion  ||| S:13333 E:13343 ||| FW
and  ||| S:13343 E:13347 ||| CC
3H-inositol  ||| S:13347 E:13359 ||| CD
phosphate  ||| S:13359 E:13369 ||| JJ
accumulation ||| S:13369 E:13381 ||| NN
.  ||| S:13381 E:13383 ||| .
Arguing  ||| S:13383 E:13399 ||| VBG
for  ||| S:13399 E:13403 ||| IN
the  ||| S:13403 E:13407 ||| DT
specificity  ||| S:13407 E:13419 ||| NN
of  ||| S:13419 E:13422 ||| IN
this  ||| S:13422 E:13427 ||| DT
effect  ||| S:13427 E:13434 ||| NN
is  ||| S:13434 E:13437 ||| VBZ
the  ||| S:13437 E:13441 ||| DT
stimulation  ||| S:13441 E:13453 ||| NN
of  ||| S:13453 E:13456 ||| IN
LH  ||| S:13456 E:13467 ||| NNP
secretion  ||| S:13467 E:13477 ||| NN
by  ||| S:13477 E:13480 ||| IN
a  ||| S:13480 E:13482 ||| DT
calcium  ||| S:13482 E:13490 ||| JJ
ionophore  ||| S:13490 E:13500 ||| NN
and  ||| S:13500 E:13504 ||| CC
the  ||| S:13504 E:13508 ||| DT
failure  ||| S:13508 E:13516 ||| NN
of  ||| S:13516 E:13519 ||| IN
LH  ||| S:13519 E:13530 ||| NNP
stores  ||| S:13530 E:13537 ||| NNS
and  ||| S:13537 E:13541 ||| CC
GnRH-receptor  ||| S:13541 E:13555 ||| JJ
binding  ||| S:13555 E:13563 ||| NN
to  ||| S:13563 E:13566 ||| TO
be  ||| S:13566 E:13569 ||| VB
affected  ||| S:13569 E:13578 ||| VBN
by  ||| S:13578 E:13581 ||| IN
RGS3 ||| S:13581 E:13585 ||| CD
.  ||| S:13585 E:13595 ||| .
Moreover ||| S:13595 E:13603 ||| RB
,  ||| S:13603 E:13605 ||| ,
our  ||| S:13605 E:13609 ||| PRP$
finding  ||| S:13609 E:13617 ||| NN
that  ||| S:13617 E:13622 ||| IN
GnRH-stimulated  ||| S:13622 E:13638 ||| NNP
IP  ||| S:13638 E:13650 ||| NNP
3  ||| S:13650 E:13652 ||| CD
production  ||| S:13652 E:13663 ||| NN
was  ||| S:13663 E:13667 ||| VBD
inhibited  ||| S:13667 E:13677 ||| RB
supports  ||| S:13677 E:13686 ||| VBZ
the  ||| S:13686 E:13698 ||| DT
locus  ||| S:13698 E:13704 ||| NN
of  ||| S:13704 E:13707 ||| IN
the  ||| S:13707 E:13711 ||| DT
RGS3  ||| S:13711 E:13716 ||| JJ
effect  ||| S:13716 E:13723 ||| NN
as  ||| S:13723 E:13726 ||| IN
residing  ||| S:13726 E:13735 ||| NN
at  ||| S:13735 E:13738 ||| IN
phospholipase  ||| S:13738 E:13752 ||| JJ
C  ||| S:13752 E:13754 ||| NNP
or  ||| S:13754 E:13765 ||| CC
earlier  ||| S:13765 E:13773 ||| RBR
in  ||| S:13773 E:13776 ||| IN
the  ||| S:13776 E:13780 ||| DT
transduction  ||| S:13780 E:13793 ||| JJ
pathway ||| S:13793 E:13800 ||| NN
,  ||| S:13800 E:13802 ||| ,
most  ||| S:13802 E:13807 ||| RBS
likely  ||| S:13807 E:13814 ||| JJ
at  ||| S:13814 E:13817 ||| IN
the  ||| S:13817 E:13821 ||| DT
Gα  ||| S:13821 E:13832 ||| JJ
protein  ||| S:13832 E:13840 ||| NN
because  ||| S:13840 E:13848 ||| IN
of  ||| S:13848 E:13851 ||| IN
our  ||| S:13851 E:13855 ||| PRP$
studies  ||| S:13855 E:13863 ||| NNS
both  ||| S:13863 E:13868 ||| CC
earlier  ||| S:13868 E:13876 ||| RBR
[  ||| S:13876 E:13878 ||| -LRB-
9  ||| S:13878 E:13880 ||| CD
]  ||| S:13880 E:13882 ||| -RRB-
and  ||| S:13882 E:13886 ||| CC
here  ||| S:13886 E:13899 ||| RB
showing  ||| S:13899 E:13907 ||| VBG
that  ||| S:13907 E:13912 ||| IN
RGS3  ||| S:13912 E:13917 ||| FW
binds  ||| S:13917 E:13923 ||| FW
Gqα  ||| S:13923 E:13936 ||| FW
in  ||| S:13936 E:13939 ||| FW
vitro ||| S:13939 E:13944 ||| FW
.  ||| S:13944 E:13946 ||| .
Finally ||| S:13946 E:13953 ||| RB
,  ||| S:13953 E:13955 ||| ,
the  ||| S:13955 E:13959 ||| DT
stronger  ||| S:13959 E:13976 ||| JJR
inhibitory  ||| S:13976 E:13987 ||| JJ
effect  ||| S:13987 E:13994 ||| NN
of  ||| S:13994 E:13997 ||| IN
RGS3T  ||| S:13997 E:14003 ||| CD
than  ||| S:14003 E:14008 ||| IN
RGS  ||| S:14008 E:14012 ||| NNP
3  ||| S:14012 E:14014 ||| CD
on  ||| S:14014 E:14017 ||| IN
COS  ||| S:14017 E:14021 ||| NNP
cell  ||| S:14021 E:14026 ||| NN
function  ||| S:14026 E:14043 ||| NN
was  ||| S:14043 E:14047 ||| VBD
presumed  ||| S:14047 E:14056 ||| VBN
to  ||| S:14056 E:14059 ||| TO
be  ||| S:14059 E:14062 ||| VB
true  ||| S:14062 E:14067 ||| JJ
also  ||| S:14067 E:14072 ||| RB
for  ||| S:14072 E:14076 ||| IN
gonadotrope  ||| S:14076 E:14088 ||| JJ
function  ||| S:14088 E:14097 ||| NN
and  ||| S:14097 E:14109 ||| CC
therefore  ||| S:14109 E:14119 ||| RB
was  ||| S:14119 E:14123 ||| VBD
not  ||| S:14123 E:14127 ||| RB
tested  ||| S:14127 E:14134 ||| VBN
here ||| S:14134 E:14138 ||| RB
.  ||| S:14138 E:14148 ||| .
The  ||| S:14148 E:14152 ||| DT
determination  ||| S:14152 E:14166 ||| NN
of  ||| S:14166 E:14169 ||| IN
RGS  ||| S:14169 E:14173 ||| NNP
specificity  ||| S:14173 E:14185 ||| NN
for  ||| S:14185 E:14189 ||| IN
receptor-G  ||| S:14189 E:14208 ||| JJ
protein  ||| S:14208 E:14216 ||| NN
pairs  ||| S:14216 E:14222 ||| NNS
are  ||| S:14222 E:14226 ||| VBP
currently  ||| S:14226 E:14236 ||| RB
unknown ||| S:14236 E:14243 ||| JJ
;  ||| S:14243 E:14245 ||| :
i.e. ||| S:14245 E:14249 ||| FW
,  ||| S:14249 E:14251 ||| ,
we  ||| S:14251 E:14254 ||| PRP
and  ||| S:14254 E:14258 ||| CC
others  ||| S:14258 E:14273 ||| NNS
have  ||| S:14273 E:14278 ||| VBP
found  ||| S:14278 E:14284 ||| VBN
that  ||| S:14284 E:14289 ||| IN
several  ||| S:14289 E:14297 ||| JJ
RGSs  ||| S:14297 E:14302 ||| JJ
interact  ||| S:14302 E:14311 ||| NN
with  ||| S:14311 E:14316 ||| IN
Gqα  ||| S:14316 E:14320 ||| NNP
but  ||| S:14320 E:14324 ||| CC
only  ||| S:14324 E:14337 ||| RB
one ||| S:14337 E:14340 ||| CD
,  ||| S:14340 E:14342 ||| ,
RGS3 ||| S:14342 E:14346 ||| NNP
,  ||| S:14346 E:14348 ||| ,
has  ||| S:14348 E:14352 ||| VBZ
potent  ||| S:14352 E:14359 ||| JJ
inhibitory  ||| S:14359 E:14370 ||| JJ
activity  ||| S:14370 E:14379 ||| NN
on  ||| S:14379 E:14382 ||| IN
GnRH  ||| S:14382 E:14387 ||| JJ
receptor  ||| S:14387 E:14404 ||| NN
signaling ||| S:14404 E:14413 ||| NN
.  ||| S:14413 E:14415 ||| .
For  ||| S:14415 E:14419 ||| IN
instance ||| S:14419 E:14427 ||| NN
,  ||| S:14427 E:14429 ||| ,
RGS4  ||| S:14429 E:14434 ||| NNP
and  ||| S:14434 E:14438 ||| CC
RGS-GAIP  ||| S:14438 E:14447 ||| NNP
[  ||| S:14447 E:14449 ||| -LRB-
11  ||| S:14449 E:14452 ||| CD
]  ||| S:14452 E:14454 ||| -RRB-
,  ||| S:14454 E:14456 ||| ,
RGS3  ||| S:14456 E:14461 ||| NNP
[  ||| S:14461 E:14471 ||| -LRB-
9  ||| S:14471 E:14473 ||| CD
]  ||| S:14473 E:14475 ||| -RRB-
,  ||| S:14475 E:14477 ||| ,
RGS2  ||| S:14477 E:14482 ||| NNP
[  ||| S:14482 E:14484 ||| -LRB-
46  ||| S:14484 E:14487 ||| CD
]  ||| S:14487 E:14489 ||| -RRB-
,  ||| S:14489 E:14491 ||| ,
and  ||| S:14491 E:14495 ||| CC
RGS7  ||| S:14495 E:14500 ||| NNP
( ||| S:14500 E:14501 ||| -LRB-
our  ||| S:14501 E:14505 ||| PRP$
unpublished  ||| S:14505 E:14517 ||| JJ
findings ||| S:14517 E:14525 ||| NNS
)  ||| S:14525 E:14527 ||| -RRB-
all  ||| S:14527 E:14539 ||| DT
bind  ||| S:14539 E:14544 ||| NN
Gqα ||| S:14544 E:14547 ||| NNP
,  ||| S:14547 E:14549 ||| ,
the  ||| S:14549 E:14553 ||| DT
established  ||| S:14553 E:14565 ||| JJ
G  ||| S:14565 E:14567 ||| NNP
protein  ||| S:14567 E:14575 ||| NN
that  ||| S:14575 E:14580 ||| IN
transduces  ||| S:14580 E:14591 ||| JJ
GnRH  ||| S:14591 E:14604 ||| JJ
receptor  ||| S:14604 E:14613 ||| NN
signaling  ||| S:14613 E:14623 ||| NNS
[  ||| S:14623 E:14625 ||| -LRB-
38  ||| S:14625 E:14628 ||| CD
]  ||| S:14628 E:14630 ||| -RRB-
.  ||| S:14630 E:14632 ||| .
Nevertheless ||| S:14632 E:14644 ||| RB
,  ||| S:14644 E:14646 ||| ,
RGS2  ||| S:14646 E:14651 ||| NNP
and  ||| S:14651 E:14655 ||| CC
4  ||| S:14655 E:14657 ||| CD
[  ||| S:14657 E:14659 ||| -LRB-
9  ||| S:14659 E:14661 ||| CD
]  ||| S:14661 E:14671 ||| -RRB-
,  ||| S:14671 E:14673 ||| ,
and  ||| S:14673 E:14677 ||| CC
RGS-GAIP  ||| S:14677 E:14686 ||| JJ
and  ||| S:14686 E:14690 ||| CC
RGS7  ||| S:14690 E:14695 ||| NNP
( ||| S:14695 E:14696 ||| -LRB-
our  ||| S:14696 E:14700 ||| PRP$
unpublished  ||| S:14700 E:14712 ||| JJ
data ||| S:14712 E:14716 ||| NNS
)  ||| S:14716 E:14718 ||| -RRB-
are  ||| S:14718 E:14722 ||| VBP
weak  ||| S:14722 E:14727 ||| JJ
or  ||| S:14727 E:14738 ||| CC
null  ||| S:14738 E:14743 ||| JJ
inhibitors  ||| S:14743 E:14754 ||| NN
of  ||| S:14754 E:14757 ||| IN
GnRH  ||| S:14757 E:14762 ||| JJ
receptor  ||| S:14762 E:14771 ||| NN
signaling ||| S:14771 E:14780 ||| NN
.  ||| S:14780 E:14782 ||| .
A  ||| S:14782 E:14784 ||| DT
recent  ||| S:14784 E:14791 ||| JJ
report  ||| S:14791 E:14806 ||| NN
seems  ||| S:14806 E:14812 ||| VBZ
to  ||| S:14812 E:14815 ||| TO
have  ||| S:14815 E:14820 ||| VB
clarified  ||| S:14820 E:14830 ||| VBN
this  ||| S:14830 E:14835 ||| DT
issue ||| S:14835 E:14840 ||| NN
:  ||| S:14840 E:14842 ||| :
RGS4  ||| S:14842 E:14847 ||| NNP
must  ||| S:14847 E:14852 ||| MD
bind  ||| S:14852 E:14857 ||| VB
not  ||| S:14857 E:14861 ||| RB
only  ||| S:14861 E:14874 ||| RB
Gqα  ||| S:14874 E:14878 ||| NNP
but  ||| S:14878 E:14882 ||| CC
also  ||| S:14882 E:14887 ||| RB
selected  ||| S:14887 E:14896 ||| VBN
Gq-coupled  ||| S:14896 E:14907 ||| JJ
receptors  ||| S:14907 E:14917 ||| NNS
before  ||| S:14917 E:14924 ||| IN
it  ||| S:14924 E:14927 ||| PRP
can  ||| S:14927 E:14939 ||| MD
inhibit  ||| S:14939 E:14947 ||| VB
receptor  ||| S:14947 E:14956 ||| JJ
signaling  ||| S:14956 E:14966 ||| NNS
[  ||| S:14966 E:14968 ||| -LRB-
47  ||| S:14968 E:14971 ||| CD
48  ||| S:14971 E:14974 ||| CD
]  ||| S:14974 E:14976 ||| -RRB-
.  ||| S:14976 E:14978 ||| .
Based  ||| S:14978 E:14984 ||| VBN
on  ||| S:14984 E:14987 ||| IN
this  ||| S:14987 E:15000 ||| DT
finding ||| S:15000 E:15007 ||| NN
,  ||| S:15007 E:15009 ||| ,
we  ||| S:15009 E:15012 ||| PRP
propose  ||| S:15012 E:15020 ||| VBP
that  ||| S:15020 E:15025 ||| IN
RGS3 ||| S:15025 E:15029 ||| NNP
's  ||| S:15029 E:15032 ||| POS
binding  ||| S:15032 E:15040 ||| JJ
to  ||| S:15040 E:15043 ||| TO
the  ||| S:15043 E:15047 ||| DT
GnRH  ||| S:15047 E:15060 ||| JJ
receptor  ||| S:15060 E:15069 ||| NN
as  ||| S:15069 E:15072 ||| IN
well  ||| S:15072 E:15077 ||| RB
as  ||| S:15077 E:15080 ||| RB
to  ||| S:15080 E:15083 ||| TO
Gqα  ||| S:15083 E:15087 ||| NNP
accounts  ||| S:15087 E:15096 ||| NNS
for  ||| S:15096 E:15100 ||| IN
its  ||| S:15100 E:15104 ||| PRP$
specific  ||| S:15104 E:15121 ||| JJ
inhibiting  ||| S:15121 E:15132 ||| NN
of  ||| S:15132 E:15135 ||| IN
GnRH  ||| S:15135 E:15140 ||| JJ
receptor  ||| S:15140 E:15149 ||| NN
signaling ||| S:15149 E:15158 ||| NN
.  ||| S:15158 E:15182 ||| .
Conclusions  ||| S:15182 E:15202 ||| NNS
The  ||| S:15202 E:15206 ||| DT
results  ||| S:15206 E:15214 ||| NNS
of  ||| S:15214 E:15217 ||| IN
the  ||| S:15217 E:15221 ||| DT
current  ||| S:15221 E:15229 ||| JJ
investigation  ||| S:15229 E:15243 ||| NN
as  ||| S:15243 E:15246 ||| IN
well  ||| S:15246 E:15251 ||| RB
as  ||| S:15251 E:15262 ||| IN
those  ||| S:15262 E:15268 ||| DT
presented  ||| S:15268 E:15278 ||| VBN
earlier  ||| S:15278 E:15286 ||| RBR
[  ||| S:15286 E:15288 ||| -LRB-
31  ||| S:15288 E:15291 ||| CD
]  ||| S:15291 E:15293 ||| -RRB-
nominate  ||| S:15293 E:15302 ||| VB
two  ||| S:15302 E:15306 ||| CD
molecular  ||| S:15306 E:15324 ||| JJ
mechanisms  ||| S:15324 E:15335 ||| NNS
as  ||| S:15335 E:15338 ||| IN
playing  ||| S:15338 E:15346 ||| VBG
roles  ||| S:15346 E:15352 ||| NNS
in  ||| S:15352 E:15355 ||| IN
setting  ||| S:15355 E:15363 ||| VBG
the  ||| S:15363 E:15367 ||| DT
responsiveness  ||| S:15367 E:15390 ||| JJ
level  ||| S:15390 E:15396 ||| NN
of  ||| S:15396 E:15399 ||| IN
GnRH  ||| S:15399 E:15404 ||| JJ
receptor  ||| S:15404 E:15413 ||| NN
signaling ||| S:15413 E:15422 ||| NNS
;  ||| S:15422 E:15424 ||| :
i.e. ||| S:15424 E:15428 ||| FW
,  ||| S:15428 E:15430 ||| ,
the  ||| S:15430 E:15434 ||| DT
RGS3  ||| S:15434 E:15439 ||| JJ
system  ||| S:15439 E:15454 ||| NN
acts  ||| S:15454 E:15459 ||| NNS
at  ||| S:15459 E:15462 ||| IN
the  ||| S:15462 E:15466 ||| DT
G  ||| S:15466 E:15468 ||| NNP
protein  ||| S:15468 E:15476 ||| NN
transducing  ||| S:15476 E:15488 ||| NN
step  ||| S:15488 E:15493 ||| NN
and  ||| S:15493 E:15497 ||| CC
the  ||| S:15497 E:15501 ||| DT
GRK ||| S:15501 E:15504 ||| NNP
/ ||| S:15504 E:15505 ||| NNP
β  ||| S:15505 E:15515 ||| VBD
arrestin  ||| S:15515 E:15524 ||| JJ
system  ||| S:15524 E:15531 ||| NN
acts  ||| S:15531 E:15536 ||| NNS
at  ||| S:15536 E:15539 ||| IN
the  ||| S:15539 E:15543 ||| DT
level  ||| S:15543 E:15549 ||| NN
of  ||| S:15549 E:15552 ||| IN
the  ||| S:15552 E:15556 ||| DT
receptor ||| S:15556 E:15564 ||| NN
.  ||| S:15564 E:15566 ||| .
Future  ||| S:15566 E:15581 ||| JJ
studies  ||| S:15581 E:15589 ||| NNS
must  ||| S:15589 E:15594 ||| MD
address  ||| S:15594 E:15602 ||| VB
whether  ||| S:15602 E:15610 ||| IN
both ||| S:15610 E:15614 ||| DT
,  ||| S:15614 E:15616 ||| ,
neither ||| S:15616 E:15623 ||| RB
,  ||| S:15623 E:15625 ||| ,
or  ||| S:15625 E:15628 ||| CC
only  ||| S:15628 E:15633 ||| RB
one  ||| S:15633 E:15637 ||| CD
of  ||| S:15637 E:15648 ||| IN
these  ||| S:15648 E:15654 ||| DT
mechanisms  ||| S:15654 E:15665 ||| NNS
are  ||| S:15665 E:15669 ||| VBP
physiologically  ||| S:15669 E:15685 ||| JJ
relevant ||| S:15685 E:15693 ||| JJ
.  ||| S:15693 E:15717 ||| .
Materials  ||| S:15717 E:15727 ||| NNS
and  ||| S:15727 E:15731 ||| CC
Methods  ||| S:15731 E:15758 ||| NNP
cDNA  ||| S:15758 E:15763 ||| JJ
transfection  ||| S:15763 E:15776 ||| NN
of  ||| S:15776 E:15779 ||| IN
COS-1  ||| S:15779 E:15785 ||| CD
cells  ||| S:15785 E:15791 ||| NNS
and  ||| S:15791 E:15795 ||| CC
measurement  ||| S:15795 E:15807 ||| NN
of  ||| S:15807 E:15820 ||| IN
IP  ||| S:15820 E:15823 ||| NNP
3production  ||| S:15823 E:15845 ||| NNP
cDNA  ||| S:15845 E:15850 ||| NNP
representing  ||| S:15850 E:15863 ||| VBG
the  ||| S:15863 E:15867 ||| DT
rat  ||| S:15867 E:15871 ||| JJ
GnRH  ||| S:15871 E:15876 ||| JJ
receptor  ||| S:15876 E:15885 ||| NN
was  ||| S:15885 E:15889 ||| VBD
cloned  ||| S:15889 E:15906 ||| VBN
into  ||| S:15906 E:15911 ||| IN
pcDNA3  ||| S:15911 E:15918 ||| NNP
as  ||| S:15918 E:15921 ||| RB
described  ||| S:15921 E:15931 ||| VBN
and  ||| S:15931 E:15935 ||| CC
validated  ||| S:15935 E:15945 ||| VBP
previously  ||| S:15945 E:15956 ||| RB
[  ||| S:15956 E:15958 ||| -LRB-
22  ||| S:15958 E:15961 ||| CD
23  ||| S:15961 E:15974 ||| CD
]  ||| S:15974 E:15976 ||| -RRB-
.  ||| S:15976 E:15978 ||| .
cDNAs  ||| S:15978 E:15984 ||| FW
representing  ||| S:15984 E:15997 ||| FW
RGS3  ||| S:15997 E:16002 ||| FW
and  ||| S:16002 E:16006 ||| CC
RGS3T  ||| S:16006 E:16012 ||| NNP
( ||| S:16012 E:16013 ||| -LRB-
RGS3  ||| S:16013 E:16018 ||| FW
amino  ||| S:16018 E:16024 ||| FW
acids  ||| S:16024 E:16040 ||| FW
314-519 ||| S:16040 E:16047 ||| FW
)  ||| S:16047 E:16049 ||| -RRB-
were  ||| S:16049 E:16054 ||| VBD
cloned  ||| S:16054 E:16061 ||| VBN
into  ||| S:16061 E:16066 ||| IN
the  ||| S:16066 E:16070 ||| DT
eukaryotic  ||| S:16070 E:16081 ||| JJ
expression  ||| S:16081 E:16102 ||| NN
vector ||| S:16102 E:16108 ||| NN
,  ||| S:16108 E:16110 ||| ,
rcCMV ||| S:16110 E:16115 ||| NNP
,  ||| S:16115 E:16117 ||| ,
as  ||| S:16117 E:16120 ||| RB
described  ||| S:16120 E:16130 ||| VBN
[  ||| S:16130 E:16132 ||| -LRB-
24  ||| S:16132 E:16135 ||| CD
]  ||| S:16135 E:16137 ||| -RRB-
.  ||| S:16137 E:16139 ||| .
COS-1  ||| S:16139 E:16145 ||| NNP
cells  ||| S:16145 E:16151 ||| NNS
cultured  ||| S:16151 E:16170 ||| VBP
as  ||| S:16170 E:16173 ||| RB
detailed  ||| S:16173 E:16182 ||| VBN
before  ||| S:16182 E:16189 ||| IN
[  ||| S:16189 E:16191 ||| -LRB-
23  ||| S:16191 E:16194 ||| CD
]  ||| S:16194 E:16196 ||| -RRB-
were  ||| S:16196 E:16201 ||| VBD
co-transfected  ||| S:16201 E:16216 ||| JJ
with  ||| S:16216 E:16221 ||| IN
GnRH  ||| S:16221 E:16236 ||| JJ
receptor  ||| S:16236 E:16245 ||| NN
cDNA  ||| S:16245 E:16250 ||| NN
and  ||| S:16250 E:16254 ||| CC
RGS3  ||| S:16254 E:16259 ||| NNP
or  ||| S:16259 E:16262 ||| CC
RGS3T  ||| S:16262 E:16268 ||| CD
cDNA  ||| S:16268 E:16273 ||| JJ
using  ||| S:16273 E:16279 ||| VBG
Lipofectamine  ||| S:16279 E:16303 ||| NNP
( ||| S:16303 E:16304 ||| -LRB-
Life  ||| S:16304 E:16309 ||| NNP
Technologies ||| S:16309 E:16321 ||| NNPS
,  ||| S:16321 E:16323 ||| ,
Gaithersburg ||| S:16323 E:16335 ||| NNP
,  ||| S:16335 E:16337 ||| ,
MD ||| S:16337 E:16339 ||| NNP
)  ||| S:16339 E:16341 ||| -RRB-
[  ||| S:16341 E:16343 ||| -LRB-
23  ||| S:16343 E:16346 ||| CD
]  ||| S:16346 E:16348 ||| -RRB-
,  ||| S:16348 E:16350 ||| ,
and  ||| S:16350 E:16354 ||| CC
72  ||| S:16354 E:16357 ||| CD
h  ||| S:16357 E:16369 ||| NNS
later ||| S:16369 E:16374 ||| RB
,  ||| S:16374 E:16376 ||| ,
treated  ||| S:16376 E:16384 ||| VBN
with  ||| S:16384 E:16389 ||| IN
10  ||| S:16389 E:16392 ||| CD
-7M  ||| S:16392 E:16396 ||| CD
GnRH-A  ||| S:16396 E:16403 ||| NN
for  ||| S:16403 E:16407 ||| IN
0 ||| S:16407 E:16408 ||| CD
,  ||| S:16408 E:16410 ||| ,
10 ||| S:16410 E:16412 ||| CD
,  ||| S:16412 E:16414 ||| ,
20 ||| S:16414 E:16416 ||| CD
,  ||| S:16416 E:16418 ||| ,
or  ||| S:16418 E:16421 ||| CC
30  ||| S:16421 E:16434 ||| CD
sec  ||| S:16434 E:16438 ||| NN
before  ||| S:16438 E:16445 ||| IN
being  ||| S:16445 E:16451 ||| VBG
collected  ||| S:16451 E:16461 ||| VBN
for  ||| S:16461 E:16465 ||| IN
IP  ||| S:16465 E:16479 ||| NNP
3  ||| S:16479 E:16481 ||| CD
measurements  ||| S:16481 E:16494 ||| NNS
[  ||| S:16494 E:16496 ||| -LRB-
22  ||| S:16496 E:16499 ||| CD
23  ||| S:16499 E:16502 ||| CD
]  ||| S:16502 E:16504 ||| -RRB-
.  ||| S:16504 E:16516 ||| .
IP  ||| S:16516 E:16530 ||| NNP
3  ||| S:16530 E:16532 ||| CD
measurements  ||| S:16532 E:16545 ||| NNS
were  ||| S:16545 E:16550 ||| VBD
performed  ||| S:16550 E:16560 ||| VBN
on  ||| S:16560 E:16563 ||| IN
COS-1  ||| S:16563 E:16579 ||| CD
cell  ||| S:16579 E:16584 ||| NN
cytosolic  ||| S:16584 E:16594 ||| NNS
preparations  ||| S:16594 E:16607 ||| VBP
using  ||| S:16607 E:16613 ||| VBG
a  ||| S:16613 E:16615 ||| DT
radioreceptor  ||| S:16615 E:16629 ||| JJ
assay  ||| S:16629 E:16645 ||| NN
in  ||| S:16645 E:16648 ||| IN
which  ||| S:16648 E:16654 ||| WDT
IP  ||| S:16654 E:16668 ||| NNP
3  ||| S:16668 E:16670 ||| CD
and  ||| S:16670 E:16674 ||| CC
3H-IP  ||| S:16674 E:16691 ||| CD
3  ||| S:16691 E:16693 ||| CD
compete  ||| S:16693 E:16701 ||| NN
for  ||| S:16701 E:16705 ||| IN
binding  ||| S:16705 E:16713 ||| VBG
to  ||| S:16713 E:16716 ||| TO
IP  ||| S:16716 E:16730 ||| NNP
3  ||| S:16730 E:16732 ||| CD
receptors  ||| S:16732 E:16742 ||| NNS
prepared  ||| S:16742 E:16751 ||| VBN
from  ||| S:16751 E:16756 ||| IN
calf  ||| S:16756 E:16771 ||| FW
cerebellum  ||| S:16771 E:16782 ||| FW
membranes  ||| S:16782 E:16792 ||| FW
[  ||| S:16792 E:16794 ||| -LRB-
22  ||| S:16794 E:16797 ||| CD
23  ||| S:16797 E:16800 ||| CD
]  ||| S:16800 E:16802 ||| -RRB-
.  ||| S:16802 E:16832 ||| .
RGS3  ||| S:16832 E:16837 ||| NNP
binding  ||| S:16837 E:16845 ||| NN
of  ||| S:16845 E:16848 ||| IN
Gα-proteins  ||| S:16848 E:16860 ||| JJ
in  ||| S:16860 E:16863 ||| IN
vitro  ||| S:16863 E:16879 ||| CD
RGS3  ||| S:16879 E:16884 ||| CD
protein  ||| S:16884 E:16892 ||| NN
fused  ||| S:16892 E:16898 ||| NN
to  ||| S:16898 E:16901 ||| TO
glutathione-S-transferase  ||| S:16901 E:16937 ||| NNP
( ||| S:16937 E:16938 ||| -LRB-
RSG3-GST  ||| S:16938 E:16947 ||| NNP
fusion  ||| S:16947 E:16954 ||| NN
protein ||| S:16954 E:16961 ||| NN
)  ||| S:16961 E:16963 ||| -RRB-
was  ||| S:16963 E:16967 ||| VBD
produced  ||| S:16967 E:16976 ||| VBN
in  ||| S:16976 E:16979 ||| IN
the  ||| S:16979 E:16983 ||| DT
pGEX-5x-1  ||| S:16983 E:17003 ||| JJ
system  ||| S:17003 E:17010 ||| NN
of  ||| S:17010 E:17013 ||| IN
Pharmacia  ||| S:17013 E:17023 ||| NNP
as  ||| S:17023 E:17026 ||| RB
detailed  ||| S:17026 E:17035 ||| VBN
previously  ||| S:17035 E:17046 ||| RB
[  ||| S:17046 E:17048 ||| -LRB-
9  ||| S:17048 E:17050 ||| CD
]  ||| S:17050 E:17052 ||| -RRB-
.  ||| S:17052 E:17064 ||| .
35S-Met  ||| S:17064 E:17072 ||| FW
labeled  ||| S:17072 E:17080 ||| FW
Gα-proteins  ||| S:17080 E:17092 ||| NNP
were  ||| S:17092 E:17097 ||| VBD
prepared  ||| S:17097 E:17117 ||| VBN
in  ||| S:17117 E:17120 ||| IN
vitro  ||| S:17120 E:17126 ||| NNS
using  ||| S:17126 E:17132 ||| VBG
a  ||| S:17132 E:17144 ||| DT
transcription ||| S:17144 E:17157 ||| FW
/ ||| S:17157 E:17158 ||| FW
translation  ||| S:17158 E:17170 ||| FW
protocol  ||| S:17170 E:17179 ||| FW
[  ||| S:17179 E:17181 ||| -LRB-
9  ||| S:17181 E:17183 ||| CD
]  ||| S:17183 E:17185 ||| -RRB-
.  ||| S:17185 E:17187 ||| .
cDNAs  ||| S:17187 E:17193 ||| JJ
for  ||| S:17193 E:17197 ||| IN
Gqα  ||| S:17197 E:17211 ||| NNP
[  ||| S:17211 E:17213 ||| -LRB-
25  ||| S:17213 E:17216 ||| CD
]  ||| S:17216 E:17218 ||| -RRB-
and  ||| S:17218 E:17222 ||| CC
Gzα  ||| S:17222 E:17226 ||| NNP
[  ||| S:17226 E:17228 ||| -LRB-
26  ||| S:17228 E:17231 ||| CD
]  ||| S:17231 E:17233 ||| -RRB-
were  ||| S:17233 E:17238 ||| VBD
obtained  ||| S:17238 E:17247 ||| VBN
from  ||| S:17247 E:17252 ||| IN
M.  ||| S:17252 E:17255 ||| NNP
I.  ||| S:17255 E:17258 ||| NNP
Simon ||| S:17258 E:17263 ||| NNP
;  ||| S:17263 E:17265 ||| :
for  ||| S:17265 E:17279 ||| IN
Gsα  ||| S:17279 E:17283 ||| NNP
( ||| S:17283 E:17284 ||| -LRB-
ref ||| S:17284 E:17287 ||| NN
.  ||| S:17287 E:17289 ||| .
No.  ||| S:17289 E:17293 ||| NNP
63315 ||| S:17293 E:17298 ||| CD
)  ||| S:17298 E:17300 ||| -RRB-
and  ||| S:17300 E:17304 ||| CC
Gi2α  ||| S:17304 E:17309 ||| NNP
( ||| S:17309 E:17310 ||| -LRB-
ref ||| S:17310 E:17313 ||| NN
.  ||| S:17313 E:17315 ||| .
No.  ||| S:17315 E:17319 ||| NNP
63311 ||| S:17319 E:17324 ||| CD
)  ||| S:17324 E:17326 ||| -RRB-
were  ||| S:17326 E:17341 ||| VBD
obtained  ||| S:17341 E:17350 ||| VBN
from  ||| S:17350 E:17355 ||| IN
the  ||| S:17355 E:17359 ||| DT
American  ||| S:17359 E:17368 ||| NNP
Type  ||| S:17368 E:17373 ||| NNP
Culture  ||| S:17373 E:17381 ||| NNP
Collection  ||| S:17381 E:17402 ||| NNP
( ||| S:17402 E:17403 ||| -LRB-
ATCC ||| S:17403 E:17407 ||| NNP
) ||| S:17407 E:17408 ||| -RRB-
;  ||| S:17408 E:17410 ||| :
for  ||| S:17410 E:17414 ||| IN
Gαo  ||| S:17414 E:17418 ||| NNP
[  ||| S:17418 E:17420 ||| -LRB-
27  ||| S:17420 E:17423 ||| CD
]  ||| S:17423 E:17425 ||| -RRB-
was  ||| S:17425 E:17429 ||| VBD
obtained  ||| S:17429 E:17438 ||| VBN
from  ||| S:17438 E:17443 ||| IN
Eva  ||| S:17443 E:17447 ||| NNP
G.  ||| S:17447 E:17450 ||| NNP
Neer ||| S:17450 E:17454 ||| NNP
;  ||| S:17454 E:17456 ||| :
for  ||| S:17456 E:17470 ||| IN
Gi1α ||| S:17470 E:17474 ||| NNP
,  ||| S:17474 E:17476 ||| ,
[  ||| S:17476 E:17478 ||| -LRB-
28  ||| S:17478 E:17481 ||| CD
]  ||| S:17481 E:17483 ||| -RRB-
from  ||| S:17483 E:17488 ||| IN
G.  ||| S:17488 E:17491 ||| NNP
R.  ||| S:17491 E:17494 ||| NNP
Post ||| S:17494 E:17498 ||| NNP
;  ||| S:17498 E:17500 ||| :
and ||| S:17500 E:17503 ||| CC
,  ||| S:17503 E:17505 ||| ,
for  ||| S:17505 E:17509 ||| IN
Gi3α  ||| S:17509 E:17514 ||| NNP
[  ||| S:17514 E:17516 ||| -LRB-
29  ||| S:17516 E:17519 ||| CD
]  ||| S:17519 E:17521 ||| -RRB-
from  ||| S:17521 E:17536 ||| IN
M.  ||| S:17536 E:17539 ||| NNP
G.  ||| S:17539 E:17542 ||| NNP
Farquhar ||| S:17542 E:17550 ||| NNP
.  ||| S:17550 E:17552 ||| .
Binding  ||| S:17552 E:17560 ||| JJ
studies  ||| S:17560 E:17568 ||| NNS
of  ||| S:17568 E:17571 ||| IN
recombinant  ||| S:17571 E:17583 ||| JJ
RGS3-GST  ||| S:17583 E:17602 ||| CD
fusion  ||| S:17602 E:17609 ||| NN
protein  ||| S:17609 E:17617 ||| NN
to  ||| S:17617 E:17620 ||| TO
35S-Met-Gα-proteins  ||| S:17620 E:17640 ||| NNP
were  ||| S:17640 E:17645 ||| VBD
performed  ||| S:17645 E:17655 ||| VBN
as  ||| S:17655 E:17668 ||| IN
detailed  ||| S:17668 E:17677 ||| JJ
[  ||| S:17677 E:17679 ||| -LRB-
9  ||| S:17679 E:17681 ||| CD
]  ||| S:17681 E:17683 ||| -RRB-
.  ||| S:17683 E:17685 ||| .
Glutathione-coupled  ||| S:17685 E:17705 ||| JJ
beads  ||| S:17705 E:17711 ||| NN
were  ||| S:17711 E:17716 ||| VBD
used  ||| S:17716 E:17721 ||| VBN
to  ||| S:17721 E:17734 ||| TO
select  ||| S:17734 E:17741 ||| VB
35S-Gα  ||| S:17741 E:17748 ||| CD
proteins  ||| S:17748 E:17757 ||| NNS
bound  ||| S:17757 E:17763 ||| VBN
to  ||| S:17763 E:17766 ||| TO
RGS3-GST ||| S:17766 E:17774 ||| CD
,  ||| S:17774 E:17776 ||| ,
and  ||| S:17776 E:17780 ||| CC
were  ||| S:17780 E:17785 ||| VBD
then  ||| S:17785 E:17800 ||| RB
eluted  ||| S:17800 E:17807 ||| VBN
for  ||| S:17807 E:17811 ||| IN
separation  ||| S:17811 E:17822 ||| NN
by  ||| S:17822 E:17825 ||| IN
SDS ||| S:17825 E:17828 ||| NNP
/ ||| S:17828 E:17829 ||| NNP
PAGE  ||| S:17829 E:17834 ||| NNP
[  ||| S:17834 E:17836 ||| -LRB-
9  ||| S:17836 E:17838 ||| CD
]  ||| S:17838 E:17840 ||| -RRB-
.  ||| S:17840 E:17842 ||| .
The  ||| S:17842 E:17846 ||| DT
amount  ||| S:17846 E:17853 ||| NN
and  ||| S:17853 E:17867 ||| CC
molecular  ||| S:17867 E:17877 ||| JJ
size  ||| S:17877 E:17882 ||| NN
of  ||| S:17882 E:17885 ||| IN
35S-Gα  ||| S:17885 E:17892 ||| CD
protein  ||| S:17892 E:17900 ||| NN
were  ||| S:17900 E:17905 ||| VBD
determined  ||| S:17905 E:17916 ||| VBN
using  ||| S:17916 E:17922 ||| VBG
a  ||| S:17922 E:17934 ||| DT
Phosphor  ||| S:17934 E:17943 ||| JJ
imaging  ||| S:17943 E:17951 ||| NN
device  ||| S:17951 E:17958 ||| NN
( ||| S:17958 E:17959 ||| -LRB-
Molecular  ||| S:17959 E:17969 ||| NNP
Dynamics ||| S:17969 E:17977 ||| NNPS
) ||| S:17977 E:17978 ||| -RRB-
.  ||| S:17978 E:18008 ||| .
Preparation  ||| S:18008 E:18020 ||| NN
of  ||| S:18020 E:18023 ||| IN
Adeno-RGS3  ||| S:18023 E:18044 ||| NNP
Recombinant  ||| S:18044 E:18056 ||| NNP
adenovirus  ||| S:18056 E:18067 ||| VBZ
containing  ||| S:18067 E:18078 ||| VBG
RGS3  ||| S:18078 E:18083 ||| NNP
cDNA  ||| S:18083 E:18088 ||| NNP
was  ||| S:18088 E:18102 ||| VBD
prepared  ||| S:18102 E:18111 ||| VBN
using  ||| S:18111 E:18117 ||| VBG
procedures  ||| S:18117 E:18128 ||| NNS
previously  ||| S:18128 E:18139 ||| RB
described  ||| S:18139 E:18149 ||| VBN
in  ||| S:18149 E:18152 ||| IN
detail  ||| S:18152 E:18169 ||| NN
by  ||| S:18169 E:18172 ||| IN
Becker  ||| S:18172 E:18190 ||| NNP
et  ||| S:18190 E:18193 ||| FW
al.  ||| S:18193 E:18197 ||| FW
[  ||| S:18197 E:18199 ||| -LRB-
30  ||| S:18199 E:18202 ||| CD
]  ||| S:18202 E:18204 ||| -RRB-
and  ||| S:18204 E:18208 ||| CC
by  ||| S:18208 E:18211 ||| IN
us  ||| S:18211 E:18214 ||| PRP
[  ||| S:18214 E:18216 ||| -LRB-
31  ||| S:18216 E:18219 ||| CD
]  ||| S:18219 E:18221 ||| -RRB-
.  ||| S:18221 E:18233 ||| .
Human  ||| S:18233 E:18239 ||| NNP
RGS3  ||| S:18239 E:18244 ||| NNP
cDNA  ||| S:18244 E:18249 ||| NNP
[  ||| S:18249 E:18251 ||| -LRB-
24  ||| S:18251 E:18254 ||| CD
]  ||| S:18254 E:18256 ||| -RRB-
was  ||| S:18256 E:18260 ||| VBD
restricted  ||| S:18260 E:18271 ||| VBN
from  ||| S:18271 E:18276 ||| IN
the  ||| S:18276 E:18280 ||| DT
pRC ||| S:18280 E:18283 ||| JJ
/ ||| S:18283 E:18284 ||| NNP
CMV  ||| S:18284 E:18298 ||| NNP
vector  ||| S:18298 E:18305 ||| NN
with  ||| S:18305 E:18310 ||| IN
EcoRI ||| S:18310 E:18315 ||| NNP
,  ||| S:18315 E:18317 ||| ,
and  ||| S:18317 E:18321 ||| CC
then  ||| S:18321 E:18326 ||| RB
subcloned  ||| S:18326 E:18336 ||| VBN
into  ||| S:18336 E:18341 ||| IN
the  ||| S:18341 E:18355 ||| DT
corresponding  ||| S:18355 E:18369 ||| JJ
site  ||| S:18369 E:18374 ||| NN
of  ||| S:18374 E:18377 ||| IN
the  ||| S:18377 E:18381 ||| DT
pACCMVpLpa  ||| S:18381 E:18392 ||| JJ
plasmid ||| S:18392 E:18399 ||| NN
.  ||| S:18399 E:18401 ||| .
The  ||| S:18401 E:18405 ||| DT
proper  ||| S:18405 E:18422 ||| JJ
orientation  ||| S:18422 E:18434 ||| NN
of  ||| S:18434 E:18437 ||| IN
the  ||| S:18437 E:18441 ||| DT
RGS3  ||| S:18441 E:18446 ||| NNP
cDNA  ||| S:18446 E:18451 ||| NNP
was  ||| S:18451 E:18455 ||| VBD
confirmed  ||| S:18455 E:18465 ||| VBN
by  ||| S:18465 E:18468 ||| IN
nucleotide  ||| S:18468 E:18489 ||| JJ
sequencing ||| S:18489 E:18499 ||| NN
.  ||| S:18499 E:18501 ||| .
The  ||| S:18501 E:18505 ||| DT
procedure  ||| S:18505 E:18515 ||| NN
for  ||| S:18515 E:18519 ||| IN
preparation  ||| S:18519 E:18531 ||| NN
of  ||| S:18531 E:18534 ||| IN
the  ||| S:18534 E:18548 ||| DT
adenovirus  ||| S:18548 E:18559 ||| NN
was  ||| S:18559 E:18563 ||| VBD
co-transfection  ||| S:18563 E:18579 ||| JJ
of  ||| S:18579 E:18582 ||| IN
a  ||| S:18582 E:18584 ||| DT
human  ||| S:18584 E:18590 ||| JJ
embryonic  ||| S:18590 E:18610 ||| JJ
kidney  ||| S:18610 E:18617 ||| NN
cell  ||| S:18617 E:18622 ||| NN
line  ||| S:18622 E:18627 ||| NN
( ||| S:18627 E:18628 ||| -LRB-
HEK  ||| S:18628 E:18632 ||| NNP
293 ||| S:18632 E:18635 ||| CD
)  ||| S:18635 E:18637 ||| -RRB-
with  ||| S:18637 E:18642 ||| IN
the  ||| S:18642 E:18646 ||| DT
pACCMVpLpa  ||| S:18646 E:18657 ||| JJ
plasmid  ||| S:18657 E:18675 ||| NN
and  ||| S:18675 E:18679 ||| CC
another  ||| S:18679 E:18687 ||| DT
plasmid  ||| S:18687 E:18695 ||| NN
( ||| S:18695 E:18696 ||| -LRB-
pJM17 ||| S:18696 E:18701 ||| NNP
)  ||| S:18701 E:18703 ||| -RRB-
containing  ||| S:18703 E:18714 ||| VBG
most  ||| S:18714 E:18719 ||| JJS
of  ||| S:18719 E:18722 ||| IN
the  ||| S:18722 E:18726 ||| DT
viral  ||| S:18726 E:18742 ||| JJ
genome  ||| S:18742 E:18749 ||| NNS
[  ||| S:18749 E:18751 ||| -LRB-
30  ||| S:18751 E:18754 ||| CD
]  ||| S:18754 E:18756 ||| -RRB-
.  ||| S:18756 E:18758 ||| .
A  ||| S:18758 E:18760 ||| DT
relatively  ||| S:18760 E:18771 ||| RB
rare  ||| S:18771 E:18776 ||| JJ
recombination  ||| S:18776 E:18790 ||| NN
of  ||| S:18790 E:18793 ||| IN
the  ||| S:18793 E:18807 ||| DT
two  ||| S:18807 E:18811 ||| CD
plasmids  ||| S:18811 E:18820 ||| NN
occurs  ||| S:18820 E:18827 ||| VBZ
in  ||| S:18827 E:18830 ||| IN
the  ||| S:18830 E:18834 ||| DT
HEK  ||| S:18834 E:18838 ||| NNP
293  ||| S:18838 E:18842 ||| CD
cells  ||| S:18842 E:18848 ||| NNS
that  ||| S:18848 E:18863 ||| WDT
reconstitutes  ||| S:18863 E:18877 ||| VBZ
the  ||| S:18877 E:18881 ||| DT
adenoviral  ||| S:18881 E:18892 ||| JJ
genome ||| S:18892 E:18898 ||| NN
.  ||| S:18898 E:18900 ||| .
The  ||| S:18900 E:18904 ||| DT
recombination  ||| S:18904 E:18928 ||| JJ
event  ||| S:18928 E:18934 ||| NN
reconstituting  ||| S:18934 E:18949 ||| VBD
adeno-RGS3  ||| S:18949 E:18960 ||| NNP
was  ||| S:18960 E:18964 ||| VBD
confirmed  ||| S:18964 E:18974 ||| VBN
using  ||| S:18974 E:18980 ||| VBG
PCR  ||| S:18980 E:18994 ||| NNP
analysis  ||| S:18994 E:19003 ||| NN
to  ||| S:19003 E:19006 ||| TO
detect  ||| S:19006 E:19013 ||| VB
the  ||| S:19013 E:19017 ||| DT
presence  ||| S:19017 E:19026 ||| NN
of  ||| S:19026 E:19029 ||| IN
RGS3  ||| S:19029 E:19034 ||| NNP
cDNA ||| S:19034 E:19038 ||| NNP
.  ||| S:19038 E:19040 ||| .
Next ||| S:19040 E:19044 ||| JJ
,  ||| S:19044 E:19056 ||| ,
adeno-RGS3  ||| S:19056 E:19067 ||| NNP
was  ||| S:19067 E:19071 ||| VBD
isolated  ||| S:19071 E:19080 ||| VBN
by  ||| S:19080 E:19083 ||| IN
clonal  ||| S:19083 E:19090 ||| JJ
selection  ||| S:19090 E:19100 ||| NN
in  ||| S:19100 E:19103 ||| IN
HEK  ||| S:19103 E:19107 ||| NNP
293  ||| S:19107 E:19121 ||| CD
cells  ||| S:19121 E:19127 ||| NNS
followed  ||| S:19127 E:19136 ||| VBN
by  ||| S:19136 E:19139 ||| IN
a  ||| S:19139 E:19141 ||| DT
second  ||| S:19141 E:19148 ||| JJ
PCR  ||| S:19148 E:19152 ||| NN
to  ||| S:19152 E:19155 ||| TO
confirm  ||| S:19155 E:19163 ||| VB
the  ||| S:19163 E:19167 ||| DT
presence  ||| S:19167 E:19176 ||| NN
of  ||| S:19176 E:19189 ||| IN
RGS3  ||| S:19189 E:19194 ||| NNP
cDNA ||| S:19194 E:19198 ||| NNP
.  ||| S:19198 E:19200 ||| .
Finally ||| S:19200 E:19207 ||| RB
,  ||| S:19207 E:19209 ||| ,
large-scale  ||| S:19209 E:19221 ||| JJ
amplification  ||| S:19221 E:19235 ||| NN
and  ||| S:19235 E:19249 ||| CC
titering  ||| S:19249 E:19258 ||| NN
of  ||| S:19258 E:19261 ||| IN
adeno-RGS3  ||| S:19261 E:19272 ||| NNP
was  ||| S:19272 E:19276 ||| VBD
performed  ||| S:19276 E:19286 ||| VBN
in  ||| S:19286 E:19289 ||| IN
HEK  ||| S:19289 E:19293 ||| NNP
293  ||| S:19293 E:19297 ||| CD
cells ||| S:19297 E:19302 ||| NNS
.  ||| S:19302 E:19314 ||| .
This  ||| S:19314 E:19319 ||| DT
virus  ||| S:19319 E:19325 ||| NN
preparation  ||| S:19325 E:19337 ||| NN
was  ||| S:19337 E:19341 ||| VBD
used  ||| S:19341 E:19346 ||| VBN
for  ||| S:19346 E:19350 ||| IN
infection  ||| S:19350 E:19360 ||| NN
of  ||| S:19360 E:19363 ||| IN
rat  ||| S:19363 E:19377 ||| JJ
pituitary  ||| S:19377 E:19387 ||| JJ
cells  ||| S:19387 E:19393 ||| NNS
[  ||| S:19393 E:19395 ||| -LRB-
31  ||| S:19395 E:19398 ||| CD
]  ||| S:19398 E:19400 ||| -RRB-
.  ||| S:19400 E:19430 ||| .
Culture  ||| S:19430 E:19438 ||| NN
and  ||| S:19438 E:19442 ||| CC
infection  ||| S:19442 E:19452 ||| NN
of  ||| S:19452 E:19455 ||| IN
rat  ||| S:19455 E:19459 ||| FW
pituitary  ||| S:19459 E:19469 ||| FW
cells  ||| S:19469 E:19485 ||| FW
Anterior  ||| S:19485 E:19494 ||| FW
pituitary  ||| S:19494 E:19504 ||| FW
glands  ||| S:19504 E:19511 ||| NN
were  ||| S:19511 E:19516 ||| VBD
obtained  ||| S:19516 E:19525 ||| VBN
from  ||| S:19525 E:19530 ||| IN
female  ||| S:19530 E:19547 ||| JJ
Charles  ||| S:19547 E:19555 ||| NNP
River  ||| S:19555 E:19561 ||| NNP
CD  ||| S:19561 E:19564 ||| NNP
rats  ||| S:19564 E:19569 ||| NNS
that  ||| S:19569 E:19574 ||| WDT
were  ||| S:19574 E:19579 ||| VBD
maintained  ||| S:19579 E:19590 ||| VBN
in  ||| S:19590 E:19593 ||| IN
accordance  ||| S:19593 E:19614 ||| NN
with  ||| S:19614 E:19619 ||| IN
the  ||| S:19619 E:19623 ||| DT
NIH  ||| S:19623 E:19627 ||| NNP
Guide  ||| S:19627 E:19633 ||| NNP
for  ||| S:19633 E:19637 ||| IN
the  ||| S:19637 E:19641 ||| DT
Care  ||| S:19641 E:19646 ||| NNP
and  ||| S:19646 E:19650 ||| CC
Use  ||| S:19650 E:19654 ||| NN
of  ||| S:19654 E:19657 ||| IN
Laboratory  ||| S:19657 E:19678 ||| NNP
Animals  ||| S:19678 E:19686 ||| NNPS
using  ||| S:19686 E:19692 ||| VBG
an  ||| S:19692 E:19695 ||| DT
experimental  ||| S:19695 E:19708 ||| JJ
protocol  ||| S:19708 E:19717 ||| NN
that  ||| S:19717 E:19722 ||| WDT
had  ||| S:19722 E:19726 ||| VBD
been  ||| S:19726 E:19741 ||| VBN
approved  ||| S:19741 E:19750 ||| VBN
by  ||| S:19750 E:19753 ||| IN
the  ||| S:19753 E:19757 ||| DT
Institutional  ||| S:19757 E:19771 ||| NNP
Animal  ||| S:19771 E:19778 ||| NNP
Care  ||| S:19778 E:19783 ||| NNP
and  ||| S:19783 E:19787 ||| CC
Use  ||| S:19787 E:19801 ||| NNP
Committee ||| S:19801 E:19810 ||| NNP
.  ||| S:19810 E:19812 ||| .
The  ||| S:19812 E:19816 ||| DT
pituitaries  ||| S:19816 E:19828 ||| NN
were  ||| S:19828 E:19833 ||| VBD
dispersed  ||| S:19833 E:19843 ||| VBN
with  ||| S:19843 E:19848 ||| IN
trypsin  ||| S:19848 E:19856 ||| VBG
as  ||| S:19856 E:19869 ||| RB
described  ||| S:19869 E:19879 ||| VBN
before  ||| S:19879 E:19886 ||| IN
[  ||| S:19886 E:19888 ||| -LRB-
32  ||| S:19888 E:19891 ||| CD
]  ||| S:19891 E:19893 ||| -RRB-
.  ||| S:19893 E:19895 ||| .
The  ||| S:19895 E:19899 ||| DT
mono-dispersed  ||| S:19899 E:19914 ||| JJ
cells  ||| S:19914 E:19920 ||| NNS
were  ||| S:19920 E:19935 ||| VBD
plated  ||| S:19935 E:19942 ||| VBN
into  ||| S:19942 E:19947 ||| IN
poly-L-lysine  ||| S:19947 E:19961 ||| JJ
coated  ||| S:19961 E:19968 ||| JJ
60  ||| S:19968 E:19971 ||| CD
mm  ||| S:19971 E:19974 ||| CD
plastic  ||| S:19974 E:19982 ||| JJ
Petri  ||| S:19982 E:19998 ||| JJ
dishes  ||| S:19998 E:20005 ||| NNS
in  ||| S:20005 E:20008 ||| IN
DMEM ||| S:20008 E:20012 ||| NNP
/ ||| S:20012 E:20013 ||| CD
10 ||| S:20013 E:20015 ||| CD
%  ||| S:20015 E:20017 ||| NN
gelding  ||| S:20017 E:20025 ||| NN
horse  ||| S:20025 E:20031 ||| NN
serum  ||| S:20031 E:20037 ||| VBZ
containing  ||| S:20037 E:20048 ||| VBG
10  ||| S:20048 E:20051 ||| CD
-9M  ||| S:20051 E:20065 ||| CD
estradiol  ||| S:20065 E:20075 ||| NN
to  ||| S:20075 E:20078 ||| TO
optimize  ||| S:20078 E:20087 ||| VB
the  ||| S:20087 E:20091 ||| DT
GnRH-responsiveness  ||| S:20091 E:20111 ||| JJ
of  ||| S:20111 E:20114 ||| IN
the  ||| S:20114 E:20128 ||| DT
gonadotropes  ||| S:20128 E:20141 ||| NN
[  ||| S:20141 E:20143 ||| -LRB-
33  ||| S:20143 E:20146 ||| CD
]  ||| S:20146 E:20148 ||| -RRB-
,  ||| S:20148 E:20150 ||| ,
and  ||| S:20150 E:20154 ||| CC
incubated  ||| S:20154 E:20164 ||| JJ
overnight  ||| S:20164 E:20174 ||| JJ
at  ||| S:20174 E:20177 ||| IN
37°C  ||| S:20177 E:20182 ||| CD
in  ||| S:20182 E:20195 ||| IN
8 ||| S:20195 E:20196 ||| CD
%  ||| S:20196 E:20198 ||| NN
CO  ||| S:20198 E:20212 ||| NNP
2  ||| S:20212 E:20214 ||| CD
-92 ||| S:20214 E:20217 ||| CD
%  ||| S:20217 E:20219 ||| NN
air ||| S:20219 E:20222 ||| NN
.  ||| S:20222 E:20234 ||| .
Pituitary  ||| S:20234 E:20244 ||| JJ
cells  ||| S:20244 E:20250 ||| NNS
were  ||| S:20250 E:20255 ||| VBD
infected  ||| S:20255 E:20264 ||| VBN
using  ||| S:20264 E:20270 ||| VBG
a  ||| S:20270 E:20272 ||| DT
volume  ||| S:20272 E:20279 ||| NN
of  ||| S:20279 E:20292 ||| IN
adeno-RGS3  ||| S:20292 E:20303 ||| NNP
or  ||| S:20303 E:20306 ||| CC
adeno-β  ||| S:20306 E:20314 ||| JJ
galactosidase  ||| S:20314 E:20328 ||| JJ
necessary  ||| S:20328 E:20338 ||| JJ
to  ||| S:20338 E:20341 ||| TO
achieve  ||| S:20341 E:20359 ||| VB
the  ||| S:20359 E:20363 ||| DT
chosen  ||| S:20363 E:20370 ||| JJ
multiplicity  ||| S:20370 E:20383 ||| NN
of  ||| S:20383 E:20386 ||| IN
infection  ||| S:20386 E:20396 ||| NN
( ||| S:20396 E:20397 ||| -LRB-
M.O.I. ||| S:20397 E:20403 ||| NNP
)  ||| S:20403 E:20405 ||| -RRB-
diluted  ||| S:20405 E:20413 ||| VBN
to  ||| S:20413 E:20426 ||| TO
0.3  ||| S:20426 E:20430 ||| CD
ml ||| S:20430 E:20432 ||| NNS
;  ||| S:20432 E:20434 ||| :
this  ||| S:20434 E:20439 ||| DT
was  ||| S:20439 E:20443 ||| VBD
further  ||| S:20443 E:20451 ||| RB
diluted  ||| S:20451 E:20459 ||| VBN
with  ||| S:20459 E:20464 ||| IN
1.2  ||| S:20464 E:20468 ||| CD
ml  ||| S:20468 E:20471 ||| NN
of  ||| S:20471 E:20474 ||| IN
TS  ||| S:20474 E:20477 ||| NNP
buffer  ||| S:20477 E:20494 ||| NN
( ||| S:20494 E:20495 ||| -LRB-
8.0  ||| S:20495 E:20499 ||| FW
gm ||| S:20499 E:20501 ||| FW
/ ||| S:20501 E:20502 ||| FW
L  ||| S:20502 E:20504 ||| NNP
NaCI ||| S:20504 E:20508 ||| NNP
,  ||| S:20508 E:20510 ||| ,
380  ||| S:20510 E:20514 ||| CD
mg ||| S:20514 E:20516 ||| CD
/ ||| S:20516 E:20517 ||| CD
L  ||| S:20517 E:20519 ||| NNP
KCl ||| S:20519 E:20522 ||| NNP
,  ||| S:20522 E:20524 ||| ,
100  ||| S:20524 E:20528 ||| CD
mg ||| S:20528 E:20530 ||| CD
/ ||| S:20530 E:20531 ||| CD
L  ||| S:20531 E:20533 ||| NNP
Na  ||| S:20533 E:20547 ||| NNP
2  ||| S:20547 E:20549 ||| CD
HPO  ||| S:20549 E:20564 ||| CD
4  ||| S:20564 E:20566 ||| CD
,  ||| S:20566 E:20568 ||| ,
3.0  ||| S:20568 E:20572 ||| FW
gm ||| S:20572 E:20574 ||| FW
/ ||| S:20574 E:20575 ||| FW
L  ||| S:20575 E:20577 ||| NNP
Tris  ||| S:20577 E:20582 ||| NNP
HCI ||| S:20582 E:20585 ||| NNP
,  ||| S:20585 E:20587 ||| ,
200  ||| S:20587 E:20591 ||| CD
mg ||| S:20591 E:20593 ||| CD
/ ||| S:20593 E:20594 ||| CD
L  ||| S:20594 E:20596 ||| NNP
CaCl  ||| S:20596 E:20612 ||| NNP
2  ||| S:20612 E:20614 ||| CD
·  ||| S:20614 E:20616 ||| CD
2H  ||| S:20616 E:20630 ||| CD
2  ||| S:20630 E:20632 ||| CD
O ||| S:20632 E:20633 ||| NNP
,  ||| S:20633 E:20635 ||| ,
100  ||| S:20635 E:20639 ||| CD
mg ||| S:20639 E:20641 ||| CD
/ ||| S:20641 E:20642 ||| CD
L  ||| S:20642 E:20644 ||| NNP
MgCl  ||| S:20644 E:20660 ||| NNP
2  ||| S:20660 E:20662 ||| CD
·  ||| S:20662 E:20664 ||| CD
6H  ||| S:20664 E:20678 ||| CD
2  ||| S:20678 E:20680 ||| CD
O ||| S:20680 E:20681 ||| NNS
;  ||| S:20681 E:20683 ||| :
pH  ||| S:20683 E:20686 ||| JJ
7.4 ||| S:20686 E:20689 ||| CD
) ||| S:20689 E:20690 ||| -RRB-
.  ||| S:20690 E:20692 ||| .
The  ||| S:20692 E:20696 ||| DT
pituitary  ||| S:20696 E:20706 ||| JJ
cell  ||| S:20706 E:20721 ||| NN
culture  ||| S:20721 E:20729 ||| NN
medium  ||| S:20729 E:20736 ||| NN
was  ||| S:20736 E:20740 ||| VBD
aspirated  ||| S:20740 E:20750 ||| JJ
and  ||| S:20750 E:20754 ||| CC
replaced  ||| S:20754 E:20763 ||| VBN
with  ||| S:20763 E:20768 ||| IN
the  ||| S:20768 E:20772 ||| DT
virus  ||| S:20772 E:20788 ||| NN
solution ||| S:20788 E:20796 ||| NN
,  ||| S:20796 E:20798 ||| ,
and  ||| S:20798 E:20802 ||| CC
the  ||| S:20802 E:20806 ||| DT
cells  ||| S:20806 E:20812 ||| NNS
were  ||| S:20812 E:20817 ||| VBD
incubated  ||| S:20817 E:20827 ||| VBN
at  ||| S:20827 E:20830 ||| IN
37°C  ||| S:20830 E:20835 ||| CD
in  ||| S:20835 E:20838 ||| IN
a  ||| S:20838 E:20840 ||| DT
CO  ||| S:20840 E:20854 ||| NNP
2  ||| S:20854 E:20856 ||| CD
incubator  ||| S:20856 E:20866 ||| NN
for  ||| S:20866 E:20870 ||| IN
approximately  ||| S:20870 E:20884 ||| RB
72  ||| S:20884 E:20897 ||| CD
h ||| S:20897 E:20898 ||| NNS
.  ||| S:20898 E:20910 ||| .
Next ||| S:20910 E:20914 ||| JJ
,  ||| S:20914 E:20916 ||| ,
the  ||| S:20916 E:20920 ||| DT
cells  ||| S:20920 E:20926 ||| NNS
were  ||| S:20926 E:20931 ||| VBD
collected  ||| S:20931 E:20941 ||| VBN
by  ||| S:20941 E:20944 ||| IN
trypsinization  ||| S:20944 E:20959 ||| NN
and  ||| S:20959 E:20973 ||| CC
counted  ||| S:20973 E:20981 ||| VBN
using  ||| S:20981 E:20987 ||| VBG
a  ||| S:20987 E:20989 ||| DT
hemocytometer ||| S:20989 E:21002 ||| NN
;  ||| S:21002 E:21004 ||| :
then ||| S:21004 E:21008 ||| RB
,  ||| S:21008 E:21010 ||| ,
they  ||| S:21010 E:21015 ||| PRP
were  ||| S:21015 E:21020 ||| VBD
checked  ||| S:21020 E:21038 ||| VBN
for  ||| S:21038 E:21042 ||| IN
viability  ||| S:21042 E:21052 ||| NN
using  ||| S:21052 E:21058 ||| VBG
trypan  ||| S:21058 E:21065 ||| JJ
blue  ||| S:21065 E:21070 ||| JJ
[  ||| S:21070 E:21072 ||| -LRB-
31  ||| S:21072 E:21075 ||| CD
]  ||| S:21075 E:21077 ||| -RRB-
.  ||| S:21077 E:21079 ||| .
The  ||| S:21079 E:21083 ||| DT
cells  ||| S:21083 E:21089 ||| NNS
were  ||| S:21089 E:21104 ||| VBD
replated  ||| S:21104 E:21113 ||| VBN
for  ||| S:21113 E:21117 ||| IN
2  ||| S:21117 E:21119 ||| CD
h  ||| S:21119 E:21121 ||| NN
at  ||| S:21121 E:21124 ||| IN
37°C  ||| S:21124 E:21129 ||| CD
in  ||| S:21129 E:21132 ||| IN
DMEM  ||| S:21132 E:21137 ||| NNP
-0.1 ||| S:21137 E:21141 ||| NNP
%  ||| S:21141 E:21143 ||| NN
bovine  ||| S:21143 E:21150 ||| FW
serum  ||| S:21150 E:21166 ||| FW
albumin  ||| S:21166 E:21174 ||| FW
( ||| S:21174 E:21175 ||| -LRB-
BSA ||| S:21175 E:21178 ||| NNP
)  ||| S:21178 E:21180 ||| -RRB-
and  ||| S:21180 E:21184 ||| CC
subjected  ||| S:21184 E:21194 ||| VBN
to  ||| S:21194 E:21197 ||| TO
x-gal  ||| S:21197 E:21203 ||| JJ
staining  ||| S:21203 E:21212 ||| NN
for  ||| S:21212 E:21226 ||| IN
determination  ||| S:21226 E:21240 ||| NN
of  ||| S:21240 E:21243 ||| IN
the  ||| S:21243 E:21247 ||| DT
fraction  ||| S:21247 E:21256 ||| NN
of  ||| S:21256 E:21259 ||| IN
cells  ||| S:21259 E:21265 ||| NNS
infected  ||| S:21265 E:21274 ||| VBN
by  ||| S:21274 E:21277 ||| IN
the  ||| S:21277 E:21291 ||| DT
virus  ||| S:21291 E:21297 ||| NN
[  ||| S:21297 E:21299 ||| -LRB-
31  ||| S:21299 E:21302 ||| CD
]  ||| S:21302 E:21304 ||| -RRB-
,  ||| S:21304 E:21306 ||| ,
or  ||| S:21306 E:21309 ||| CC
to  ||| S:21309 E:21312 ||| TO
stimulation  ||| S:21312 E:21324 ||| VB
by  ||| S:21324 E:21327 ||| IN
GnRH-A  ||| S:21327 E:21334 ||| JJ
for  ||| S:21334 E:21348 ||| IN
measurement  ||| S:21348 E:21360 ||| NN
of  ||| S:21360 E:21363 ||| IN
LH  ||| S:21363 E:21366 ||| NNP
release ||| S:21366 E:21373 ||| NN
.  ||| S:21373 E:21403 ||| .
GnRH-stimulated  ||| S:21403 E:21419 ||| NNP
LH  ||| S:21419 E:21422 ||| NNP
secretion  ||| S:21422 E:21442 ||| VBD
Pituitary  ||| S:21442 E:21452 ||| JJ
cells  ||| S:21452 E:21458 ||| NNS
that  ||| S:21458 E:21463 ||| WDT
had  ||| S:21463 E:21467 ||| VBD
been  ||| S:21467 E:21472 ||| VBN
re-trypsinized  ||| S:21472 E:21487 ||| JJ
72  ||| S:21487 E:21490 ||| CD
h  ||| S:21490 E:21502 ||| NN
after  ||| S:21502 E:21508 ||| IN
infection  ||| S:21508 E:21518 ||| NN
and  ||| S:21518 E:21522 ||| CC
then  ||| S:21522 E:21527 ||| RB
replated  ||| S:21527 E:21536 ||| JJ
( ||| S:21536 E:21537 ||| -LRB-
100,000  ||| S:21537 E:21545 ||| CD
cells ||| S:21545 E:21550 ||| NNS
/ ||| S:21550 E:21551 ||| VBP
well  ||| S:21551 E:21556 ||| RB
in  ||| S:21556 E:21569 ||| IN
a  ||| S:21569 E:21571 ||| DT
24-well  ||| S:21571 E:21579 ||| JJ
poly-L-lysine  ||| S:21579 E:21593 ||| JJ
coated  ||| S:21593 E:21600 ||| JJ
plate ||| S:21600 E:21605 ||| NN
)  ||| S:21605 E:21607 ||| -RRB-
for  ||| S:21607 E:21611 ||| IN
a  ||| S:21611 E:21613 ||| DT
2  ||| S:21613 E:21615 ||| CD
h  ||| S:21615 E:21627 ||| CD
preincubation  ||| S:21627 E:21641 ||| NNS
were  ||| S:21641 E:21646 ||| VBD
subsequently  ||| S:21646 E:21659 ||| RB
treated  ||| S:21659 E:21667 ||| VBN
with  ||| S:21667 E:21672 ||| IN
a  ||| S:21672 E:21674 ||| DT
GnRH  ||| S:21674 E:21689 ||| JJ
agonist  ||| S:21689 E:21697 ||| NNS
( ||| S:21697 E:21698 ||| -LRB-
1  ||| S:21698 E:21700 ||| CD
ml  ||| S:21700 E:21703 ||| NN
of  ||| S:21703 E:21706 ||| IN
10  ||| S:21706 E:21709 ||| CD
-7M  ||| S:21709 E:21713 ||| FW
D-Ala  ||| S:21713 E:21719 ||| FW
6-  ||| S:21719 E:21722 ||| FW
des  ||| S:21722 E:21726 ||| FW
Gly  ||| S:21726 E:21730 ||| FW
10-  ||| S:21730 E:21734 ||| FW
GnRH  ||| S:21734 E:21749 ||| FW
ethylamide ||| S:21749 E:21759 ||| FW
;  ||| S:21759 E:21761 ||| :
GnRH-A ||| S:21761 E:21767 ||| NNP
,  ||| S:21767 E:21769 ||| ,
Sigma ||| S:21769 E:21774 ||| NNP
,  ||| S:21774 E:21776 ||| ,
St.  ||| S:21776 E:21780 ||| NNP
Louis ||| S:21780 E:21785 ||| NNP
,  ||| S:21785 E:21787 ||| ,
MO ||| S:21787 E:21789 ||| NNP
)  ||| S:21789 E:21791 ||| -RRB-
or  ||| S:21791 E:21794 ||| CC
a  ||| S:21794 E:21796 ||| DT
calcium  ||| S:21796 E:21814 ||| JJ
ionophore  ||| S:21814 E:21824 ||| NNS
( ||| S:21824 E:21825 ||| -LRB-
A23187 ||| S:21825 E:21831 ||| NNP
,  ||| S:21831 E:21833 ||| ,
Sigma ||| S:21833 E:21838 ||| NNP
)  ||| S:21838 E:21840 ||| -RRB-
for  ||| S:21840 E:21844 ||| IN
3  ||| S:21844 E:21846 ||| CD
h  ||| S:21846 E:21848 ||| NNS
as  ||| S:21848 E:21851 ||| RB
described  ||| S:21851 E:21861 ||| VBN
by  ||| S:21861 E:21864 ||| IN
Conn  ||| S:21864 E:21880 ||| NNP
et  ||| S:21880 E:21883 ||| FW
al.  ||| S:21883 E:21887 ||| FW
[  ||| S:21887 E:21889 ||| -LRB-
34  ||| S:21889 E:21892 ||| CD
]  ||| S:21892 E:21894 ||| -RRB-
.  ||| S:21894 E:21896 ||| .
The  ||| S:21896 E:21900 ||| DT
medium  ||| S:21900 E:21907 ||| NN
was  ||| S:21907 E:21921 ||| VBD
removed  ||| S:21921 E:21929 ||| VBN
and  ||| S:21929 E:21933 ||| CC
centrifuged  ||| S:21933 E:21945 ||| NN
at  ||| S:21945 E:21948 ||| IN
200  ||| S:21948 E:21952 ||| CD
×  ||| S:21952 E:21954 ||| CD
g  ||| S:21954 E:21956 ||| NN
for  ||| S:21956 E:21960 ||| IN
10  ||| S:21960 E:21963 ||| CD
min  ||| S:21963 E:21967 ||| NN
to  ||| S:21967 E:21970 ||| TO
pellet  ||| S:21970 E:21987 ||| VB
any  ||| S:21987 E:21991 ||| DT
detached  ||| S:21991 E:22000 ||| JJ
cells ||| S:22000 E:22005 ||| NNS
.  ||| S:22005 E:22007 ||| .
The  ||| S:22007 E:22011 ||| DT
supernatant  ||| S:22011 E:22023 ||| JJ
solution  ||| S:22023 E:22032 ||| NN
was  ||| S:22032 E:22036 ||| VBD
either  ||| S:22036 E:22053 ||| RB
used  ||| S:22053 E:22058 ||| VBN
immediately  ||| S:22058 E:22070 ||| RB
or  ||| S:22070 E:22073 ||| CC
stored  ||| S:22073 E:22080 ||| VBD
at  ||| S:22080 E:22083 ||| IN
-20°C  ||| S:22083 E:22089 ||| CD
prior  ||| S:22089 E:22095 ||| JJ
to  ||| S:22095 E:22098 ||| TO
RIA ||| S:22098 E:22101 ||| NNP
.  ||| S:22101 E:22113 ||| .
LH  ||| S:22113 E:22116 ||| NNP
RIAs  ||| S:22116 E:22121 ||| NNP
were  ||| S:22121 E:22126 ||| VBD
performed  ||| S:22126 E:22136 ||| VBN
using  ||| S:22136 E:22142 ||| VBG
reagents  ||| S:22142 E:22151 ||| NNS
and  ||| S:22151 E:22155 ||| CC
instructions  ||| S:22155 E:22178 ||| NNS
provided  ||| S:22178 E:22187 ||| VBN
by  ||| S:22187 E:22190 ||| IN
Dr.  ||| S:22190 E:22194 ||| NNP
A.  ||| S:22194 E:22197 ||| NNP
F.  ||| S:22197 E:22200 ||| NNP
Parlow  ||| S:22200 E:22207 ||| NNP
on  ||| S:22207 E:22210 ||| IN
behalf  ||| S:22210 E:22217 ||| NN
of  ||| S:22217 E:22220 ||| IN
the  ||| S:22220 E:22224 ||| DT
National  ||| S:22224 E:22243 ||| NNP
Hormone  ||| S:22243 E:22251 ||| NNP
and  ||| S:22251 E:22255 ||| CC
Pituitary  ||| S:22255 E:22265 ||| NNP
Program ||| S:22265 E:22272 ||| NNP
,  ||| S:22272 E:22274 ||| ,
National  ||| S:22274 E:22283 ||| NNP
Institute  ||| S:22283 E:22293 ||| NNP
of  ||| S:22293 E:22306 ||| IN
Diabetes  ||| S:22306 E:22315 ||| NNP
and  ||| S:22315 E:22319 ||| CC
Digestive  ||| S:22319 E:22329 ||| NNP
and  ||| S:22329 E:22333 ||| CC
Kidney  ||| S:22333 E:22340 ||| NNP
Diseases ||| S:22340 E:22348 ||| NNP
,  ||| S:22348 E:22350 ||| ,
NIH ||| S:22350 E:22353 ||| NNP
.  ||| S:22353 E:22355 ||| .
Rat  ||| S:22355 E:22359 ||| NNP
LH  ||| S:22359 E:22372 ||| NNP
( ||| S:22372 E:22373 ||| -LRB-
NIDDK-rLH-l-9 ||| S:22373 E:22386 ||| NNP
)  ||| S:22386 E:22388 ||| -RRB-
was  ||| S:22388 E:22392 ||| VBD
radioiodinated ||| S:22392 E:22406 ||| CD
,  ||| S:22406 E:22408 ||| ,
the  ||| S:22408 E:22412 ||| DT
LH  ||| S:22412 E:22415 ||| NNP
antiserum  ||| S:22415 E:22435 ||| NNS
( ||| S:22435 E:22436 ||| -LRB-
NIDDK-anti-rLH-S-11 ||| S:22436 E:22455 ||| NNP
)  ||| S:22455 E:22457 ||| -RRB-
was  ||| S:22457 E:22461 ||| VBD
prepared  ||| S:22461 E:22470 ||| VBN
in  ||| S:22470 E:22473 ||| IN
rabbits ||| S:22473 E:22480 ||| NN
,  ||| S:22480 E:22482 ||| ,
and  ||| S:22482 E:22486 ||| CC
the  ||| S:22486 E:22500 ||| DT
reference  ||| S:22500 E:22510 ||| NN
standard  ||| S:22510 E:22519 ||| NN
was  ||| S:22519 E:22523 ||| VBD
NIDDK-rLH-RP3 ||| S:22523 E:22536 ||| CD
.  ||| S:22536 E:22538 ||| .
The  ||| S:22538 E:22542 ||| DT
mean  ||| S:22542 E:22547 ||| JJ
EC  ||| S:22547 E:22561 ||| NNP
50  ||| S:22561 E:22564 ||| CD
of  ||| S:22564 E:22567 ||| IN
the  ||| S:22567 E:22571 ||| DT
standard  ||| S:22571 E:22580 ||| JJ
curves  ||| S:22580 E:22587 ||| NNS
( ||| S:22587 E:22588 ||| -LRB-
n  ||| S:22588 E:22590 ||| CD
=  ||| S:22590 E:22592 ||| SYM
10 ||| S:22592 E:22594 ||| CD
)  ||| S:22594 E:22596 ||| -RRB-
was  ||| S:22596 E:22610 ||| VBD
0.59  ||| S:22610 E:22615 ||| CD
ng  ||| S:22615 E:22618 ||| NN
with  ||| S:22618 E:22623 ||| IN
a  ||| S:22623 E:22625 ||| DT
coefficient  ||| S:22625 E:22637 ||| NN
of  ||| S:22637 E:22640 ||| IN
variation  ||| S:22640 E:22650 ||| NN
of  ||| S:22650 E:22653 ||| IN
4.4 ||| S:22653 E:22656 ||| CD
% ||| S:22656 E:22657 ||| NN
.  ||| S:22657 E:22687 ||| .
GNRH-stimulated  ||| S:22687 E:22703 ||| NNP
3H-inositol  ||| S:22703 E:22715 ||| NNP
phosphate  ||| S:22715 E:22725 ||| JJ
accumulation  ||| S:22725 E:22748 ||| NN
in  ||| S:22748 E:22751 ||| IN
pituitary  ||| S:22751 E:22761 ||| JJ
cells  ||| S:22761 E:22777 ||| NNS
Total  ||| S:22777 E:22783 ||| JJ
[  ||| S:22783 E:22785 ||| -LRB-
3H ||| S:22785 E:22787 ||| NNP
]  ||| S:22787 E:22789 ||| -RRB-
inositol  ||| S:22789 E:22798 ||| JJ
phosphate  ||| S:22798 E:22808 ||| JJ
accumulation  ||| S:22808 E:22821 ||| NN
was  ||| S:22821 E:22835 ||| VBD
determined  ||| S:22835 E:22846 ||| VBN
in  ||| S:22846 E:22849 ||| IN
[  ||| S:22849 E:22851 ||| -LRB-
3H ||| S:22851 E:22853 ||| NNP
]  ||| S:22853 E:22855 ||| -RRB-
myoinositol-labeled  ||| S:22855 E:22875 ||| JJ
pituitary  ||| S:22875 E:22885 ||| JJ
cells  ||| S:22885 E:22901 ||| NNS
as  ||| S:22901 E:22904 ||| RB
described  ||| S:22904 E:22914 ||| VBN
earlier  ||| S:22914 E:22922 ||| RBR
[  ||| S:22922 E:22924 ||| -LRB-
22  ||| S:22924 E:22927 ||| CD
]  ||| S:22927 E:22929 ||| -RRB-
.  ||| S:22929 E:22931 ||| .
At  ||| S:22931 E:22934 ||| IN
48  ||| S:22934 E:22937 ||| CD
h  ||| S:22937 E:22939 ||| NN
after  ||| S:22939 E:22945 ||| IN
infection  ||| S:22945 E:22955 ||| NN
of  ||| S:22955 E:22968 ||| IN
the  ||| S:22968 E:22972 ||| DT
pituitary  ||| S:22972 E:22982 ||| JJ
cells ||| S:22982 E:22987 ||| NNS
,  ||| S:22987 E:22989 ||| ,
the  ||| S:22989 E:22993 ||| DT
incubation  ||| S:22993 E:23004 ||| JJ
medium  ||| S:23004 E:23011 ||| NN
was  ||| S:23011 E:23015 ||| VBD
removed  ||| S:23015 E:23033 ||| VBN
and  ||| S:23033 E:23037 ||| CC
replaced  ||| S:23037 E:23046 ||| VBN
with  ||| S:23046 E:23051 ||| IN
a  ||| S:23051 E:23053 ||| DT
balanced  ||| S:23053 E:23062 ||| JJ
salt  ||| S:23062 E:23067 ||| NN
solution  ||| S:23067 E:23076 ||| NN
( ||| S:23076 E:23077 ||| -LRB-
10  ||| S:23077 E:23080 ||| CD
mM  ||| S:23080 E:23083 ||| JJ
Hepes ||| S:23083 E:23088 ||| NNP
,  ||| S:23088 E:23100 ||| ,
pH7.4 ||| S:23100 E:23105 ||| NNP
,  ||| S:23105 E:23107 ||| ,
135  ||| S:23107 E:23111 ||| CD
mM  ||| S:23111 E:23114 ||| JJ
NaCI ||| S:23114 E:23118 ||| NN
,  ||| S:23118 E:23120 ||| ,
4.5  ||| S:23120 E:23124 ||| CD
mM  ||| S:23124 E:23127 ||| JJ
KCL ||| S:23127 E:23130 ||| NNP
,  ||| S:23130 E:23132 ||| ,
1.5  ||| S:23132 E:23136 ||| CD
mM  ||| S:23136 E:23139 ||| JJ
CaCl  ||| S:23139 E:23155 ||| JJ
2  ||| S:23155 E:23157 ||| CD
,  ||| S:23157 E:23159 ||| ,
0.5  ||| S:23159 E:23163 ||| CD
mM  ||| S:23163 E:23166 ||| JJ
MgCL  ||| S:23166 E:23182 ||| JJ
2  ||| S:23182 E:23184 ||| CD
,  ||| S:23184 E:23186 ||| ,
1.0  ||| S:23186 E:23190 ||| CD
mM  ||| S:23190 E:23193 ||| JJ
NaH  ||| S:23193 E:23208 ||| JJ
2  ||| S:23208 E:23210 ||| CD
PO4 ||| S:23210 E:23213 ||| CD
,  ||| S:23213 E:23215 ||| ,
5.6  ||| S:23215 E:23219 ||| CD
mM  ||| S:23219 E:23222 ||| JJ
glucose ||| S:23222 E:23229 ||| NN
,  ||| S:23229 E:23231 ||| ,
0.3 ||| S:23231 E:23234 ||| CD
%  ||| S:23234 E:23236 ||| NN
BSA ||| S:23236 E:23239 ||| NNP
,  ||| S:23239 E:23241 ||| ,
and  ||| S:23241 E:23255 ||| CC
10  ||| S:23255 E:23258 ||| CD
-9M  ||| S:23258 E:23262 ||| CD
estradiol ||| S:23262 E:23271 ||| CD
)  ||| S:23271 E:23273 ||| -RRB-
containing  ||| S:23273 E:23284 ||| VBG
5  ||| S:23284 E:23286 ||| CD
μCi  ||| S:23286 E:23290 ||| NN
of  ||| S:23290 E:23293 ||| IN
[  ||| S:23293 E:23305 ||| -LRB-
3H ||| S:23305 E:23307 ||| NNP
] ||| S:23307 E:23308 ||| -RRB-
-myoinositol ||| S:23308 E:23320 ||| JJ
/ ||| S:23320 E:23321 ||| CD
ml  ||| S:23321 E:23324 ||| NN
of  ||| S:23324 E:23327 ||| IN
medium ||| S:23327 E:23333 ||| NN
.  ||| S:23333 E:23335 ||| .
After  ||| S:23335 E:23341 ||| IN
a  ||| S:23341 E:23343 ||| DT
further  ||| S:23343 E:23351 ||| JJ
24  ||| S:23351 E:23354 ||| CD
h ||| S:23354 E:23355 ||| NN
,  ||| S:23355 E:23357 ||| ,
the  ||| S:23357 E:23371 ||| DT
pituitary  ||| S:23371 E:23381 ||| JJ
cells  ||| S:23381 E:23387 ||| NNS
were  ||| S:23387 E:23392 ||| VBD
recovered  ||| S:23392 E:23402 ||| VBN
by  ||| S:23402 E:23405 ||| IN
trypinization ||| S:23405 E:23418 ||| NN
,  ||| S:23418 E:23420 ||| ,
counted ||| S:23420 E:23427 ||| VBN
,  ||| S:23427 E:23439 ||| ,
and  ||| S:23439 E:23443 ||| CC
replated  ||| S:23443 E:23452 ||| NN
in  ||| S:23452 E:23455 ||| IN
balanced  ||| S:23455 E:23464 ||| JJ
salt  ||| S:23464 E:23469 ||| NN
solution  ||| S:23469 E:23478 ||| NN
( ||| S:23478 E:23479 ||| -LRB-
400,000  ||| S:23479 E:23487 ||| CD
-  ||| S:23487 E:23489 ||| :
500,000  ||| S:23489 E:23507 ||| CD
cells ||| S:23507 E:23512 ||| NNS
/ ||| S:23512 E:23513 ||| VBP
well  ||| S:23513 E:23518 ||| RB
in  ||| S:23518 E:23521 ||| IN
a  ||| S:23521 E:23523 ||| DT
24-well  ||| S:23523 E:23531 ||| JJ
plate ||| S:23531 E:23536 ||| NN
)  ||| S:23536 E:23538 ||| -RRB-
for  ||| S:23538 E:23542 ||| IN
a  ||| S:23542 E:23544 ||| DT
2  ||| S:23544 E:23546 ||| CD
h  ||| S:23546 E:23548 ||| CD
preincubation ||| S:23548 E:23561 ||| NNS
.  ||| S:23561 E:23573 ||| .
Then ||| S:23573 E:23577 ||| RB
,  ||| S:23577 E:23579 ||| ,
the  ||| S:23579 E:23583 ||| DT
cells  ||| S:23583 E:23589 ||| NNS
were  ||| S:23589 E:23594 ||| VBD
stimulated  ||| S:23594 E:23605 ||| VBN
with  ||| S:23605 E:23610 ||| IN
GnRH-A  ||| S:23610 E:23617 ||| NNP
( ||| S:23617 E:23618 ||| -LRB-
10  ||| S:23618 E:23621 ||| CD
-7M  ||| S:23621 E:23625 ||| CD
for  ||| S:23625 E:23639 ||| IN
one  ||| S:23639 E:23643 ||| CD
hr ||| S:23643 E:23645 ||| CD
)  ||| S:23645 E:23647 ||| -RRB-
in  ||| S:23647 E:23650 ||| IN
the  ||| S:23650 E:23654 ||| DT
presence  ||| S:23654 E:23663 ||| NN
of  ||| S:23663 E:23666 ||| IN
5  ||| S:23666 E:23668 ||| CD
mM  ||| S:23668 E:23671 ||| JJ
LiCI.  ||| S:23671 E:23677 ||| NNP
[  ||| S:23677 E:23679 ||| -LRB-
3H ||| S:23679 E:23681 ||| NNP
] ||| S:23681 E:23682 ||| -RRB-
-inositol  ||| S:23682 E:23702 ||| JJ
phosphate  ||| S:23702 E:23712 ||| JJ
accumulation  ||| S:23712 E:23725 ||| NN
in  ||| S:23725 E:23728 ||| IN
the  ||| S:23728 E:23732 ||| DT
cells  ||| S:23732 E:23738 ||| NNS
was  ||| S:23738 E:23742 ||| VBD
then  ||| S:23742 E:23747 ||| RB
measured  ||| S:23747 E:23766 ||| VBN
using  ||| S:23766 E:23772 ||| VBG
ion  ||| S:23772 E:23776 ||| JJ
exchange  ||| S:23776 E:23785 ||| NN
chromatography  ||| S:23785 E:23800 ||| VBZ
followed  ||| S:23800 E:23809 ||| VBN
by  ||| S:23809 E:23812 ||| IN
liquid  ||| S:23812 E:23829 ||| JJ
scintillation  ||| S:23829 E:23843 ||| JJ
spectroscopy  ||| S:23843 E:23856 ||| NNS
[  ||| S:23856 E:23858 ||| -LRB-
22  ||| S:23858 E:23861 ||| CD
]  ||| S:23861 E:23863 ||| -RRB-
.  ||| S:23863 E:23893 ||| .
Immunoblots  ||| S:23893 E:23905 ||| NNP
for  ||| S:23905 E:23909 ||| IN
RGS3  ||| S:23909 E:23924 ||| CD
An  ||| S:23924 E:23927 ||| DT
antibody  ||| S:23927 E:23936 ||| NN
to  ||| S:23936 E:23939 ||| TO
hexa-histidine-tagged  ||| S:23939 E:23961 ||| JJ
human  ||| S:23961 E:23967 ||| JJ
RGS3T  ||| S:23967 E:23973 ||| NN
was  ||| S:23973 E:23987 ||| VBD
prepared  ||| S:23987 E:23996 ||| VBN
in  ||| S:23996 E:23999 ||| IN
chickens ||| S:23999 E:24007 ||| NNS
.  ||| S:24007 E:24009 ||| .
RGS3T  ||| S:24009 E:24015 ||| NNP
[  ||| S:24015 E:24017 ||| -LRB-
24  ||| S:24017 E:24020 ||| CD
]  ||| S:24020 E:24022 ||| -RRB-
is  ||| S:24022 E:24025 ||| VBZ
the  ||| S:24025 E:24029 ||| DT
carboxy  ||| S:24029 E:24047 ||| JJ
terminal  ||| S:24047 E:24056 ||| NN
206  ||| S:24056 E:24060 ||| CD
amino  ||| S:24060 E:24066 ||| CD
acids  ||| S:24066 E:24072 ||| NNS
( ||| S:24072 E:24073 ||| -LRB-
a.a.  ||| S:24073 E:24078 ||| NNP
314-519 ||| S:24078 E:24085 ||| NNP
)  ||| S:24085 E:24087 ||| -RRB-
of  ||| S:24087 E:24090 ||| IN
RGS3  ||| S:24090 E:24095 ||| NNP
and  ||| S:24095 E:24099 ||| CC
is  ||| S:24099 E:24112 ||| VBZ
represented  ||| S:24112 E:24124 ||| VBN
by  ||| S:24124 E:24127 ||| IN
nt  ||| S:24127 E:24130 ||| JJ
1227-1847  ||| S:24130 E:24140 ||| NN
of  ||| S:24140 E:24143 ||| IN
RGS3  ||| S:24143 E:24148 ||| NNP
cDNA  ||| S:24148 E:24153 ||| NNP
( ||| S:24153 E:24154 ||| -LRB-
Genbank  ||| S:24154 E:24172 ||| UH
Accession  ||| S:24172 E:24182 ||| UH
# ||| S:24182 E:24183 ||| #
U27655 ||| S:24183 E:24189 ||| CD
) ||| S:24189 E:24190 ||| -RRB-
.  ||| S:24190 E:24192 ||| .
To  ||| S:24192 E:24195 ||| TO
prepare  ||| S:24195 E:24203 ||| VB
hexa-histidine  ||| S:24203 E:24218 ||| JJ
amino  ||| S:24218 E:24234 ||| JJ
terminally-tagged  ||| S:24234 E:24252 ||| JJ
RGS3T ||| S:24252 E:24257 ||| NN
,  ||| S:24257 E:24259 ||| ,
we  ||| S:24259 E:24262 ||| PRP
modified  ||| S:24262 E:24271 ||| VBD
RGS3T  ||| S:24271 E:24277 ||| NNP
cDNA  ||| S:24277 E:24282 ||| NNP
[  ||| S:24282 E:24284 ||| -LRB-
24  ||| S:24284 E:24287 ||| CD
]  ||| S:24287 E:24299 ||| -RRB-
using  ||| S:24299 E:24305 ||| VBG
PCR  ||| S:24305 E:24309 ||| NNP
with  ||| S:24309 E:24314 ||| IN
primers  ||| S:24314 E:24322 ||| NNS
containing  ||| S:24322 E:24333 ||| VBG
restriction  ||| S:24333 E:24345 ||| NN
sites  ||| S:24345 E:24351 ||| NNS
( ||| S:24351 E:24352 ||| -LRB-
the  ||| S:24352 E:24366 ||| DT
5 ||| S:24366 E:24367 ||| CD
'  ||| S:24367 E:24369 ||| POS
primer  ||| S:24369 E:24376 ||| NN
incorporated  ||| S:24376 E:24389 ||| VBN
a  ||| S:24389 E:24391 ||| DT
Bam  ||| S:24391 E:24395 ||| NNP
HI  ||| S:24395 E:24398 ||| NNP
site ||| S:24398 E:24402 ||| NN
,  ||| S:24402 E:24404 ||| ,
whereas  ||| S:24404 E:24412 ||| IN
the  ||| S:24412 E:24416 ||| DT
3 ||| S:24416 E:24417 ||| CD
'  ||| S:24417 E:24429 ||| POS
primer  ||| S:24429 E:24436 ||| NN
bore  ||| S:24436 E:24441 ||| VBD
an  ||| S:24441 E:24444 ||| DT
Nde  ||| S:24444 E:24448 ||| NNP
1  ||| S:24448 E:24450 ||| CD
site ||| S:24450 E:24454 ||| NN
) ||| S:24454 E:24455 ||| -RRB-
.  ||| S:24455 E:24457 ||| .
The  ||| S:24457 E:24461 ||| DT
PCR  ||| S:24461 E:24465 ||| NNP
product  ||| S:24465 E:24473 ||| NN
was  ||| S:24473 E:24477 ||| VBD
then  ||| S:24477 E:24492 ||| RB
cloned  ||| S:24492 E:24499 ||| VBN
into  ||| S:24499 E:24504 ||| IN
the  ||| S:24504 E:24508 ||| DT
pET15b  ||| S:24508 E:24515 ||| JJ
vector  ||| S:24515 E:24522 ||| NN
which  ||| S:24522 E:24528 ||| WDT
carries  ||| S:24528 E:24536 ||| VBZ
an  ||| S:24536 E:24539 ||| DT
N-terminal  ||| S:24539 E:24560 ||| JJ
Histag  ||| S:24560 E:24567 ||| NNP
sequence  ||| S:24567 E:24576 ||| VBD
followed  ||| S:24576 E:24585 ||| VBN
by  ||| S:24585 E:24588 ||| IN
BamH1  ||| S:24588 E:24594 ||| NNP
and  ||| S:24594 E:24598 ||| CC
Nde  ||| S:24598 E:24602 ||| NNP
1  ||| S:24602 E:24604 ||| CD
cloning  ||| S:24604 E:24612 ||| CD
sites  ||| S:24612 E:24628 ||| NNS
( ||| S:24628 E:24629 ||| -LRB-
Novagen  ||| S:24629 E:24637 ||| NNP
Inc. ||| S:24637 E:24641 ||| NNP
,  ||| S:24641 E:24643 ||| ,
Madison ||| S:24643 E:24650 ||| NNP
,  ||| S:24650 E:24652 ||| ,
WI ||| S:24652 E:24654 ||| NNP
) ||| S:24654 E:24655 ||| -RRB-
.  ||| S:24655 E:24657 ||| .
The  ||| S:24657 E:24661 ||| DT
resulting  ||| S:24661 E:24671 ||| VBG
plasmid  ||| S:24671 E:24679 ||| JJ
DNA  ||| S:24679 E:24693 ||| NN
was  ||| S:24693 E:24697 ||| VBD
nucleotide-sequenced  ||| S:24697 E:24718 ||| JJ
to  ||| S:24718 E:24721 ||| TO
confirm  ||| S:24721 E:24729 ||| VB
the  ||| S:24729 E:24733 ||| DT
presence  ||| S:24733 E:24742 ||| NN
of  ||| S:24742 E:24745 ||| IN
RGS3T  ||| S:24745 E:24761 ||| NNP
cDNA ||| S:24761 E:24765 ||| NNP
.  ||| S:24765 E:24767 ||| .
The  ||| S:24767 E:24771 ||| DT
cDNA  ||| S:24771 E:24776 ||| NN
was  ||| S:24776 E:24780 ||| VBD
then  ||| S:24780 E:24785 ||| RB
used  ||| S:24785 E:24790 ||| VBN
to  ||| S:24790 E:24793 ||| TO
transform  ||| S:24793 E:24814 ||| VB
E.  ||| S:24814 E:24817 ||| NNP
coli  ||| S:24817 E:24822 ||| NNS
of  ||| S:24822 E:24825 ||| IN
the  ||| S:24825 E:24829 ||| DT
BL21 ||| S:24829 E:24833 ||| NNP
( ||| S:24833 E:24834 ||| -LRB-
DE3 ||| S:24834 E:24837 ||| NNP
)  ||| S:24837 E:24839 ||| -RRB-
strain ||| S:24839 E:24845 ||| NN
.  ||| S:24845 E:24857 ||| .
Protein  ||| S:24857 E:24865 ||| NN
induction  ||| S:24865 E:24875 ||| NNS
was  ||| S:24875 E:24879 ||| VBD
performed  ||| S:24879 E:24889 ||| VBN
using  ||| S:24889 E:24905 ||| VBG
isopropyl-β-D-thiogalactopyranoside  ||| S:24905 E:24941 ||| JJ
( ||| S:24941 E:24942 ||| -LRB-
IPTG ||| S:24942 E:24946 ||| NNP
)  ||| S:24946 E:24948 ||| -RRB-
as  ||| S:24948 E:24951 ||| RB
described  ||| S:24951 E:24971 ||| VBN
by  ||| S:24971 E:24974 ||| IN
Novagen  ||| S:24974 E:24982 ||| NNP
Inc ||| S:24982 E:24985 ||| NNP
.  ||| S:24985 E:24987 ||| .
Inclusion  ||| S:24987 E:24997 ||| JJ
bodies  ||| S:24997 E:25004 ||| NNS
containing  ||| S:25004 E:25015 ||| VBG
the  ||| S:25015 E:25019 ||| DT
protein  ||| S:25019 E:25037 ||| NN
were  ||| S:25037 E:25042 ||| VBD
prepared  ||| S:25042 E:25051 ||| VBN
and  ||| S:25051 E:25055 ||| CC
then  ||| S:25055 E:25060 ||| RB
solubized  ||| S:25060 E:25070 ||| VBN
in  ||| S:25070 E:25073 ||| IN
6  ||| S:25073 E:25075 ||| CD
M  ||| S:25075 E:25077 ||| NNP
guanidine ||| S:25077 E:25086 ||| NN
.  ||| S:25086 E:25088 ||| .
The  ||| S:25088 E:25102 ||| DT
Histag  ||| S:25102 E:25109 ||| NNP
RGS3T  ||| S:25109 E:25115 ||| NNP
protein  ||| S:25115 E:25123 ||| NN
was  ||| S:25123 E:25127 ||| VBD
purified  ||| S:25127 E:25136 ||| VBN
on  ||| S:25136 E:25139 ||| IN
a  ||| S:25139 E:25141 ||| DT
Ni  ||| S:25141 E:25144 ||| NNP
2+resin  ||| S:25144 E:25152 ||| NNP
using  ||| S:25152 E:25158 ||| VBG
a  ||| S:25158 E:25170 ||| DT
Pharmacia  ||| S:25170 E:25180 ||| NNP
Hi-Trap  ||| S:25180 E:25188 ||| NNP
1  ||| S:25188 E:25190 ||| CD
ml  ||| S:25190 E:25193 ||| JJ
Chelating  ||| S:25193 E:25203 ||| NNP
Column  ||| S:25203 E:25210 ||| NNP
( ||| S:25210 E:25211 ||| -LRB-
Pharmacia  ||| S:25211 E:25231 ||| NNP
Biotech ||| S:25231 E:25238 ||| NNP
,  ||| S:25238 E:25240 ||| ,
Piscataway ||| S:25240 E:25250 ||| NNP
,  ||| S:25250 E:25252 ||| ,
NJ ||| S:25252 E:25254 ||| NNP
) ||| S:25254 E:25255 ||| -RRB-
.  ||| S:25255 E:25267 ||| .
Antibodies  ||| S:25267 E:25278 ||| NNS
to  ||| S:25278 E:25281 ||| TO
Histag  ||| S:25281 E:25288 ||| NNP
RGS3T  ||| S:25288 E:25294 ||| NNP
protein  ||| S:25294 E:25302 ||| NN
were  ||| S:25302 E:25307 ||| VBD
prepared  ||| S:25307 E:25316 ||| VBN
in  ||| S:25316 E:25329 ||| IN
chickens  ||| S:25329 E:25338 ||| NNS
( ||| S:25338 E:25339 ||| -LRB-
Aves  ||| S:25339 E:25344 ||| NNP
Labs ||| S:25344 E:25348 ||| NNPS
,  ||| S:25348 E:25350 ||| ,
Inc. ||| S:25350 E:25354 ||| NNP
,  ||| S:25354 E:25356 ||| ,
Tigard ||| S:25356 E:25362 ||| NNP
,  ||| S:25362 E:25364 ||| ,
OR ||| S:25364 E:25366 ||| NNP
) ||| S:25366 E:25367 ||| -RRB-
.  ||| S:25367 E:25369 ||| .
A  ||| S:25369 E:25371 ||| DT
chicken  ||| S:25371 E:25379 ||| NN
was  ||| S:25379 E:25393 ||| VBD
injected  ||| S:25393 E:25402 ||| VBN
with  ||| S:25402 E:25407 ||| IN
145  ||| S:25407 E:25411 ||| CD
μg  ||| S:25411 E:25414 ||| NN
of  ||| S:25414 E:25417 ||| IN
RGS3T  ||| S:25417 E:25423 ||| CD
into  ||| S:25423 E:25428 ||| IN
the  ||| S:25428 E:25432 ||| DT
breast  ||| S:25432 E:25439 ||| NN
muscle  ||| S:25439 E:25446 ||| NN
on  ||| S:25446 E:25459 ||| IN
four  ||| S:25459 E:25464 ||| CD
separate  ||| S:25464 E:25473 ||| JJ
occasions ||| S:25473 E:25482 ||| NNS
;  ||| S:25482 E:25484 ||| :
the  ||| S:25484 E:25488 ||| DT
first  ||| S:25488 E:25494 ||| JJ
injection  ||| S:25494 E:25504 ||| NN
was  ||| S:25504 E:25508 ||| VBD
in  ||| S:25508 E:25521 ||| IN
complete  ||| S:25521 E:25530 ||| JJ
Freund ||| S:25530 E:25536 ||| NNP
's  ||| S:25536 E:25539 ||| POS
adjuvant ||| S:25539 E:25547 ||| NN
,  ||| S:25547 E:25549 ||| ,
whereas  ||| S:25549 E:25557 ||| IN
injections  ||| S:25557 E:25568 ||| JJ
2-4  ||| S:25568 E:25572 ||| NN
were  ||| S:25572 E:25587 ||| VBD
made  ||| S:25587 E:25592 ||| VBN
in  ||| S:25592 E:25595 ||| IN
a  ||| S:25595 E:25597 ||| DT
1 ||| S:25597 E:25598 ||| CD
: ||| S:25598 E:25599 ||| :
1  ||| S:25599 E:25601 ||| CD
dilution  ||| S:25601 E:25610 ||| NN
of  ||| S:25610 E:25613 ||| IN
complete  ||| S:25613 E:25622 ||| JJ
and  ||| S:25622 E:25626 ||| CC
incomplete  ||| S:25626 E:25647 ||| JJ
Freund ||| S:25647 E:25653 ||| NNP
's  ||| S:25653 E:25656 ||| POS
adjuvant ||| S:25656 E:25664 ||| NN
.  ||| S:25664 E:25666 ||| .
One  ||| S:25666 E:25670 ||| CD
week  ||| S:25670 E:25675 ||| NN
after  ||| S:25675 E:25681 ||| IN
the  ||| S:25681 E:25685 ||| DT
last  ||| S:25685 E:25690 ||| JJ
injection ||| S:25690 E:25699 ||| NN
,  ||| S:25699 E:25701 ||| ,
6  ||| S:25701 E:25713 ||| CD
immune  ||| S:25713 E:25720 ||| JJ
eggs  ||| S:25720 E:25725 ||| NNS
were  ||| S:25725 E:25730 ||| VBD
collected ||| S:25730 E:25739 ||| VBN
,  ||| S:25739 E:25741 ||| ,
and  ||| S:25741 E:25745 ||| CC
the  ||| S:25745 E:25749 ||| DT
IgY  ||| S:25749 E:25753 ||| JJ
fraction  ||| S:25753 E:25762 ||| NN
purified  ||| S:25762 E:25781 ||| NN
from  ||| S:25781 E:25786 ||| IN
the  ||| S:25786 E:25790 ||| DT
6  ||| S:25790 E:25792 ||| CD
eggs  ||| S:25792 E:25797 ||| NNS
as  ||| S:25797 E:25800 ||| IN
well  ||| S:25800 E:25805 ||| RB
as  ||| S:25805 E:25808 ||| RB
from  ||| S:25808 E:25813 ||| IN
3  ||| S:25813 E:25815 ||| CD
pre-immune  ||| S:25815 E:25826 ||| JJ
eggs  ||| S:25826 E:25841 ||| NNS
collected  ||| S:25841 E:25851 ||| VBN
from  ||| S:25851 E:25856 ||| IN
the  ||| S:25856 E:25860 ||| DT
same  ||| S:25860 E:25865 ||| JJ
hen ||| S:25865 E:25868 ||| NN
.  ||| S:25868 E:25880 ||| .
Immunoblots  ||| S:25880 E:25892 ||| NNP
for  ||| S:25892 E:25896 ||| IN
RGS3  ||| S:25896 E:25901 ||| CD
expression  ||| S:25901 E:25912 ||| NN
in  ||| S:25912 E:25915 ||| IN
pituitary  ||| S:25915 E:25925 ||| JJ
cells  ||| S:25925 E:25941 ||| NNS
were  ||| S:25941 E:25946 ||| VBD
performed  ||| S:25946 E:25956 ||| VBN
as  ||| S:25956 E:25959 ||| RB
described  ||| S:25959 E:25969 ||| VBN
previously  ||| S:25969 E:25980 ||| RB
by  ||| S:25980 E:25983 ||| IN
us  ||| S:25983 E:25986 ||| PRP
[  ||| S:25986 E:25988 ||| -LRB-
22  ||| S:25988 E:25991 ||| CD
23  ||| S:25991 E:25994 ||| CD
]  ||| S:25994 E:25996 ||| -RRB-
.  ||| S:25996 E:26008 ||| .
In  ||| S:26008 E:26011 ||| IN
brief ||| S:26011 E:26016 ||| JJ
,  ||| S:26016 E:26018 ||| ,
rat  ||| S:26018 E:26022 ||| JJ
pituitary  ||| S:26022 E:26032 ||| JJ
cells  ||| S:26032 E:26038 ||| NNS
at  ||| S:26038 E:26041 ||| IN
72  ||| S:26041 E:26044 ||| CD
h  ||| S:26044 E:26046 ||| NN
after  ||| S:26046 E:26052 ||| IN
adeno-RGS3  ||| S:26052 E:26073 ||| CD
infection  ||| S:26073 E:26083 ||| NN
( ||| S:26083 E:26084 ||| -LRB-
5  ||| S:26084 E:26086 ||| CD
M.O.I. ||| S:26086 E:26092 ||| CD
)  ||| S:26092 E:26094 ||| -RRB-
were  ||| S:26094 E:26099 ||| VBD
collected  ||| S:26099 E:26109 ||| VBN
by  ||| S:26109 E:26112 ||| IN
trypsinization ||| S:26112 E:26126 ||| NN
,  ||| S:26126 E:26138 ||| ,
homogenized ||| S:26138 E:26149 ||| NN
,  ||| S:26149 E:26151 ||| ,
and  ||| S:26151 E:26155 ||| CC
a  ||| S:26155 E:26157 ||| DT
protein  ||| S:26157 E:26165 ||| NN
determination  ||| S:26165 E:26179 ||| NN
made ||| S:26179 E:26183 ||| VBD
.  ||| S:26183 E:26185 ||| .
Fifty  ||| S:26185 E:26191 ||| JJ
μg  ||| S:26191 E:26204 ||| JJ
protein  ||| S:26204 E:26212 ||| NN
samples  ||| S:26212 E:26220 ||| NNS
were  ||| S:26220 E:26225 ||| VBD
heated  ||| S:26225 E:26232 ||| VBN
in  ||| S:26232 E:26235 ||| IN
SDS-PAGE  ||| S:26235 E:26244 ||| JJ
sample  ||| S:26244 E:26251 ||| NN
buffer  ||| S:26251 E:26268 ||| NN
containing  ||| S:26268 E:26279 ||| VBG
β-mercaptoethanol  ||| S:26279 E:26297 ||| JJ
and  ||| S:26297 E:26301 ||| CC
then  ||| S:26301 E:26306 ||| RB
electrophoresed  ||| S:26306 E:26322 ||| VBN
on  ||| S:26322 E:26335 ||| IN
a  ||| S:26335 E:26337 ||| DT
10 ||| S:26337 E:26339 ||| CD
%  ||| S:26339 E:26341 ||| NN
SDS-polyacrylamide  ||| S:26341 E:26360 ||| JJ
gel ||| S:26360 E:26363 ||| NN
.  ||| S:26363 E:26365 ||| .
Separated  ||| S:26365 E:26375 ||| JJ
proteins  ||| S:26375 E:26384 ||| NNS
were  ||| S:26384 E:26399 ||| VBD
electroblotted  ||| S:26399 E:26414 ||| VBN
onto  ||| S:26414 E:26419 ||| IN
nylon  ||| S:26419 E:26425 ||| JJ
membranes  ||| S:26425 E:26435 ||| NNS
( ||| S:26435 E:26436 ||| -LRB-
Millipore  ||| S:26436 E:26446 ||| NNP
Corp. ||| S:26446 E:26451 ||| NNP
,  ||| S:26451 E:26463 ||| ,
Bedford ||| S:26463 E:26470 ||| NNP
,  ||| S:26470 E:26472 ||| ,
MA ||| S:26472 E:26474 ||| NNP
)  ||| S:26474 E:26476 ||| -RRB-
which  ||| S:26476 E:26482 ||| WDT
were  ||| S:26482 E:26487 ||| VBD
then  ||| S:26487 E:26492 ||| RB
incubated  ||| S:26492 E:26502 ||| VBN
for  ||| S:26502 E:26506 ||| IN
2  ||| S:26506 E:26508 ||| CD
h  ||| S:26508 E:26510 ||| NN
in  ||| S:26510 E:26513 ||| IN
a  ||| S:26513 E:26525 ||| DT
blocking  ||| S:26525 E:26534 ||| JJ
solution  ||| S:26534 E:26543 ||| NN
containing  ||| S:26543 E:26554 ||| VBG
5 ||| S:26554 E:26555 ||| CD
%  ||| S:26555 E:26557 ||| NN
non-fat  ||| S:26557 E:26565 ||| JJ
dry  ||| S:26565 E:26569 ||| JJ
milk  ||| S:26569 E:26574 ||| NN
in  ||| S:26574 E:26587 ||| IN
phosphate  ||| S:26587 E:26597 ||| JJ
buffered  ||| S:26597 E:26606 ||| NNS
saline  ||| S:26606 E:26613 ||| VBP
containing  ||| S:26613 E:26624 ||| VBG
0.02 ||| S:26624 E:26628 ||| CD
%  ||| S:26628 E:26630 ||| NN
Tween-20 ||| S:26630 E:26638 ||| NN
.  ||| S:26638 E:26640 ||| .
The  ||| S:26640 E:26654 ||| DT
primary  ||| S:26654 E:26662 ||| JJ
antibody  ||| S:26662 E:26671 ||| NN
( ||| S:26671 E:26672 ||| -LRB-
chicken  ||| S:26672 E:26680 ||| NN
IgY ||| S:26680 E:26683 ||| NN
,  ||| S:26683 E:26685 ||| ,
62.5  ||| S:26685 E:26690 ||| CD
μg ||| S:26690 E:26692 ||| CD
/ ||| S:26692 E:26693 ||| CD
ml ||| S:26693 E:26695 ||| CD
)  ||| S:26695 E:26697 ||| -RRB-
was  ||| S:26697 E:26701 ||| VBD
diluted  ||| S:26701 E:26709 ||| VBN
in  ||| S:26709 E:26722 ||| IN
blocking  ||| S:26722 E:26731 ||| VBG
solution  ||| S:26731 E:26740 ||| NN
and  ||| S:26740 E:26744 ||| CC
incubated  ||| S:26744 E:26754 ||| JJ
overnight  ||| S:26754 E:26764 ||| JJ
at  ||| S:26764 E:26767 ||| IN
4°C  ||| S:26767 E:26771 ||| CD
with  ||| S:26771 E:26776 ||| IN
the  ||| S:26776 E:26790 ||| DT
nylon  ||| S:26790 E:26796 ||| JJ
membrane ||| S:26796 E:26804 ||| NN
.  ||| S:26804 E:26806 ||| .
Blots  ||| S:26806 E:26812 ||| NNP
were  ||| S:26812 E:26817 ||| VBD
then  ||| S:26817 E:26822 ||| RB
incubated  ||| S:26822 E:26832 ||| VBN
for  ||| S:26832 E:26836 ||| IN
2  ||| S:26836 E:26838 ||| CD
h  ||| S:26838 E:26840 ||| NN
at  ||| S:26840 E:26843 ||| IN
room  ||| S:26843 E:26858 ||| NN
temperature  ||| S:26858 E:26870 ||| NN
in  ||| S:26870 E:26873 ||| IN
alkaline  ||| S:26873 E:26882 ||| FW
phosphatase-conjugated  ||| S:26882 E:26905 ||| FW
goat  ||| S:26905 E:26920 ||| FW
anti-chicken  ||| S:26920 E:26933 ||| FW
IgY  ||| S:26933 E:26937 ||| FW
( ||| S:26937 E:26938 ||| -LRB-
0.1  ||| S:26938 E:26942 ||| CD
μg ||| S:26942 E:26944 ||| CD
/ ||| S:26944 E:26945 ||| CD
ml  ||| S:26945 E:26948 ||| NNS
diluted  ||| S:26948 E:26956 ||| VBN
in  ||| S:26956 E:26959 ||| IN
blocking  ||| S:26959 E:26968 ||| VBG
solution ||| S:26968 E:26976 ||| NN
;  ||| S:26976 E:26988 ||| :
Aves  ||| S:26988 E:26993 ||| NNP
Labs ||| S:26993 E:26997 ||| NNPS
,  ||| S:26997 E:26999 ||| ,
Tigard ||| S:26999 E:27005 ||| NNP
,  ||| S:27005 E:27007 ||| ,
OR ||| S:27007 E:27009 ||| NNP
) ||| S:27009 E:27010 ||| -RRB-
.  ||| S:27010 E:27012 ||| .
Color  ||| S:27012 E:27018 ||| NN
development  ||| S:27018 E:27030 ||| NN
was  ||| S:27030 E:27034 ||| VBD
achieved  ||| S:27034 E:27043 ||| VBN
by  ||| S:27043 E:27056 ||| IN
incubating  ||| S:27056 E:27067 ||| VBG
the  ||| S:27067 E:27071 ||| DT
membrane  ||| S:27071 E:27080 ||| NN
in  ||| S:27080 E:27083 ||| IN
substrate  ||| S:27083 E:27103 ||| NNS
[ ||| S:27103 E:27104 ||| -LRB-
( ||| S:27104 E:27105 ||| -LRB-
5-bromo-4-chloro-3-indolyl  ||| S:27105 E:27142 ||| FW
phosphate-nitrobluetetra-zolium  ||| S:27142 E:27174 ||| FW
chloride ||| S:27174 E:27182 ||| FW
)  ||| S:27182 E:27194 ||| -RRB-
( ||| S:27194 E:27195 ||| -LRB-
BCIP-NBT ||| S:27195 E:27203 ||| NNP
) ||| S:27203 E:27204 ||| -RRB-
] ||| S:27204 E:27205 ||| -RRB-
.  ||| S:27205 E:27235 ||| .
Assay  ||| S:27235 E:27241 ||| NNP
of  ||| S:27241 E:27244 ||| IN
LH  ||| S:27244 E:27247 ||| NNP
contents  ||| S:27247 E:27256 ||| NNS
in  ||| S:27256 E:27259 ||| IN
pituitary  ||| S:27259 E:27269 ||| JJ
cells  ||| S:27269 E:27285 ||| NNS
For  ||| S:27285 E:27289 ||| IN
LH  ||| S:27289 E:27292 ||| NNP
RIA  ||| S:27292 E:27296 ||| NNP
measurements  ||| S:27296 E:27309 ||| NNS
of  ||| S:27309 E:27312 ||| IN
cell  ||| S:27312 E:27317 ||| NN
contents ||| S:27317 E:27325 ||| NNS
,  ||| S:27325 E:27327 ||| ,
1  ||| S:27327 E:27329 ||| CD
×  ||| S:27329 E:27331 ||| CD
10  ||| S:27331 E:27344 ||| CD
5anterior  ||| S:27344 E:27354 ||| CD
pituitary  ||| S:27354 E:27364 ||| CD
cells  ||| S:27364 E:27370 ||| NNS
infected ||| S:27370 E:27378 ||| VBN
,  ||| S:27378 E:27380 ||| ,
or  ||| S:27380 E:27383 ||| CC
not ||| S:27383 E:27386 ||| RB
,  ||| S:27386 E:27388 ||| ,
72  ||| S:27388 E:27391 ||| CD
h  ||| S:27391 E:27403 ||| NNS
previously  ||| S:27403 E:27414 ||| RB
with  ||| S:27414 E:27419 ||| IN
adeno-RGS3  ||| S:27419 E:27430 ||| NNP
or  ||| S:27430 E:27433 ||| CC
adeno-βgal  ||| S:27433 E:27444 ||| NNP
were  ||| S:27444 E:27449 ||| VBD
trypsinized  ||| S:27449 E:27471 ||| JJ
and  ||| S:27471 E:27475 ||| CC
plated  ||| S:27475 E:27482 ||| NN
for  ||| S:27482 E:27486 ||| IN
2  ||| S:27486 E:27488 ||| CD
h ||| S:27488 E:27489 ||| NNS
.  ||| S:27489 E:27491 ||| .
LH  ||| S:27491 E:27494 ||| NNP
was  ||| S:27494 E:27498 ||| VBD
extracted  ||| S:27498 E:27508 ||| VBN
from  ||| S:27508 E:27513 ||| IN
the  ||| S:27513 E:27517 ||| DT
cells  ||| S:27517 E:27523 ||| NNS
[  ||| S:27523 E:27525 ||| -LRB-
36  ||| S:27525 E:27538 ||| CD
]  ||| S:27538 E:27540 ||| -RRB-
by  ||| S:27540 E:27543 ||| IN
removing  ||| S:27543 E:27552 ||| VBG
and  ||| S:27552 E:27556 ||| CC
discarding  ||| S:27556 E:27567 ||| VBG
the  ||| S:27567 E:27571 ||| DT
medium  ||| S:27571 E:27578 ||| NN
and  ||| S:27578 E:27582 ||| CC
adding  ||| S:27582 E:27589 ||| VBG
1  ||| S:27589 E:27591 ||| CD
ml  ||| S:27591 E:27604 ||| CD
extraction  ||| S:27604 E:27615 ||| JJ
buffer  ||| S:27615 E:27622 ||| NN
( ||| S:27622 E:27623 ||| -LRB-
150  ||| S:27623 E:27627 ||| CD
mM  ||| S:27627 E:27630 ||| JJ
NaCI ||| S:27630 E:27634 ||| NN
,  ||| S:27634 E:27636 ||| ,
50  ||| S:27636 E:27639 ||| CD
mM  ||| S:27639 E:27642 ||| JJ
Tris ||| S:27642 E:27646 ||| NNP
,  ||| S:27646 E:27648 ||| ,
5  ||| S:27648 E:27650 ||| CD
mM  ||| S:27650 E:27653 ||| JJ
EDTA ||| S:27653 E:27657 ||| NNP
,  ||| S:27657 E:27669 ||| ,
and  ||| S:27669 E:27673 ||| CC
1  ||| S:27673 E:27675 ||| CD
mM  ||| S:27675 E:27678 ||| JJ
bacitracin ||| S:27678 E:27688 ||| NN
,  ||| S:27688 E:27690 ||| ,
pH  ||| S:27690 E:27693 ||| JJ
7.4 ||| S:27693 E:27696 ||| CD
)  ||| S:27696 E:27698 ||| -RRB-
followed  ||| S:27698 E:27707 ||| VBD
by  ||| S:27707 E:27710 ||| IN
freeze-thawing  ||| S:27710 E:27735 ||| JJ
twice ||| S:27735 E:27740 ||| RB
.  ||| S:27740 E:27742 ||| .
After  ||| S:27742 E:27748 ||| IN
centrifugation ||| S:27748 E:27762 ||| NN
,  ||| S:27762 E:27764 ||| ,
the  ||| S:27764 E:27768 ||| DT
supernatant  ||| S:27768 E:27780 ||| NN
was  ||| S:27780 E:27784 ||| VBD
removed  ||| S:27784 E:27802 ||| VBN
and  ||| S:27802 E:27806 ||| CC
subjected  ||| S:27806 E:27816 ||| VBN
to  ||| S:27816 E:27819 ||| TO
LH  ||| S:27819 E:27822 ||| NNP
RIA  ||| S:27822 E:27826 ||| NNP
as  ||| S:27826 E:27829 ||| RB
described  ||| S:27829 E:27839 ||| VBN
above ||| S:27839 E:27844 ||| IN
.  ||| S:27844 E:27874 ||| .
Measurements  ||| S:27874 E:27887 ||| NNS
of  ||| S:27887 E:27890 ||| IN
GnRH  ||| S:27890 E:27895 ||| JJ
receptors  ||| S:27895 E:27905 ||| NNS
by  ||| S:27905 E:27908 ||| IN
receptor  ||| S:27908 E:27927 ||| NN
radioassay  ||| S:27927 E:27938 ||| NNS
( ||| S:27938 E:27939 ||| -LRB-
RRA ||| S:27939 E:27942 ||| NNP
)  ||| S:27942 E:27954 ||| -RRB-
About  ||| S:27954 E:27960 ||| IN
3  ||| S:27960 E:27962 ||| CD
×  ||| S:27962 E:27964 ||| CD
10  ||| S:27964 E:27967 ||| CD
6pituitary  ||| S:27967 E:27978 ||| CD
cells  ||| S:27978 E:27984 ||| NNS
infected ||| S:27984 E:27992 ||| VBN
,  ||| S:27992 E:27994 ||| ,
or  ||| S:27994 E:27997 ||| CC
not ||| S:27997 E:28000 ||| RB
,  ||| S:28000 E:28002 ||| ,
72  ||| S:28002 E:28005 ||| CD
h  ||| S:28005 E:28017 ||| NNS
previously  ||| S:28017 E:28028 ||| RB
with  ||| S:28028 E:28033 ||| IN
adeno-βgal  ||| S:28033 E:28044 ||| JJ
or  ||| S:28044 E:28047 ||| CC
adeno-RGS3  ||| S:28047 E:28058 ||| NNP
were  ||| S:28058 E:28073 ||| VBD
trypsinized ||| S:28073 E:28084 ||| CD
,  ||| S:28084 E:28086 ||| ,
and  ||| S:28086 E:28090 ||| CC
cell  ||| S:28090 E:28095 ||| NN
membranes  ||| S:28095 E:28105 ||| VBZ
containing  ||| S:28105 E:28116 ||| VBG
the  ||| S:28116 E:28120 ||| DT
GnRH  ||| S:28120 E:28135 ||| JJ
receptors  ||| S:28135 E:28145 ||| NNS
were  ||| S:28145 E:28150 ||| VBD
prepared  ||| S:28150 E:28159 ||| VBN
by  ||| S:28159 E:28162 ||| IN
placing  ||| S:28162 E:28170 ||| VBG
the  ||| S:28170 E:28174 ||| DT
cells  ||| S:28174 E:28180 ||| NNS
in  ||| S:28180 E:28183 ||| IN
a  ||| S:28183 E:28185 ||| DT
Dounce  ||| S:28185 E:28202 ||| JJ
homogenizer  ||| S:28202 E:28214 ||| NNS
( ||| S:28214 E:28215 ||| -LRB-
Kontes  ||| S:28215 E:28222 ||| NNP
Co. ||| S:28222 E:28225 ||| NNP
,  ||| S:28225 E:28227 ||| ,
Vineland ||| S:28227 E:28235 ||| NNP
,  ||| S:28235 E:28237 ||| ,
NJ ||| S:28237 E:28239 ||| NNP
)  ||| S:28239 E:28241 ||| -RRB-
and  ||| S:28241 E:28245 ||| CC
disrupting  ||| S:28245 E:28266 ||| VBG
them  ||| S:28266 E:28271 ||| PRP
with  ||| S:28271 E:28276 ||| IN
30  ||| S:28276 E:28279 ||| CD
strokes  ||| S:28279 E:28287 ||| NNS
of  ||| S:28287 E:28290 ||| IN
the  ||| S:28290 E:28294 ||| DT
pestle ||| S:28294 E:28300 ||| NN
.  ||| S:28300 E:28302 ||| .
The  ||| S:28302 E:28306 ||| DT
cell  ||| S:28306 E:28311 ||| NN
membranes  ||| S:28311 E:28331 ||| NNS
were  ||| S:28331 E:28336 ||| VBD
pelleted  ||| S:28336 E:28345 ||| VBN
by  ||| S:28345 E:28348 ||| IN
centrifugation  ||| S:28348 E:28363 ||| NN
at  ||| S:28363 E:28366 ||| IN
26,000  ||| S:28366 E:28373 ||| CD
×  ||| S:28373 E:28386 ||| CD
g  ||| S:28386 E:28388 ||| NNS
and  ||| S:28388 E:28392 ||| CC
then  ||| S:28392 E:28397 ||| RB
resuspended  ||| S:28397 E:28409 ||| VBN
in  ||| S:28409 E:28412 ||| IN
10  ||| S:28412 E:28415 ||| CD
mM  ||| S:28415 E:28428 ||| JJ
Tris  ||| S:28428 E:28433 ||| JJ
buffer ||| S:28433 E:28439 ||| NN
.  ||| S:28439 E:28441 ||| .
The  ||| S:28441 E:28445 ||| DT
GnRH  ||| S:28445 E:28450 ||| JJ
RRA  ||| S:28450 E:28454 ||| NN
on  ||| S:28454 E:28457 ||| IN
the  ||| S:28457 E:28461 ||| DT
membranes  ||| S:28461 E:28471 ||| NN
was  ||| S:28471 E:28475 ||| VBD
performed  ||| S:28475 E:28495 ||| VBN
as  ||| S:28495 E:28498 ||| RB
described  ||| S:28498 E:28508 ||| VBN
previously  ||| S:28508 E:28519 ||| RB
[  ||| S:28519 E:28521 ||| -LRB-
22  ||| S:28521 E:28524 ||| CD
23  ||| S:28524 E:28527 ||| CD
]  ||| S:28527 E:28529 ||| -RRB-
.  ||| S:28529 E:28531 ||| .
Cell  ||| S:28531 E:28536 ||| NN
membranes  ||| S:28536 E:28546 ||| NNS
and  ||| S:28546 E:28550 ||| CC
1  ||| S:28550 E:28562 ||| CD
×  ||| S:28562 E:28564 ||| CD
10  ||| S:28564 E:28567 ||| CD
5cpm  ||| S:28567 E:28572 ||| CD
[  ||| S:28572 E:28574 ||| -LRB-
125I ||| S:28574 E:28578 ||| NNP
] ||| S:28578 E:28579 ||| -RRB-
GnRH-A  ||| S:28579 E:28586 ||| NNP
were  ||| S:28586 E:28591 ||| VBD
incubated  ||| S:28591 E:28601 ||| VBN
at  ||| S:28601 E:28604 ||| IN
0°C  ||| S:28604 E:28608 ||| CD
for  ||| S:28608 E:28612 ||| IN
90  ||| S:28612 E:28615 ||| CD
min ||| S:28615 E:28618 ||| NNS
.  ||| S:28618 E:28630 ||| .
Nonspecific  ||| S:28630 E:28642 ||| JJ
binding  ||| S:28642 E:28650 ||| NN
was  ||| S:28650 E:28654 ||| VBD
determined  ||| S:28654 E:28665 ||| VBN
as  ||| S:28665 E:28668 ||| IN
counts  ||| S:28668 E:28675 ||| NNS
per  ||| S:28675 E:28679 ||| IN
min  ||| S:28679 E:28693 ||| VBG
bound  ||| S:28693 E:28699 ||| VBN
in  ||| S:28699 E:28702 ||| IN
the  ||| S:28702 E:28706 ||| DT
presence  ||| S:28706 E:28715 ||| NN
of  ||| S:28715 E:28718 ||| IN
10  ||| S:28718 E:28721 ||| CD
-6M  ||| S:28721 E:28725 ||| CD
unlabeled  ||| S:28725 E:28735 ||| JJ
GnRH-A ||| S:28735 E:28741 ||| NN
.  ||| S:28741 E:28743 ||| .
Bound  ||| S:28743 E:28759 ||| NNP
and  ||| S:28759 E:28763 ||| CC
free  ||| S:28763 E:28768 ||| JJ
[  ||| S:28768 E:28770 ||| -LRB-
125I ||| S:28770 E:28774 ||| NNP
] ||| S:28774 E:28775 ||| -RRB-
GnRH-A  ||| S:28775 E:28782 ||| NNP
were  ||| S:28782 E:28787 ||| VBD
separated  ||| S:28787 E:28797 ||| VBN
by  ||| S:28797 E:28800 ||| IN
filtration ||| S:28800 E:28810 ||| NN
.  ||| S:28810 E:28812 ||| .
The  ||| S:28812 E:28826 ||| DT
filters  ||| S:28826 E:28834 ||| NNS
were  ||| S:28834 E:28839 ||| VBD
counted  ||| S:28839 E:28847 ||| VBN
by  ||| S:28847 E:28850 ||| IN
γ-scintillation  ||| S:28850 E:28866 ||| JJ
spectrometry ||| S:28866 E:28878 ||| NN
.  ||| S:28878 E:28908 ||| .
Data  ||| S:28908 E:28913 ||| NNP
analysis  ||| S:28913 E:28932 ||| NN
The  ||| S:28932 E:28936 ||| DT
results  ||| S:28936 E:28944 ||| NNS
are  ||| S:28944 E:28948 ||| VBP
presented  ||| S:28948 E:28958 ||| VBN
as  ||| S:28958 E:28961 ||| IN
the  ||| S:28961 E:28965 ||| DT
mean  ||| S:28965 E:28970 ||| JJ
±  ||| S:28970 E:28972 ||| NNP
SEM  ||| S:28972 E:28976 ||| NNP
of  ||| S:28976 E:28979 ||| IN
at  ||| S:28979 E:28992 ||| IN
least  ||| S:28992 E:28998 ||| JJS
three  ||| S:28998 E:29004 ||| CD
independent  ||| S:29004 E:29016 ||| JJ
experiments  ||| S:29016 E:29028 ||| NNS
unless  ||| S:29028 E:29035 ||| IN
indicated  ||| S:29035 E:29055 ||| VBN
otherwise ||| S:29055 E:29064 ||| RB
.  ||| S:29064 E:29066 ||| .
The  ||| S:29066 E:29070 ||| DT
statistical  ||| S:29070 E:29082 ||| JJ
tests  ||| S:29082 E:29088 ||| NNS
were  ||| S:29088 E:29093 ||| VBD
one-way  ||| S:29093 E:29101 ||| JJ
or  ||| S:29101 E:29104 ||| CC
two-way  ||| S:29104 E:29122 ||| JJ
analyses  ||| S:29122 E:29131 ||| NNS
of  ||| S:29131 E:29134 ||| IN
variance  ||| S:29134 E:29143 ||| NN
with  ||| S:29143 E:29148 ||| IN
significant  ||| S:29148 E:29160 ||| JJ
differences  ||| S:29160 E:29172 ||| NNS
( ||| S:29172 E:29173 ||| -LRB-
p  ||| S:29173 E:29175 ||| CD
< ||| S:29175 E:29176 ||| SYM
0.05 ||| S:29187 E:29191 ||| CD
)  ||| S:29191 E:29193 ||| -RRB-
identified  ||| S:29193 E:29204 ||| VBN
by  ||| S:29204 E:29207 ||| IN
the  ||| S:29207 E:29211 ||| DT
Student  ||| S:29211 E:29219 ||| NN
-  ||| S:29219 E:29221 ||| :
Newman-Keuls  ||| S:29221 E:29234 ||| JJ
method ||| S:29234 E:29240 ||| NN
.  ||| S:29240 E:29252 ||| .
Statistical  ||| S:29252 E:29264 ||| JJ
analysis  ||| S:29264 E:29273 ||| NN
was  ||| S:29273 E:29277 ||| VBD
performed  ||| S:29277 E:29287 ||| VBN
using  ||| S:29287 E:29293 ||| VBG
Sigma  ||| S:29293 E:29299 ||| NNP
Stat  ||| S:29299 E:29314 ||| NNP
Statistical  ||| S:29314 E:29326 ||| NNP
Software  ||| S:29326 E:29335 ||| NNP
for  ||| S:29335 E:29339 ||| IN
Windows  ||| S:29339 E:29347 ||| NNP
( ||| S:29347 E:29348 ||| -LRB-
Jandel  ||| S:29348 E:29355 ||| NNP
Scientific ||| S:29355 E:29365 ||| NNP
,  ||| S:29365 E:29367 ||| ,
San  ||| S:29367 E:29381 ||| NNP
Rafael ||| S:29381 E:29387 ||| NNP
,  ||| S:29387 E:29389 ||| ,
CA ||| S:29389 E:29391 ||| NNP
) ||| S:29391 E:29392 ||| -RRB-
.  ||| S:29392 E:29418 ||| .
